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Preface
Cardiovascular diseases account for the majority of disease-related deaths in the
modern Western world. Coronary artery disease causes up to 66% of these cases. The typical
patient at risk presents with the signs of an acute myocardial infarction due to progressive
coronary atherosclerosis. The patient endures large scale loss of ventricular myocardium
through cell death during this medical emergency. Current therapeutic tools for the treatment
of myocardial infarction include reperfusion by thrombolytic therapy or revascularization
through balloon angioplasty or bypass surgery. The majority of patients admitted for acute
myocardial infarction will not only suffer from the detrimental effects of ischemia, but also
from those of additional reperfusion related injury. Despite improved treatment modalities,
the prevention of atherosclerosis and myocardial infarction is obviously the main target.
Therefore, the policy of governmental and healthcare institutions shifts towards preventive
medicine. In the meantime it is of the utmost importance to develop strategies to limit
myocardial damage due to ischemia and reperfusion. The scientific work performed on human
stem cells could provide a spectacular breakthrough in daily practice. However, standard
therapeutic implications are not expected in the nearby future.
Another branch of experimental cardiology focuses on molecular interventions.
Through direct intervention in active and vital intracellular signaling cascades beneficial
cellular responses could be stimulated, while maladaptive responses could be inhibited. The
experiments described in this thesis explore the possibility to intervene in the intracellular
signaling cascades involved in apoptotic cell death during myocardial ischemia-reperfusion.
The aims of the studies presented here were defined as follows:
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Aim 1: to investigate the possibility of inhibiting the process of ischemia-reperfusion 
induced cardiomyocyte apoptosis through molecular intervention, by genetic 
modification, in the MEK1-ERK1/2 and calcineurin-NFAT pathways.
Aim 2: A.  to develop a protocol for in vivo closed-chest left ventricular pressure-
volume (PV) assessment.
 B. to determine the effects of molecular intervention in ischemia-reperfusion 
induced apoptosis on cardiac performance by closed-chest PV 
relationship measurements.
Chapter one reviews the contribution of genetically engineered mice in the elucidation
of molecular pathways in cardiac remodeling. The concept of murine genome engineering
enabled researchers to investigate the spectrum of functions of various proteins involved in
the intracellular signaling pathways mediating processes as hypertrophy and apoptosis. The
techniques of gene targeting have been improved allowing inducible, cell type specific gene
deletion and overexpression experiments. Furthermore, the tools to measure murine cardiac
function have been extended with pressure volume (PV-loop) relationship recordings and
magnetic resonance imaging. This chapter reviews the contribution of genetically engineered
mice to the elucidation of molecular pathways in cardiac remodeling.
Chapter two reviews the molecular pathways active at the onset and during
development of hypertrophy, and the progression into heart failure. Conventional views
identify myocardial hypertrophy as a compensatory response to increased workload, prone to
evoke end-stage heart disease. Recent findings in genetic models of myocardial hypertrophy
and human studies have provided the molecular basis for a novel concept, which favors the
existence of either compensatory or maladaptive forms of hypertrophy, of which only the
latter leads to cardiac failure. Furthermore, the concept that hypertrophy compensates for
DJ Lips, Introduction Cardiomyocyte Survival Pathways
augmented wall stress is probably outdated. Here we have been able to provide the molecular
pathways that can distinguish beneficial from maladaptive hypertrophy.
Genetically engineered mice are extensively used in cardiovascular research. The in
vivo assessment of cardiac performance demands accurate measuring methods. In vivo left
ventricular PV-loop measurements provide an essential tool in the assessment of cardiac
function in genetically modified mice. PV-loops adequately represent cardiac function and
provide load and heart rate independent parameters of intrinsic myocardial contractility and
relaxation. Changes in ventricular contractility are best detected by PV derived parameters in
comparison to other methods of cardiac function determination. The concept of in vivo open-
and closed-chest left ventricular PV-loops is highlighted in chapter three.
The results from studies concerning the mitogen-activated protein kinase kinases
(MEK)1- extracellular signal-regulated kinases (ERK)1/2 pathway in genetically modified
mice are discussed in chapter four. While MEK1-ERK1/2 signaling is thought to protect the
myocardium from apoptotic insults, definitive genetic data demonstrating a necessary
function for MEK1-ERK1/2 signaling have not been reported. Here we analyzed deficiency of
the  ERK 1 and 2 gene, in Erk1-/- and Erk2+/- gene targeted mice, as well as MEK1
transgenic mice to evaluate both gain- and loss-of-function phenotypes in relation to
cardiomyocyte cell survival. Erk2 heterozygote mice showed enhanced apoptosis following
ischemia-reperfusion injury, while transgenic mice expressing activated MEK1 in the heart
were significantly protected. These results provide definitive genetic data implicating ERKs
as beneficial effectors of myocyte survival following myocardial stress stimulation.
The calcineurin-nuclear factor of activated T-cells (NFAT) pathway in cardiomyocyte
apoptosis is the main subject of chapter five. In this chapter, we discuss the role of calcium
calmodulin-activated protein phosphatase calcineurin (PP2B) in modulating cardiac apoptosis
after acute ischemia-reperfusion injury to the heart. Calcineurin Aβ gene–targeted mice
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showed a greater loss of viable myocardium, enhanced DNA degradation and a greater loss in
functional performance compared with strain-matched wild-type control mice after ischemia-
reperfusion injury. These results represent the first genetic loss-of-function data showing a
prosurvival role of calcineurin-NFAT signaling in the heart.
Another approach to investigate the role of calcineurin-NFAT in ischemia-induced
cardiomyocyte apoptosis, focusing on the endogenous inhibitor of the calcineurin-NFAT
pathway, i.e. glycogen synthase kinase (GSK)-3β, is described in chapter six. In GSK-3β
transgenic mice ischemia-reperfusion led to an 85% enlargement of the infarct areas
compared to wildtype littermates. Hypertrophic growth was attenuated in transgenic animals
following I/R. Finally, as a result of ischemia, cardiac functional deterioration was more
pronounced in GSK-3β transgenic mice than in wildtype mice. GSK-3β acts as a central
modifier in antihypertrophic and proapoptotic signaling pathways. Future research should be
performed to elucidate the possible clinical value of GSK-3β in cardiac hypertrophy and
ischemia.
In chapter seven the findings of our studies are positioned within current knowledge
concerning ischemia-induced apoptosis and molecular cardiomyocyte survival pathways.
Here the clinical relevance of our findings for the daily cardiology clinic is discussed, and
directions are provided for future reference.
Chapter 1. Transgenic mice and cardiac remodeling
1
The use of transgenic animals to assess cardiac remodeling
Daniel J. Lips, Rutger Hassink, Aart Brutel de la Rivière and Pieter A. Doevendans
In modified version published in textbook Myocardial Remodeling, ed. B.H.
Greenberg.
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Abstract
Cardiac remodeling is defined by structural, electrical and concomitant functional
alterations in the heart upon specific extrinsic and intrinsic stimuli. Pathophysiological situations
as hypertension, volume-overload and especially myocardial ischemia induce the process of
cardiac remodeling characterized by hypertrophic growth, global or local ventricular dilatation,
deposition of collagen and apoptosis of cardiomyocytes. Cardiac remodeling has been
investigated extensively in animal and human studies. The concept of genetic engineering of
murine DNA enabled researchers to investigate the spectrum of specific functions of proteins in
the intracellular signaling pathways mediating processes as hypertrophy and apoptosis. The
techniques of gene targeting have been improved allowing inducible, cell type specific gene
deletion experiments. Furthermore the tools to measure murine cardiac function have been
extended with pressure volume relationship recording and magnetic resonance imaging. This
chapter reviews the contribution of genetically engineered mice in the elucidation of molecular
pathways in cardiac remodeling.
Chapter 1. Transgenic mice and cardiac remodeling
3
Introduction
Cardiac remodeling describes the adaptive response of the myocardium in response to
pathophysiological changes. The remodeling process can be measured at different levels. First of
all, the composition of myocardial tissue will change in response to injury. Concomitantly, the
left ventricular contractile function and relaxation pattern adapt. The mechanism of remodeling,
albeit adaptive or maladaptive, can be studied at the organ, cellular or molecular level. To unravel
the importance of various signaling pathways and specific proteins, often gene targeting studies
are being performed in rodents, predominantly mice.(1) In mice, the plain effect of transgenesis
(adding genes) or gene targeting (replacing genes) on left ventricular morphology and function
can be assessed. (2-4) Specific alterations in individual genes result in (A) the absence of selected
proteins (i.e. knockout); (B) abundance of a selected protein (i.e. overexpression); (C) truncated
and/or dysfunctional proteins with a potential dominant-negative effect (D) introduction of
constitutively active proteins (dominant-positive). Because single genes are targeted, it is
possible to elucidate the specific functions of the corresponding protein in intracellular signaling
pathways. All aspects of cardiac remodeling can be investigated through this approach. In
addition, surgical interventions can be applied to induce pathology, including aortic banding,
myocardial infarction (MI) or ischemia/reperfusion (I/R). By systematic application of these
surgical interventions to various recently generated mouse lines, several crucial pathways have
been recognized and subsequently unraveled step by step. (5) The importance of genes involved
in post-ischemic cardiac remodeling, hypertrophy and heart failure, and pro- and anti-apoptotic
pathways have been studied. A fascinating observation is the close relationship between various
intracellular signaling events during distinct pathogenic conditions. For instance the family of
mitogen-activated protein kinases (MAPK) was described as a group of crucial molecules for the
development of hypertrophy in the heart. (6-8) More recent studies outlined their protective role
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in ischemia-induced apoptosis. (9,10) The reverse is true for the Akt protein. Initially identified
as a prosurvival protein (11), a potential role in ischemic heart disease and even dilated
cardiomyopathy has been proposed recently.(12) The conclusion can be drawn that intracellular
pathways may result in distinct cellular outcomes depending on the specific pathophysiological
situation. Moreover, the myocyte response is not solely determined by activation of a single
pathway, but by the relative activity of various simultaneous acting signaling molecules. Part of
the complexity involved can be elucidated by using more advanced genetic models in the adult
mouse where genes can be activated or repressed at will by the investigator. For example the
tamoxifen-induced cardiomyocyte-specific and temporally regulated gene-expression in a Mer-
Cre-Mer based mouse model, can be used to delete a floxed gene. (13) This is an example of an
inducible tissue specific knock-out approach. Here we will focus on the most recent information
available on cardiac remodeling. The most important aspect of remodeling is its effect on cardiac
function, as the morphological changes are less crucial for the final outcome or prognosis
compared to functional changes in man and mouse alike.
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Fig. 1: Signaling pathways in cardiac remodeling. Several intracellular signaling pathways
involved in the cellular adaptation of cardiac remodeling are shown. The figure presents the
signaling pathways as discussed in the text. Activation or inhibition of single molecules are
indicated by respectively (+) and (-).
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Cardiac remodeling and myocardial ischemia
Cardiac remodeling is defined by the structural and concomitant functional alterations in
the heart after an ischemic event. The ischemia-induced architectural remodeling encompasses
ventricular dilatation, myocardial hypertrophy, deposition of collagen and apoptosis in the area-
at-risk-(for-ischemia) and the remote myocardium. Cardiac remodeling in man occurs classically
within 2 to 4 weeks following the ischemic event, characterized by an enlargement of ventricular
dimensions or volumes (end-diastolic and –systolic dimensions) combined with a decrease in left
ventricular ejection fraction and increase in mass-index. Even nowadays, in the era of aggressive
medical therapy for ischemic heart disease and during acute myocardial infarction, cardiac
remodeling remains important for long term cardiac function. (14)  Current therapy of acute
myocardial infarction in the human can attenuate ventricular volume enlargement and dilation at
1 month following the ischemic event, coinciding with improvement of left ventricular geometry
and cardiac function as defined by left ventricular ejection fraction. (14) But more importantly,
cardiac death and hospitalization for clinical heart failure are still significantly higher in patients
with left ventricular remodeling following ischemia as compared to patients without. (15)
Thorough investigation into the prevention of adverse effects of cardiac remodeling has become
vital in daily cardiological practice.
Cardiac remodeling has been investigated extensively in animals (16-18) and humans,
using imaging techniques such as echocardiography (19), computer tomography (CT) (20),
radionuclide ventriculography (21) and recently magnetic resonance imaging (MRI) (14,22).
With the development of genetically altered mice an intense interest arose for murine models of
I/R and MI. (16,23) Through genetic engineering it is possible to elucidate the spectrum of
specific functions of single proteins in the intracellular signaling pathways involved in ischemia(-
reperfusion) injury. Mouse models of ischemia following the occlusion of the left anterior
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descending coronary artery permanently (MI) or temporarily (I/R), allow assessment of the
process of cardiac remodeling. These experimental studies showed the important roles of the
renin-angiotensin-system (RAS), androgenic hormones, growth factors, and tissue-matrix
components in both acute and chronic remodeling (figure 1).
The importance of the renin-angiotensin axis originates from its role in cardiomyocyte
hypertrophy and induction of fibrosis. The effector protein of the RAS is angiotensin II (Ang II).
All the components necessary to generate Ang II are present in the myocardium and cardiac Ang
II formation, from angiotensin I by angiotensin converting enzyme (ACE), appears to be
regulated independent of the systemically circulating ACE. (24) Ang II induces hypertrophic
growth mostly through the angiotensin 1 (AT1) receptor. (25) Activation of this G-protein
coupled receptor initiates the expression of growth-related genes through mitogen-actived protein
kinases (MAPK) and the family of Janus kinase /signal transducer and activator of transcription
(JAK/STAT) proteins dependent pathways. (26) Most prohypertrophic stimuli mediated by Ang
II are also instigators of cardiac fibroblasts proliferation leading to formation of excessive
collagen in the myocardial interstitium. (27) The remodeling process is dependent on the amount
of collagen deposition in both the ischemic area and the remote myocardium. Inhibition of Ang II
reduces the amount of collagen deposition and improves cardiac function during the remodeling
phase. Genetically altered mouse models have been the key in elucidating the specific roles for
the RAS components. For instance, AT1a receptor knockout mice displayed less left ventricular
remodeling and improved survival after MI. (28) In contrast to the AT1 receptor, the AT2
receptor has an inhibitory regulatory effect on MAPK and JAK/STAT activity. Therefore, cardiac
AT2 receptor overexpression led to preservation of left ventricular performance during post-MI
remodeling thereby reducing early mortality after MI. (24,29)
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Growth factors stimulate various cell types into hyperplastic or hypertrophic responses,
and initiate angiogenesis. These cellular functions enable growth factors to protect the heart for
deleterious remodeling and impaired cardiac performance. An important role for these factors
could have been anticipated as ischemia results in the loss of significant amounts of
cardiomyocytes, providing a trigger for regeneration and growth. Insuline-like growth factor
(IGF) is an endogenous protector of cardiomyocytes and induces prosurvival processes ex and in
vivo. In IGF-1 knockout mice myocardial ischemia resulted in the attenuation of DNA synthesis
and an augmentation of apoptosis rates. (30) Mice lacking isoforms of the vascular endothelial
growth factor (VEGF) showed impaired angiogenesis and worsened cardiac performance
following myocardial ischemia. (31,32) The fibroblast growth factor (FGF) is produced by
cardiomyocytes and fibroblasts. FGF mainly stimulates cellular proliferation and deposition of
collagen. The degradation of collagen is started within minutes from the start of ischemia, mainly
of collagen type 1. Loss of the myocardial collagen-network thins the infarcted myocardium that
expands during systole and promotes cardiac rupture and dilation of the left ventricle. After 5
days the initial degradation of collagen is followed by the deposition of newly formed collagen
produced by the cardiac fibroblasts stimulated by FGF. Cardiac-specific overexpression of
human FGF delays infarct development due to a higher expression of prosurvival ERK1/2
signaling pathways. (33) These studies therefore demonstrate the importance of growth factors
during the remodeling phase as they mediate proliferative processes.
Both the RAS and growth factors are involved in the induction of fibrosis and highlight
extracellular collagen organization as an important feature of cardiac remodeling. These
extracellular matrix degrading enzymes, belonging to the families of serine and matrix
metalloproteinases (MMP), are activated following MI. (34) MMP’s belong to the only
proteinase enzymes capable of degrading collagen. Targeted deletion of MMP-9 attenuated left
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ventricular enlargement and increased myocardial collagen content following infarction, leading
to a decreased incidence of cardiac rupture. (35,36) Moreover, uncontrolled MMP activity as
seen by tissue-inhibitor of MMP (TIMP)-1 deficient mice, demonstrated amplified adverse left
ventricular remodeling (i.e. significant loss of fibrillar collagen) following MI, thereby
emphasizing the importance of local endogenous control of cardiac MMP activity. (37) Adequate
control of collagen organization is reflected by the main physiological functions of the interstitial
collagen network: to retain tissue integrity and cardiac pump function. (34) The RAS, growth
factors and extracellular matrix molecules are of vital importance in maintaining these functions
following an ischemic event.  
Several other intriguing factors have been shown to be involved in post-ischemic
remodeling. Interesting data suggest that estrogens prevent deterioration of cardiac function and
remodeling after MI, while testosterone on the other hand worsened cardiac dysfunction and
remodeling. (38) Moreover, estrogen replacement therapy reduces infarct size and cardiomyocyte
apoptosis in mice. (39) In accordance with the beneficial effects post-ischemia, estrogens are also
believed to mediate hypertrophy reducing effects predominantly by the estrogen-β receptor.
(40,41) Survival pathways mediated by estrogens involve probably atrial natriuretic peptide
(ANP) expression. (42) Molecular substrates are now uncovered through studies in gene targeted
mice missing specific sex hormone receptors. Newly detected substrate or molecular interactions
could provide the biological explanations for the generally observed sex differences in
cardiovascular response to pathological conditions. 
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Fig. 2: Signaling pathways in cardiomyocyte apoptosis. The figure presents the signaling
pathways as discussed in the text. Activation or inhibition of single molecules are indicated by
respectively (+) and (-).
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Myocardial ischemia and apoptosis
Myocardial ischemia will lead to the loss of cardiomyocytes by three different
mechanisms: necrosis, apoptosis and autophagic cell death. Necrosis is well characterized by cell
swelling, disruption of cell organelles and cell membranes, and an inflammatory tissue reaction.
In apoptosis (i.e. programmed cell death) the cell undergoes shrinkage, nuclear chromatin
condensation and formation of apoptotic bodies, which are removed by macrophages without
eliciting inflammation. (43) In contrast to necrosis, apoptosis is an energy-requiring and
multiprotein involving process. Various molecular cascades lead to the degradation of nuclear
DNA. Autophagic cell death is another form of programmed cell death and seems to be of
importance in heart failure. (44) Like apoptosis, autophagic cell death is regulated and associated
with DNA fragmentation. Unlike apoptosis, it is caspase-independent and morphologically it
resembles necrosis.
 Many proteins and enzymes have been linked to the regulation of programmed cell death
under pathological conditions (figure 2). Deprivation of serum and glucose, hallmark of ischemia
in vivo, results in cardiomyocyte apoptosis. (45) Ischemia-induced apoptosis is characterized by
cytochrome C release from the mitochondria into the cytosol after 30-60 minutes by the opening
of the mitochondrial permeability transition (MPT) pores. (46,47) Cytochrome C release can be
inhibited by anti-apoptotic members of the Bcl-2 family, such as Bcl-2 and Bcl-xL, or stimulated
by pro-apoptotic members like Bad and Bax. Once released into the cytosol, cytochrome C binds
to the apoptotic protease-activating factor (Apaf)-1. (47) The cytochrome C/Apaf-1 complex
activates pro-apoptotic molecules like caspase-9 eventually leading tot the activation of the main
effector caspase, caspase-3. Caspases are the specialized cysteine-dependent proteases that cleave
major structural proteins of the cytoplasm and nucleus. (47) Secondly, apoptosis can be induced
via so-called death receptors (Fas and TNF-α), resulting in the recruitment of a death domain and
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activation of caspase-8 and effector-caspases. Fas activation induces apoptosis in cardiac
myocytes. Lymphoproliferative (lpr) mice that lack functional Fas exhibit smaller infarcts with
concomitant linear decrements in myocyte apoptosis. (48) Repressor domains and other
inhibitory proteins like FLIP (Fas-associated death domain protein -like interleukin 1β-
converting enzyme [FLICE]/caspase-8-inhibitory protein), are able to block apoptosis via the
death receptors. The two pathways come together downstream as a common pathway at the level
of the effector caspases, such as caspase-3. The generation of caspase-knockout mice by
homologous recombination provided the possibility to study the role of individual caspase
proteins. (49)
Apoptosis can be assessed by several methods, like electron microscopy, terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) or in situ end labeling
(ISEL) methods for identification of DNA fragments, Annexin-V staining (50), or by the
appearance of DNA laddering in gel electrophoresis. Technical and experimental difficulties,
however, have to be taken into account, since overestimation of the number of apoptotic
cardiomyocytes (false-positives) and misinterpretation of electron microscopic photos are pittfalls
in these studies.
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Table 1. Mouse models used in cardiac remodeling.
Molecular
target
Genetic modification Phenotype Reference
CARDIAC REMODELING
AT1a receptor Knockout Less LV remodeling, improved
survival
Harada K, et al.
Circulation 1999 28
AT2 receptor Overexpression
Knockout
Less LV remodeling, improved
survival
No different cardiac remodeling
Oishi Y, et al.
Hypertension 2003 29
Xu J, et al.
Hypertension 2002 25
IGF-1 Knockout
Overexpression
Attenuation DNA synthesis, higher
apoptosis rates
Smaller infarctions, lower apoptosis
rates
Palmen M, et al.
Cardiovasc Res 2001
30
Li O, et al. JCI 1997 70
VEGF Knockout Deterioration cardiac function,
impaired angiogenesis
Carmeliet P, et al. Nat
Med 1999 31
FGF-1 Overexpression Delayed infarct development,
prosurvival cellular signaling
Buehler A, et al.
Cardiovasc Res 2002
33
MMP-9 Knockout Attenuated LV enlargement,
augmented collagen deposition
Ducharme A, et al. J
Clin Invest 2000 35
TIMP-1 Knockout Loss of fibrillar collagen Creemers E, et al. AJP
2003 37
APOPTOSIS AND HYPERTROPHY
Fas Non-functional Smaller infarction, lower apoptosis
rate
Lee P, et al. AJP 2003
48
Caspase-3 Overexpressoin Larger infarction, higher apoptosis
rate
Condorelli G, et al.
PNAS 2001 55
Bax Knockout Smaller infarction, lower apoptosis
rate
Hochhauser E, et al.
AJP 2003 56
Mst1 Overexpression
Dominant-negative
overexpression
Higher apoptosis rate, abolishment
cardiac hypertrophy
Smaller infarction, lower apoptosis
rate
Yamamoto S, et al.
JCI 2003 57
A1 adenosine
receptor
Overexpression Smaller infarction, lower apoptosis
rate
Regan S, et al. AJP
2003 58
Caspase-1 Knockout Smaller infarction, lower apoptosis
rate
Frantz S, et al. JMCC
2003 62
Chapter 1. Transgenic mice and cardiac remodeling
14
TNF receptor Knockout Larger infarction, higher apoptosis
rate
Kurrelmeyer K, et al.
PNAS 2000 65
TNF-α Knockout Smaller infarction Maekawa N, et al.
JACC 2002 66
gp130 Overexpression
Dominant-negative
overexpression
Knockout
Cardiac hypertrophy
Attenuated hypertrophic response
Progressive pressure-induced
cardiomyopathy,
augmented apoptosis rates
Hirota H, et al. PNAS
1995 76
Uozumi H, et al. JBC
2001 77
Hirota H, et al. Cell
1999 113
STAT3 Overexpression Cardiac hypertrophy Kunisada K, et al.
PNAS 2000 80
MEKK1 Knockout Abolishment of cardiac hypertrophy,
attenuated hypertrophic response
Minamino T, et al.
PNAS 2002 81
Sadoshima J, et al. JCI
2002 88
MKP-1 Overexpression Diminished developmental myocardial
growth, attenuated hypertrophic
response
Bueno O, et al. Circ
Res 2001 84
MEK1 Overexpresson Concentric cardiac hypertrophy
Smaller infarction, lower apoptosis
rate
Bueno O, et al.
EMBO J 2000 6
Lips D, et al. 2003 10
MEK5 Overexpression Eccentric cardiac hypertrophy, sudden
death
Nicol R, et al. EMBO
J 2001 85
JNK Inducible overexpression of
MKK7D
Progressive cardiomyopathy Petrich B, et al.
FASEB J 2003 13
p38 Inducible overexpression of
MKK3bE or MKK6bE
Restrictive cardiomyopathy,
heterogeneous mycoyte atrophy
Liao P, et al. PNAS
2001 7
p38α Dominant-negative
overexpression
Hypertrophic cardiomyopathy Braz J, et al. JCI 2003
92
Calcineurin Overexpression
Dominant-negative
overexpression
Cardiac hypertrophy
Sudden cardiac death
Smaller infarction, lower apoptosis
rate
Attenuated adrenergic-stimulated
hypertrophic response
Molkentin J, et al.
Cell 1998 94
Dong D, et al. CVR
2003 95
De Windt, et al. Circ
Res 2000 96
Zou Y, et al. Circ
2001 97
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Calcineurin Aβ Knockout
Attenuated pressure-induced
hypertrophic response
Larger infarction, higher apoptosis
rate
Zou Y, et al. Circ
2001 98
Bueno O, et al. 2003
116
NFAT3c Knockout Abolishment of cardiac hypertrophy,
attenuated hypertrophic response
Wilkins B, et al. MCB
2002 100
MCIP-1 Overexpression
Knockout
Attenuated hypertrophic response
Exacerbated hypertrophi response
Rothermel B, et al.
PNAS 2001 103
Vega R, et al. PNAS
2003 105
GSK-3β Overexpression Abolishment of cardiac hypertrophy Antos C, et al. PNAS
2002 106
Cain/cabin Overexpression Attenuated hypertrophic response De Windt, et al.
PNAS 2001 107
A-kinase
anchoring protein
79
Overexpression Attenuated hypertrophic response De Windt, et al.
PNAS 2001 107
Mouse models in cardiac remodeling as discussed in the text and figures. Abbreviations used are
explained in the text. Models are listed in order of appearance in the text.
Apoptosis in ischemia-reperfusion
Notwithstanding cell necrosis being pathognomic for acute MI, apoptosis represents the
major form of cell death in continuing ischemia. (51) Prolonged periods of myocardial ischemia
are causing an increase in the rate of necrosis, whereas, reperfusion leads to an enhancement in
apoptosis. (52) Essentials for the survival of viable cells are provided when reperfusion restores
oxygen and glucose supply, thereby delivering the required energy for apoptosis and restarting or
accelerating the apoptotic process compared with the situation in continuously ischemic
myocardium. (53) Reports by Kajstura et al (51) and Fliss and Gattinger (53) described apoptosis
to be induced following 2 hours of coronary occlusion and accelerated after 45 min of ischemia
followed by 1 hour of reperfusion. Gottlieb found apoptosis in the ischemic myocardium after 30
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minutes of ischemia and 4 hours of reperfusion in the rabbit (52), but not in the permanently-
ischemic areas, suggesting that apoptosis can only start during reperfusion. Also in a more recent
study in dogs, apoptosis appeared in myocardium subjected to a brief period of ischemia
followed by reperfusion, and not in ischemic tissue without reperfusion. (54) Whether apoptosis
can be triggered during ischemia or predominantly during reperfusion remains controversial.
Current clinical reperfusion techniques, including thrombolytic therapy and primary
percutaneous transluminal coronary angioplasty (PTCA) or on pump coronary artery bypass
grafting (CABG), make inhibition of reperfusion-induced apoptosis a clinical relevant issue with
potential therapeutic possibilities. In the experimental setting pharmacological intervention and
genetic modification of the heart provide interesting tools to block or just activate apoptotic
signaling pathways. The application of such pharmacologic or genetic interventions makes it
possible to study the effects of individual molecules in the apoptotic and cardiac remodeling
process. Accordingly, the role of caspase-3 in apoptotic signaling has been revealed through such
a strategy. Cardiac- specific overexpression of caspase-3 driven by the rat alpha-myosin heavy
chain promoter in mice resulted in increased infarct size and higher mortality when exposed to
myocardial ischemia-reperfusion and demonstrated caspase-3 to be a pro-apoptotic regulator.
(55) Gene-targeting of Bax in mice inhibited caspase-3 activity and consequently decreased
TUNEL-positive cardiomyocytes and improved cardiac function of the Bax null hearts following
ischemia-reperfusion. (56) Transgenic mice have clarified that the αMHC promoter- Mst1 cDNA
construct is an efficient mediator of apoptosis through the activation of caspase-3. In this model
stimulation of cardiomyocyte apoptosis and the development of dilated cardiomyopathy was
found. (57) Overexpression of the dominant negative Mst1 transgene significantly decreased the
rate of apoptosis and the extent of myocardial loss in mice following I/R. The activity of caspase-
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3 could also be reduced by overexpressing the cardiac A1 adenosine receptors. (58)
Consequently, induction of apoptosis was attenuated in transgenic hearts exposed to I/R injury.
The discussed studies present evident genetic proof defining caspase-3 as an important
determinant in I/R induced apoptotic signaling.
Apoptosis in myocardial infarction
As stated above, reperfusion accelerates the myocardial apoptotic process. Nevertheless, the total
amount of dead cardiomyocytes is maximal in the permanently occluded myocardium. (53)
Persistence of ischemia leads to irreversible loss of cells.
The apoptotic hallmark of DNA fragmentation has not exclusively been observed during
the acute stages of infarction. (53) Heightened rates of cardiomyocyte apoptosis are continuously
present in the border zones of the infarct-area and the remote myocardium over a time-period of
12 weeks following MI. (59) This extended period designates apoptosis to be a key-player in
post-infarction cardiac remodeling. Similar findings have been reported from human studies
where the presence of high grades of apoptosis have been observed in human hearts of patients
dying within 12 to 62 days following acute MI. (60) Blockade of the apoptotic process by a
caspase-inhibitor during the subacute stage of MI has recently been shown to have beneficial
effects on persistent apoptosis rates and cardiac remodeling in rats. (61)
The application of transgenic animals has been extremely useful in elucidating molecular
mechanisms in apoptosis and cardiac remodeling following MI. The proapoptotic active caspase-
1 is known to be important for the production of various cytokines such as IFNγ and TNF-α
which contribute to the cardiac remodeling process after MI. Knockout mice lacking the caspase-
1 gene showed significant reduction in apoptosis rates at day 1 post infarction and decreased
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ventricular dilatation as assessed by echocardiography. (62) Tumor necrosis factor (TNF) itself
may have anti-apoptotic and subsequent beneficial effects on the cell survival of myocytes
injured by ischemia. (63,64) Post-infarction remodeling in TNF-receptor knockout mice was
characterized by significantly greater infarct-areas and accelerated rates of apoptosis. (65) In
knockout mice for TNF-receptors-1 and -2 the peak frequency and extent of apoptosis were
significantly elevated in response to I/R. (65) These data suggest that TNF signaling gives rise to
one or more cytoprotective signals that prevent and/or delay the development of cardiac myocyte
apoptosis after acute ischemic injury. In contrast, the infarct size in TNF-α knockout mice was
significantly reduced compared with wildtype littermates. (66) The systemic release of TNF-α in
the early course of acute MI contributes to myocardial injury by promoting leukocyte infiltration
of the myocardium, and TNF-α induces apoptosis in cardiomyocytes. (67) The systemic TNF-α
concentration during ischemia correlates with the size of myocardial infarction in for example
rabbits. (68) The use of TNF-α antibodies in ischemic-preconditioning studies reduces infarct
extent significantly. (68,69) Currently clinical trials are in progress to investigate the protective
effect of TNF-antibodies during myocardial ischemia.
The growth promoting peptide IGF-1 contributes in vivo to the protection of
cardiomyocytes against apoptosis. IGF-1 deficient mice appeared to develop increased amounts
of cardiomyocyte apoptosis 1 week post-infarction, affecting cardiac remodeling by thinning of
the ventricular walls. (30) The IGF-1 protective effect on apoptosis was confirmed by the report
that overexpression of the peptide in mice with chronic MI reduced myocyte death by blocking
apoptosis rates. (70) This resulted in preserved wall thickness and decreased ventricular
dilatation. IGF-1 induces anti-apoptotic signals in cardiomyocytes through PI3K-dependent Akt
activation (figure 1). (71,72) Transgenic mice with cardiac-specific overexpression of human
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FGF-1 showed delayed first signs of myocardial damage and postponing  maximal infarction
extension compared to wildtype animals. (33) FGF-1 provides cardioprotection at the level of the
cardiac myocyte and is at least partially mediated via activation of the mitogen activated protein
kinase (MAP) ERK-1 and -2. The presence of growth promoting peptides as IGF and FGF in the
acute and chronic phase of myocardial ischemia is beneficial for the morphological and
functional outcome.
The presented studies underscore the importance in future therapy of directly attenuating
cell death in the infarct-area border zones and the remote myocardium to prevent adverse cardiac
remodeling (i.e. wall thinning, ventricular dilatation and deteriorating cardiac performance)
following MI.
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Hypertrophy
The hypertrophic response of cardiomyocytes has been studied extensively during the past
decade using genetically modified mouse models and in vitro models. Cardiomyocyte
hypertrophic growth in vivo is triggered by various stimuli such as ventricular pressure- or
volume-overload, ischemia-(reperfusion) or drug induced. (73) Furthermore, analogues to human
hypertrophic cardiomyopathies the possibility arose to evoke hypertrophy by engineering
mutations in the sarcomeric genes of mice. Many aspects of cardiac hypertrophic growth have
been investigated with these techniques. Hypertrophy is characterized by cardiomyocyte growth,
myofibrillar disarray, fibrosis, apoptosis, arrhythmias, elevated filling and end-diastolic
pressures, decline in systolic function, cellular and mitochondrial energy inefficiency, alterations
in calcium handling and eventually transition towards heart failure. (73) The single most
powerful predictor for the development of heart failure is the presence of left ventricular
hypertrophy. (74) For this reason, much effort is currently undertaken to investigate the etiology
of molecular hypertrophic mechanisms and to unravel the signaling pathways underlying this
process (figure 3).
To date, more than 100 genetically altered mouse models of hypertrophic
cardiomyopathy, myocardial hypertrophy and heart failure have been engineered. (75) Because of
the variety of genes involved numerous molecular mechanisms in the development of
hypertrophy have been investigated. Proposed molecular mechanisms in the development of
hypertrophy include abnormalities in contractile, cytoskeletal, and intracellular calcium (Ca2+)-
regulatory proteins, alterations in excitation-contraction coupling, signal transduction system,
cardiac metabolism or myocyte apoptosis and many others. (75) All hypertrophic stimuli (i.e.
myocyte stretch, hemodynamic stress, ischemia, hormones, vasoactive peptides or
neurotransmitters) converge in several intracellular signaling cascades mediating these extrinsic
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and intrinsic growth signals into co-ordinated alterations of genetic profiles, and increments in
the overall rate of RNA transcription and protein synthesis.
An important signaling pathway in cardiomyocyte hypertrophy is initiated by the gp130
cytokine receptor. Transgenic mice expressing constitutively active gp130 protein in the heart
were created by mating mice from interleukin (IL)- 6 and IL-6-receptor transgenic mouse lines.
The continuous activation of the gp130 signaling pathways in these mice led to overt cardiac
hypertrophy. (76) In transgenic mice overexpressing a dominant-negative mutant of gp130
pressure-overload induced smaller increments in heart-to-body weight ratios, ventricular wall
thickness and cross-sectional areas of cardiomyocytes than in wildtype littermates. (77) The
gp130 protein induced hypertrophic gene program could be antagonized by monoclonal anti-
gp130 antibodies. (78) Investigations in cultured murine cardiomyocytes infected with
adenoviruses suggested that mainly the STAT3-dependent signaling pathway downstream of
gp130 promoted cardiac myocyte hypertrophy. (79) Pressure-overload activated ERKs and
STAT3 in the heart of wildtype mice, whereas pressure overload-induced activation of STAT3,
but not of ERKs, was suppressed in transgenic mice overexpressing dominant-negative gp130.
(77) Moreover, transgenic mice with cardiac-specific overexpression of the STAT3 gene
manifested myocardial hypertrophy at the age of 12 weeks. (80) These results suggest that gp130
plays a critical role in stimulus-induced cardiac hypertrophy possibly through the STAT3
signaling pathway.
ERK belongs to another important pathway through which extracellular stimuli induce
hypertrophy. Hypertrophic stimuli induce the activation of the mitogen-activated protein kinase
(MAPK) superfamily cascades. MAPKs are a widely distributed group of intracellular proteins
composed of three terminal MAPK branches; (A) the extracellular signal-regulated kinases
(ERKs); (B) c-Jun NH(2)-terminal kinases (JNKs) and (C) the stress-induced p38 MAPKs.
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Hypertrophic stimuli induce the activation of MAPKs through G-protein coupled receptors (81)
and low molecular weight GTP binding proteins Ras and Rho depending pathways (figure 3).
(82,83) A family of MAPK phosphatases (MKPs) act as the critical counteracting factors of p38,
JNK and ERK. (84) Selective ERK1/2 stimulation by cardiac specific overexpression of MEK1
(endogenous kinase activator of ERK1/2) demonstrated concentric hypertrophy without signs of
cardiomyopathy combined with improved cardiac function. (6) On the contrary, cardiac-specific
expression of activated MEK5 in transgenic mice resulted in eccentric cardiac hypertrophy that
progressed to dilated cardiomyopathy and sudden death. (85)
JNK MAPK contributes to the pressure-overload and catecholamine-induced hypertrophic
response. (82,86) Prevention of JNK activity through JNK-interacting protein 1 (JIP-1), a
cytosolic scaffolding protein, results in reduced cellular growth in response to G-protein coupled
receptor agonists. (87) Pressure-overload however caused significant levels of cardiac
hypertrophy coinciding with signs of clinical heart failure and higher mortality in mice deficient
for MEKK1 (mitogen-activated protein kinase kinase kinase; mediates JNK activation). (88)
Direct JNK-gene overexpression or deficiency in cardiomyocytes has not been published so far.
However, through an ingenious mouse model using tamoxifen-inducible cardiac-specific-gene
expression, a constitutively activated upstream activator of JNK was investigated in the adult
mouse heart. (13) Prolonged activation of JNK resulted in progressive cardiomyopathy adding
molecular proof for a regulatory role of JNK in maladaptive cardiac growth.
Stress-induced p38 MAPK activity increases significantly in mouse hearts after chronic
transverse aortic constriction, coinciding with the onset of ventricular hypertrophy. Adenoviral
overexpression of wild type p38β or a dominant-negative p38β variant respectively enhanced and
suppressed the hypertrophic response following aortic constriction. (89) p38 Activity has also
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been associated with catecholamine-induced hypertrophy. (90) Transgenic male and female mice
with fourfold phospholamban (PLB) overexpression exhibited enhanced circulating
catecholamines concurrent with p38 MAPK activation levels.(90) However, in vivo cardiac
overexpression of p38 MAPK activation resulted in varying degrees of myocyte atrophy. This
was shown using a transgenic gene-switch strategy with activated mutants of well-established
upstream activators of the p38, namely MKK3bE and MKK6bE. (7) The gene-switch strategy is
based on cre/loxP-mediated DNA recombination to restrict transgene expression to ventricular
myocytes and avoid potential adverse effects of transgene expression on the survival of the
founder transgenic animals. (91) Moreover, dominant-negative p38α transgenic mice showed
enhanced cardiac hypertrophy following both pressure-overload and catecholamine drug
infusion. (92) Further investigations in these mice revealed an enhancement of calcineurin-NFAT
signaling following reduced p38 activity, providing a possible explanation for the contradicting
results in the studies presented. However, probably both p38 and JNK MAPK activation are
directly associated with a failing cardiac phenotype. In longstanding hypertrophy only p38 and
JNK MAPKs are activated, associated with progressive deterioration to maladaptive chronic
hypertrophy and congestive heart failure. (86,93)
The calcium/calmodulin-dependent protein phosphatase calcineurin is important in
cardiac hypertrophy in response to numerous stimuli. Transgenic mice overexpressing the
activated form of calcineurin exhibited a severe form of cardiac hypertrophy with concurrent
transition towards apoptosis-independent heart failure and sudden death due to lethal
arrhythmias. (94-96) Besides the ability of calcineurin itself to provoke hypertrophic growth of
the heart, it may play a significant role in pressure-overload-induced and isoproterenol-induced
cardiac hypertrophy in transgenic mice overexpressing a dominant negative mutant of
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calcineurin. (97,98) Calcineurin was shown to dephosphorylate the transcription factor NFAT3,
enabling it to translocate to the nucleus, where NFAT interacted mainly with transcription factor
GATA4, resulting in synergistic activation of cardiac transcription. (94) NFAT3 appeared to be
required for calcineurin mediated hypertrophic signaling based on reduced cardiac growth upon
calcineurin stimulation in NFAT3 knockout mice. (99,100) Transgenic mice expressing the
activated form of calcineurin showed interaction with other developmental pathways by
inactivation of p38 and increased MKP-1 expression. (101) Calcineurin hypertrophic signaling
was furthermore interconnected with PKCα, theta, and JNK in the heart. (102) Endogenous
myocyte-enriched calcineurin-interacting protein (MCIP) counteracts calcineurin through a
negative feedback loop. Cardiac-specific expression of human MCIP1 in mice inhibited cardiac
hypertrophy provoked by constitutively active calcineurin. (103) Even hypertrophy induced by
catecholamines, exercise training or pressure-overload was attenuated, without deterioration of
ventricular performance. (103,104) Even so, the lack of MCIP1 in homozygous knock-out mice
exacerbated the hypertrophic response to activated calcineurin. (105) Another endogenous
inhibiting protein of the calcineurin-dependent hypertrophic signaling pathway is glycogen
synthase kinase (GSK)-3β. Transgenic mice that express a constitutively active form of GSK-3β
showed a significant ability to attenuate the hypertrophic response to calcineurin activation. (106)
GSK-3β mice expressing the calcineurin inhibitory domains of Cain/Cabin-1 and A-kinase
anchoring protein 79 demonstrated reduced cardiac calcineurin activity and reduced hypertrophy
in response to catecholamine infusion and pressure overload. (107) The calcium/calmodulin-
dependent protein phosphatase calcineurin is therefore an importantly regulator of cardiac
hypertrophy induced by various stimuli as shown by multiple studies in genetically engineered
mice.
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Apoptosis and its relation to cardiac hypertrophy
Cardiac hypertrophy may occur to compensate for the loss of viable cells after myocardial
ischemia. (108) Cardiomyopathy in transgenic mice is related to increased apoptosis rates.
Nix/Bnip3L, one of the mitochondrial death proteins, was shown to be upregulated in cardiac
hypertrophy, but also to play a major role in the apoptotic process. (109) As reported earlier, the
cardiac-specific overexpression of Mst1 resulted in activation of caspases and an increase of
apoptosis. Interestingly, Mst1 also prevents cardiac myocyte elongation and hypertrophy despite
increased wall stress. (57) Mst1 may inhibit signaling molecules causing hypertrophy.
However, several molecular effectors in hypertrophic signaling have been proven to be
important in anti-apoptotic signaling also, as part of the second leg of cardiomyocyte survival
pathways. For instance, the MEK1-ERK1/2 signaling pathway stimulates cardiac hypertrophic
growth associated with augmented cardiac function (i.e. adaptive hypertrophy) combined with
partial resistance to apoptosis. (10,110) The gp130 protein, another potent cardiac survival factor,
mediates cardiotrophin-1 (CT-1)-induced cardiac hypertrophy and is capable of inhibiting
cardiomyocyte apoptosis also. (111,112) In gp130 knockout mice, the application of pressure
overload by aortic banding resulted in massive apoptosis rates plus reduced cardiac hypertrophy.
(113) To date, the role of the calcineurin-NFAT pathway in pro- or anti-apoptotic responses is
not clear. (114) For instance, adrenergic stimulation led to calcineurin mediated cardiomyocyte
apoptosis (115), while other investigations found myocardial protection against I/R induced
apoptosis through calcineurin in vitro and in vivo. (96,116) It seems that NFAT activity is the
critical component mediating effects of calcineurin stimulation resulting in the activation of pro-
or antiapoptotic pathways in cardiomyocytes. (116,117) Selective NFAT inhibition during
phenylephrine stimulation prevented calcineurin mediated hypertrophy but resulted in increased
cardiomyocyte apoptosis. (117) Therefore, certain prohypertrophic and antiapoptotic pathways
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can come together as a common survival pathway, suggesting interplay between cellular
pathways in adaptive myocyte responses.
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Fig. 3: Signaling pathways in cardiomyocyte hypertrophy. Activation or inhibition of single
molecules are indicated by respectively (+) and (-).
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Hemodynamics
The use of genetically engineered mice rendered vital information about the precise role
various proteins play in the diversity of intracellular signaling pathways in the event of cellular
hypertrophy or apoptosis. The link between the genotype of the mouse and the concurrent
phenotype is investigated with the use of sophisticated molecular and cellular techniques. An
equally important aspect of the resultant phenotype is cardiac function. Genetic engineering
provides the possibility to probe the precise mechanism by which specific proteins exert their
effects on plain cardiac function, or in the process of remodeling. The small size of the murine
heart and the rapid pace at which it contracts makes measurements of cardiac performance
difficult. Various techniques have been used to assess murine cardiac function, such as
transthoracic ultrasonography (118), Langendorff perfusion systems (119), aortic flow probes
(120) and micromanometers (121). Those techniques have been and are being used extensively in
mouse studies, notwithstanding their relative inaccuracy and lack of total cardiac performance
assessment. This could theoretically be obtained by measuring cardiac pressure and volume
simultaneously. The development of new cardiac function techniques such as magnetic resonance
imaging (MRI) (122) and conductance-micromanometers  (123) provide new tools for accurate
and total cardiac performance assessment.
The concept of simultaneous in vivo pressure and volume measurements in the left
ventricle was developed by Baan et al in the early 1980’s. (124) The volume-signal is derived in
accordance with Ohm’s Law, depending on the varying amount of ventricular bloodvolume
during the cardiac cycle. An electrical current is produced by an intraventricular catheter to
measure conductance, which is directly related to the varying bloodvolume. The pressure- and
volume signals produced by the conductance-micromanometer catheter are displayed in a two-
dimensional diagram. This presentation results in pressure-volume loops representing cardiac
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performance, which can be analyzed accurately. The pressure-volume technique originates from
large animal and human studies, but has recently been miniaturized and made available for mouse
studies. (123) Pressure-volume assessment protocols have been developed (125) and
hemodynamic studies have been successfully performed in genetically engineered mice. (10,126)
The use of MRI in mice is another relatively new concept in the studies of murine
hemodynamics. (122) The noninvasive technique of MRI enables the investigator to study in vivo
murine cardiac metabolism, morphology, and function under (patho)physiological conditions  To
quantify left ventricular function high-resolution (HR) MRI is used. To date, MRI studies have
been successfully implemented in cardiac phenotyping. Evaluation of cardiac mass and function
in post-MI remodeling was performed by MRI studies in mice overexpressing the AT2 receptor.
(24) Serial MRI studies in transgenic mice overexpressing TNF-α demonstrated increased
ventricular mass and deteriorating cardiac function over time in this murine model of dilating
cardiomyopathy. (127)
To stress the importance of accurate phenotyping of cardiac performance in (genetically
altered) mice some relevant studies will be discussed in more detail. In accordance with the
general consensus hypertrophy is the increase in cardiac mass as a compensating mechanism to
withstand augmented hemodynamic stress. Cardiac hypertrophy can be defined as the increase in
myocardial mass in an effort to alleviate the elevation in wall stress according to LaPlace's
principle. Studies using a heart size-independent analysis for in vivo murine cardiac function
determination suggested that the development of cardiac hypertrophy is associated with a
heightened contractile state, perhaps as an early compensatory response to pressure overload.
(128) The systolic wall stress increases significantly in the early response to pressure-overload
concomitant with ejection fraction and fractional shortening attenuation. In time a gradual
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normalization of wall stress and cardiac performance is seen with serial measurements. (129)
Pharmacological inhibition of hypertrophic growth in pressure-overloaded mice showed
maintenance of normal LV size and systolic function, as measured by echocardiography, (130)
without reducing left ventricular wall stress. (131) Moreover, two genetically altered mouse
models (mice with myocardial expression of a carboxyl terminal peptide of G q [TgGqI] that
specifically inhibits Gq-mediated signaling and genetically altered mice that lack endogenous
norepinephrine and epinephrine created by disruption of the dopamine ß-hydroxylase gene [Dbh-/-
]) have a blunted hypertrophic response to pressure-overload and show inadequacy to normalize
the 2-fold increased wall stress. Despite the increase in wall stress cardiac function as measured
by serial echocardiography showed little deterioration in these pressure-overloaded genetic
mouse strains. (132) In contrast, wild-type mice with similar pressure overload showed a
significant increase in chamber dimensions and progressive deterioration in cardiac function.
These data suggest that under conditions of pressure overload, the development of cardiac
hypertrophy and normalization of wall stress may not be necessary to preserve cardiac function,
as previously hypothesized. The data suggest that cardiac hypertrophic growth is not mandatory
to maintain ventricular wall stress at normal levels, as augmented wall stress is not a predictor of
cardiac function decline.
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Conclusion
Genetic modification of murine DNA provides the possibility to elucidate the spectrum of
specific functions of a single molecule and its corresponding intracellular signaling pathways in
specific pathophysiological situations such as myocardial ischemia. Cardiac remodeling is
defined by the ischemia-induced structural and concomitantly functional alterations in the heart.
Murine models of I/R and MI mimic the pathophysiological changes observed in man. Cell death,
deposition of collagen and myocardial hypertrophy are the characteristics of cardiac remodeling
in man and mouse alike. The predominant factor in determining the severity of the resultant
cardiac phenotype is ventricular function (figure 4), which is best assessed by the use of in vivo
pressure-volume measurements in mice. The use of genetically modified murine models in
ischemia(-reperfusion) studies led to new knowledge about the molecular processes involved in
these processes. In spite of this, intracellular signaling is still a mystery as we lack the tools to
study several pathways simultaneously and maybe even more importantly the temporal changes
in signaling cascade interactions.
Chapter 1. Transgenic mice and cardiac remodeling
32
Fig. 4: The development of adverse cardiac remodeling in human heart disease. Presented is a
scheme of deteriorating cardiac function, mediated by the characteristics of cardiac remodeling.
Cardiac remodeling is initiated by several pathophysiological situations such as myocardial
ischemia. Activated molecular pathways and newly expressed gene transcription profiles are the
basis of cellular, histological and morphological alterations leading to the development of clinical
heart disease.
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Abstract
The implementation of molecular biological approaches has led to the discovery of single
genetic variations that contribute to the development of cardiac failure. In the present review
characteristics that are invariably associated with the development of failure in experimental
animals and clinical studies are discussed, which may provide attractive biological targets in
the treatment of human heart failure. Findings from the Framingham studies have provided
evidence that the presence of left ventricular hypertrophy is the main risk factor for
subsequent development of heart failure in man. Conventional views identify myocardial
hypertrophy as a compensatory response to increased workload, prone to evoke disease.
Recent findings in genetic models of myocardial hypertrophy and human studies have
provided the molecular basis for a novel concept, which favors the existence of either
compensatory or maladaptive forms of hypertrophy, of which only the latter leads the way to
cardiac failure. Furthermore, the concept that hypertrophy compensates for augmented wall
stress is probably outdated. Here we provide the molecular pathways that can distinguish
beneficial from maladaptive hypertrophy.
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Introduction
Heart failure is associated with high morbidity and mortality rates in modern Western
societies and can be viewed upon as the end-stage form of various forms of heart disease.(1)
The prognosis for patients with heart failure is poor and is in fact even worse than the survival
chances in patients suffering from various malignancies.(2,3) In community studies, the
annual mortality was found to be 10-20% in patients with mild-moderate symptoms requiring
hospital admission and this figure can be as high as 40-60% in patients with severe heart
failure.(4) The single most powerful predictor for the development of heart failure is the
presence of left ventricular hypertrophy.(5) For this reason, much effort is currently
undertaken to investigate the etiology of hypertrophic mechanisms and to unravel the
molecular pathways underlying this affliction. These efforts are part of an ongoing search to
find novel treatment modalities to prevent or even reverse human heart failure. Heart failure is
one of the most challenging diseases of the future due to the heterogeneous cardiac response
especially in its final stages. In addition, it is still under-represented in the public and political
attention.
A powerful tool in the hands of cardiovascular researchers is the implementation of
molecular biological approaches to investigate the role of single modifier genes on the
development of cardiac disease. Accordingly, the number of transgenic and knockout models
of hypertrophy and failure has grown exponentially in recent years, and this has provided us
with novel genetic cues about the human etiology of this affliction. The aim of the present
review is to give a brief summary of the current status of our knowledge on cardiac
hypertrophy and failure and to discuss novel biological targets that have been demonstrated to
be critical in the development of the disease in genetic models. These targets may become key
players in future treatment of human heart failure.
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Fig. 1: Percentages of risk-factors for male and female patients for the development of
subsequent heart failure. The pie-diagrams are representative for Dutch males and females
with a mean age of 69 years. The percentages of risk-factors are rather similar distributed
between sexes, the percentage myocardial infarctions being the only significant difference
between males and females. High blood pressure is the far most common risk factor for
developing heart failure. (With permission derived from Mosterd et al. Prevalence of heart
failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur
Heart J 1999;20(6):447-55).
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Heart failure
Heart failure in humans is characterized by low cardiac output due to systolic and/or
diastolic dysfunction.(6) When depending on increased ventricular performance, for example
during physical exercise, heart failure patients typically present with acute symptoms of
clinical cardiac failure, e.g. fatigue, dyspnea and sometimes anginal pain, and palpitations
(Table 1). For the diagnosis of heart failure the clinical criteria from the European Society of
Cardiology are being used.(7) The diagnosis heart failure is made confidently in the presence
of multiple symptoms and signs, combined with objective evidence of cardiac dysfunction,
usually through echocardiography (Table 1). Echocardiography is essential for both systolic
and diastolic failure.(6) In cases where the diagnosis is in doubt, the diagnosis can be stated
by an additional positive response to treatment directed towards heart failure. The degree of
cardiovascular disability is distinguished by The New York Heart Association Functional
Classification (class I–IV) or the classification of symptoms in mild, moderate and severe.
Both represent the degree of functional impairment in these patients.
Table 1. Criteria for diagnosing human heart failure
1.
Symptoms of heart failure
(at rest or during exercise)
Symptoms
• breathlessness
• ankle swelling
• fatigue
Signs
• displaced heart beat
• pitting edema
• raised venous pressure
• third heart sound
DIAGNOSTIC CRITERIA
2.
Objective evidence of cardiac dysfunction
(at rest)
3.
Response to treatment directed towards heart failure
The clinical criteria for the
diagnosis of heart failure are divided
into three parts: (1) the presence of
symptoms of heart failure; (2)
evidence of cardiac dysfunction as
measured by echocardiography; (3) in
case of doubt of the diagnosis, a
positive response towards heart
failure treatment. Patients are subject
to heart failure, when at least criteria
1 and 2 are evidently present.
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From a clinical point of view three broad categories of heart failure have been
proposed (see table 1). In this view, heart failure can originate from (1) increased
hemodynamic burden, by far the most common cause; (2) inherited mutations in genes
encoding structural components which affect contraction and relaxation, and (3) precipitating
causes initiating episodes of clinical heart failure.(8) A general misconception states that
ischemic heart disease (e.g. acute myocardial infarction (MI) or coronary artery disease) is the
most common underlying and precipitating cause of heart failure in prevalence. Instead, heart
failure in Western societies most often results from progressive hypertensive heart disease
(Figure 1).(1) Patients who survived MI have, however, a significant higher relative risk to
develop subsequent heart failure than patients with any other cardiac disease.(1-3,5)
Multiple studies have described the contribution of several characteristic changes that
are encountered in the end-stage failing heart, which distinguishes it from the non-diseased
state. The best documented characteristics on the intracellular, stromal or organ level are (1) a
genetic reprogramming which resembles the genetic expression profile of the fetal heart;
differing degrees of cardiomyocyte hypertrophy and concomitant activation of intracellular
signaling molecules; mitochondrial dysfunction; alterations at the level of the sarcomeric and
cytoskeletal architecture; aberrant intracellular calcium handling; unfavorable myofibrillar
architecture; (2) increased vulnerability or presence of necrotic or programmed cell death;
excess extracellular matrix formation; (3) a reduction of organ capillarisation and presence of
regional ischemia; evidence of systemic and myocardial (neuro)humoral stimulation;
vulnerability to (supra)ventricular dysrhythmias, and, most notably, hemodynamic
dysfunction at the systolic and/or diastolic level. Although each of these characteristic
alterations appear to form independent entities, presence of any of the above mentioned
characteristics is sufficient, at least in experimental models, to set in motion a sequence of
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events invariably resulting in organ failure, characterized by a phenotype encompassing some
or even all of the above abnormalities.
Table 2. Characteristics of cardiac hypertrophy in transition to failure
Morphology
Heart weight/body weight
Concentric hypertrophy
Eccentric hypertrophy
↑
Pronounced increase wall thickness
Pronounced ventricular dilation
Histology
Apoptosis
Necrosis
Fibrosis
Thrombosis
↑
↑
↑
↑
Cellular
Myocyte hypertrophy
Protein synthesis
ANF excretion
Gene-expression
  c-Fos
  c-Jun
  c-Myc
  ANF
  BNP
  β-MHC
  α-skeletal actin
  MLC-2a
Calcium handling
↑
↑
↑
↑
↑
↑
↑
↑
↑
↑
↓
Cardiac function
Systolic function
End-systolic pressure
Diastolic function
End-diastolic pressure
Contractility
Relaxation
β-Adrenergic response
Arrhythmias
↓
↓
↓
↑
↓
↓
↓
↑
Signaling pathways
MAPK:
  ERK 1/2
  JNK
  p38
Concentric hypertrophy
Eccentric hypertrophy; severe dilation
Eccentric hypertrophy; severe dilation
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  JAK/STAT
  CaMK/calcineurin
Concentric hypertrophy; compensating
Cardiac hypertrophy and heart failure
Distinctive features are detected in the transition towards heart failure. Histologic analyses
proved increase of apoptosis, necrosis, fibrosis and thrombosis. At the cellular level, well-
known hypertrophic markers remain elevated or increase, while the cellular calcium handling
attenuates in efficiency. All these features have their effects on cardiac function, such as
decreased contractility and relaxation, elevated end-diastolic pressure and arrhythmias.
Animal research led to the discovery of several possible causative cellular signaling pathways,
such as MAPK, JAK/STAT and CaMK/Calcineurin pathways.
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Hypertrophy
Current conceptualization states that the heart is able to augment output in the face of
increased hemodynamic demands by means of growth of cardiomyocytes. In that view,
cardiac hypertrophy can be defined as the increase in myocardial mass in an effort to alleviate
the elevation in wall stress according to LaPlace's principle (Figure 2).(9) To execute this
response, the myocardium is equipped with a host of conserved neurohumoral and
intracellular reactive cascade systems. Since the proliferative capacity of the cardiac myocyte
is absent or at best limited, the heart reduces wall stress by myocyte growth (hypertrophy),
during which process the nucleus of human cardiomyocytes undergoes polyploidy.(10,11)
The diploid set (2c) of the myocyte proliferates during this growth process to tetraploid (4c),
octoploid (8c) sets of chromosomes, or even more. The polyploidization probably enables the
cardiomyocyte to hypertrophy without losing its normal cell volume/DNA content ratio, but
the functional significance of this adaptation still remains obscure. The myocardial cell types
that do respond with proliferation (hyperplasia) in response to mitogenic stimuli, are non-
muscle cells, most notably fibroblasts, and this event does not lead to the required reduction
of wall stress.
Normal Concentric hypertrophy Eccentric hypertrophy
a b
CWS = σ = (P x b)/h x (1 – h/2b) (1 – hb/2a2)
h σ ~ σ ?
A. B. C.
P
Figure 2
Chapter 2.  Molecular aspects of cardiac failure
10
Fig. 2: Morphology of the left ventricle: differences between normal and hypertrophic hearts.
The schematic presentation of concentric and eccentric hypertrophy clearly shows the
morphologic features, which generally are detected during echocardiographic analysis. A.
Also depicted are the elements which determine circumferential wall stress (CWS) in the left
ventricle, the strongest force generated within the ventricular wall. P indicates intraventricular
pressure, a and b are the major and minor semiaxes and h is left ventricular wall thickness.
These assumptions are only correct in those situations where left ventricular function is
relatively uniform. B. Wall stress (σ) increases at any LV radius when LV pressure (e.g.
afterload) rises, for example in case of systemic hypertension or aortic stenosis. Hypertrophy
is thought to balance the augmented pressure by increasing wall thickness. C. In dilated
cardiomyopathy the enlarged ventricular diameter results in a greater wall stress.
Data derived from mouse studies, however, cast doubt on the idea that a reduction of
wall stress is required for preserving hemodynamic functioning during the development of
hypertrophy.(12) In gene-targeted mice, where Gq signaling pathway is genetically blocked,
with blunted hypertrophy after experimentally pressure-overload, maintenance of cardiac
function was observed, despite an inadequate normalization of left ventricular wall stress. The
mice with blunted hypertrophy fared better than their wild-type littermates in response to
long-term load, as shown by the absence of progressive LV dilatation and dysfunction on
serial echocardiography. (12) The observation underscores the importance of preventing or
inhibiting hypertrophic growth in the human heart as ventricular hypertrophy is proven to be a
risk factor for cardiovascular mortality in humans. (13) Not only leads hypertrophic growth of
the heart in time to increased morbidity and mortality, also the early correction of wall stress
seems unnecessary to maintain cardiac function on the long-term. Thereby, a commonly
accepted hypothesis should probably be reconsidered.
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Defined extrinsic hypertrophic stimuli consist of conditions of increased resistance to
left ventricular afterload, resulting from outflow obstructions such as aortic stenosis and
systemic hypertension. These conditions produce a state of pressure-overload. The
morphological adaptation to pressure-overload consists of concentric hypertrophy,
characterized by thickening of the myocardial walls without a significant LV lumen dilation
(Figure 2). Other defined extrinsic stimuli include volume-overload, which occurs in the
clinical setting of aortic valve regurgitation, mitral valve regurgitation, anemia or other
situations in which cardiac output is increased at normotensive pressures. Volume-overload
specifically leads to eccentric hypertrophy defined by thickening of the free walls in
conjunction with LV cavity diameter increase.(14) Ischemia, myocardial infarction and
episodes of atrial fibrillation also act as extrinsic hypertrophic stimuli.
Intrinsic stimuli involve genetic abnormalities (mutations) in sarcomeric motor protein
genes or in genes that encode components of the cytoskeletal architecture and metabolic
(mitochondrial) disorders.(5,15) Genetic mutations in sarcomeric proteins are the basis of
congenital human heart disease such as hypertrophic cardiomyopathy (HCM), with a
prevalence of 1 in 500 patients.(5,16) Characteristic myocardial changes in HCM include a
non-dilated left ventricular chamber with thickened walls, reminiscent of a concentric
hypertrophy.(5) HCM is a Mendelian trait with an autosomal dominant pattern of
inheritance.(5) Currently, mutations have been found in the human genes coding for β-myosin
heavy chain, cardiac troponin T, α-tropomyosin, myosin-binding protein C, myosin light
chain 1 and 2, cardiac α-actin genes, titin and mitochondrial DNA.(5,17-19) Mutated
cytoskeletal genes are not able to handle the mechanical workload that is required, causing
mechanical dysfunction of myocytes, thus provoking a hypertrophic response.
During both pressure and volume overload defined systemic and local neurohumoral
changes take place. The best characterized example is the renin-angiotensin-aldosteron system
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(RAAS). Rise of systemic and myocardial angiotensin II (Ang II), acting through the
angotensin (AT)-1 and AT-2 receptors, promotes fibroblast proliferation and collagen
production which is usually extensive enough to produce macroscopically visible fibrosis that
contribute to increased left ventricular stiffness and reduced compliance.(20) Independent of
the systemic influences on vascular resistance and cardiac afterload, Ang II is prominently
involved in promoting cardiomyocyte hypertrophy.(20-25) Endothelin-1 (ET-1) is another
humoral factor with systemic and local actions sufficient to induce a hypertrophic response in
cardiomyocytes.(23) ET-1 has been proven to be a local contributor to pressure-overload or
mechanical-stretch induced hypertrophy.(20,26,27) Finally, sympathetic activation is thought
to be the cause of β-adrenergic desensitization in heart failure, a consequence of
downregulation of β1-receptors and uncoupling of the β2-receptors.(28) The downregulation
and desensitization of β-adrenergic receptors is more prominent in failing then in
hypertrophied myocardium.(29) This uncoupling is thought to be caused by increased activity
of a β-adrenergic receptor kinase (βARK) and an increase in inhibitory G-protein alpha
subunits (Giα) which depress adenylyl cyclase activity.(30) The attenuation in adenylyl
cyclase activity is thought to be a causal link in the transition from cardiac hypertrophy to
cardiac failure.(29,31)
ACE-inhibition is currently accepted as a valuable therapeutic approach in the
management of heart failure.(32) Specific AT-1 antagonists overcome the potential limitations
of the use of ACE-inhibitors, such as insufficient suppression of tissue ANG II production and
bradykinin-related side effects.(33)
Numerous animal studies and clinical trials have convincingly demonstrated that beta-
blockade improves functional capacity, ventricular function and decreases mortality in
patients with heart failure of various etiologies. Amongst the effects of bèta-blockers are
improvement in function of failing myocardium, decrease in dilation and hypertrophy, and
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reduction in LV wall stress. Recent evidence indicates that beta-blockers can also inhibit the
RAAS and in this role limit progressive chamber stiffening, thereby attenuating chamber
remodeling and diastolic dysfunction in heart failure.(34)
Controversy exists as to whether LV hypertrophy should be considered either as a
pathological condition that invariably evokes disease by transforming in failure, or as
fundamentally different forms of cardiomyocyte growth exist. For example, a profound
increase in myocardial mass is observed shortly after birth due to hemodynamic demands on
the neonatal heart. Also, increased demands for cardiac work e.g. during athletic exercise or
during pregnancy evokes a considerable hypertrophic response, which is not associated with
risk for the development of decompensation and failure. In view of recent experimental
observations and the distinctive phenotypic observations in humans, we rather favor a
distinction between compensatory versus maladaptive forms of hypertrophy (Table 2). Since
the morphological and hemodynamic characteristics associated with beneficial hypertrophic
growth are fundamentally different from those following hypertension or MI, it seems feasible
to reason that fundamentally different molecular programs underlie beneficial and
maladaptive hypertrophy. In our view, maladaptive hypertrophy is invariably associated with
activation of a molecular program involving persistent activation of unfavorable intracellular
signaling modules, an increased rate of cardiomyocyte apoptosis, profound extracellular
matrix deposition leading to reduced diastolic compliance and aberrant intracellular Ca2+
handling. In the following sections these aspects are further delineated.
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Current molecular investigations
In recent years, much research has focused on the identification of intracellular
signaling cascades which mediate extrinsic and intrinsic growth signals into co-ordinated
alterations of genetic profiles. In addition to causing changes in gene expression, hypertrophic
stimuli increase the overall rate of RNA transcription and protein synthesis, both leading to
hypertrophic growth of cardiomyocytes. In the transition from compensating to
decompensating hypertrophy several intracellular molecules have found to be up- or down-
regulated and therefore thought to be mediators of this pathologic process. Preventing the
development of maladaptive hypertrophy is the ultimate goal of research into these molecules.
Hypertrophy is initiated and maintained in vitro and in vivo by several factors, such as
vasoactive peptides, peptide growth factors, hormones and neurotransmitters (i.e. ET-1, α1-
adrenergic agonists, Ang II, fibroblast growth factors (FGF), insulin-like growth factor (IGF)-
1 and cardiotrophin (CT)-1).(24,35-43) Estrogens on the other side are believed to have
hypertrophy reducing effects(44-48), which are probably mediated via increased atrial
natriuretic factor (ANF) expression. (49) The hypertrophic factors stimulate intracellular
signaling cascades which initiate a hypertrophic, fetal-like gene-program. In pathological
conditions ANF is produced by ventricular cells as part of the newly expressed ventricular
fetal gene-program. The effect of ANF on blood pressure, but also direct cellular effects could
explain the beneficial aspects of ANF. (49,50)
Most of the agonists bind to G protein coupled receptors, from which Gq/Gll and Gi/Go
are involved in the hypertrophic response.(51-53) Protein kinases (PKs) are located
downstream from these receptors, from which protein kinase C (PKC) is strongly implicated
in hypertrophic signaling.(35,54) The small GTP binding proteins (Ras and Rho families) play
important roles in the hypertrophic response through mediating the activation of the mitogen-
activated protein kinase (MAPK) superfamily cascades following PKC activation.(55,56)
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MAPKs are a widely distributed group of enzymes ending in three terminal MAPK branches
[p38-MAPKs, the extracellular signal-regulated kinases (ERKs), c-Jun NH(2)-terminal
kinases (JNKs). Figure 3]. The family of MAPKs has been shown to play causal roles in the
development of cardiac hypertrophy and the transition towards heart failure.(54,57-59)
Differential activation of single terminal branches of the MAPK families results in specific
cardiac morphologic and functional phenotypes.(57) (60) For example, ERK1/2 MAPK
activation leads to a concentric form of hypertrophy with enhanced cardiac function.(57) In
contrast single activation of ERK5 MAPK leads to eccentric cardiac hypertrophy and rapid
transition towards heart failure.(60) Furthermore, p38-MAPK and JNK activation lead to
maladaptive hypertrophy.(61-65) Like ERK1/2 overexpression, another example of beneficial
hypertrophic phenotypic alterations is observed upon activation of the phosphoinositide 3-
kinase (PI3K), which lies downstream of many receptor tyrosine kinases. Furthermore, recent
studies have indicated that pathways employing the gp130 receptor might be of benefit to the
heart. Well-known intracellular mediators of gp130 signaling include the family of Janus
Kinase (JAK), which activate the family of the Signal Transducer and Activator of
Transcription (STAT) proteins. The JAK/STAT pathway, which is activated by CT-1,
leukemia inhibitory factor (LIF) and Angiotensin II, is implicated in the hypertrophic
response, but its role is still obscure.(66-68)
MEK1/MEK2
ERK1/2
Stress, growth and differentiation factors
MKK7/MKK4
JNK
MKK3/MKK6
p38
(MAPKKs)
(MAPKs)
Extracellular
Intracellular
Nucleus
(co-)transcription factors
Gene-regulation
Figure 3
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Fig. 3: Simple presentation of the three kinase modules and MAPK subfamilies. The mitogen-
activated protein kinase (MAPK) pathways consist of three separate terminal branches: the
extracellular signal-regulated kinases\ (ERK), c-Jun NH(2)-terminal kinases (JNKs) and the
p38 MAPK pathways. These translocate to the nucleus after activation and set gene
transcription. The MAPKs are activated by MAPK kinases (MAPKKs) upon extracellular
stimulation. The MAPKK differ per kinase module. MEK1 and MEK2 MAPKKs activate
ERK MAPKs; MKK7 and MKK4 activate JNK and MMK3/MKK6 are upstream of p38
MAPKs.
Because of these findings, it has been hypothesized that specific intracellular protein
activation programs lead to specific cardiac phenotypes. Similar results are presented in
human studies.(65) For example, involving the MAPK-family, the activation of JNK and p38-
MAPKs is augmented in failing human hearts, while ERK activation remains on a physiologic
level. This finding indicates an association between p38-MAPK, JNKs and a failing cardiac
phenotype in human. Further understanding of the mechanisms, through which differential
activation of MAPKs may lead to distinctive cardiac phenotypes, is essential for future
clinical therapy.
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Intracellular calcium handling
Intracellular Ca2+ concentrations and handling are also involved in the hypertrophic
response. The Ca2+/calmodulin-dependent protein kinase II and the Ca2+/calmodulin-
dependent protein phosphatase (calcineurin), from which the activity is Ca2+ dependent, are
involved in the cardiac hypertrophic response.(69-74) Activated calcineurin promotes the
dephosphorylation of the transcription factor NF-AT3, which sequentially migrates into the
nucleus and interacts with the transcription factor GATA4 to induce hypertrophic gene-
program expression.
Fig. 4 The β-adrenergic pathway leading to SR Ca2+ uptake. Following β-adrenergic
stimulation of the adrenergic G-protein, coupled receptors the Gsα- and Gsβγ-subunits detach
from each other. The Gsα-subunit stimulates the membrane bound adenylcyclase to form
cyclic AMP (cAMP) from ATP. The cAMP stimulates protein kinase A (PKA) to
dephosphorylate the phospholamban protein (PLB) attached to the sarcoplasmic reticulum
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Ca2+-ATPase (SERCA). Upon dephosphorylation PLB looses its ability to bind SERCA.
SERCA, without the PLB binding, increases actively the sarcoplasmic reticulum Ca2+-uptake,
which directly increases relaxation and indirectly increases contractility.
In pressure-overload ventricular hypertrophy, after the early-response phase, a
reduction in the expression of sarcoplasmatic reticulum Ca2+ ATPase (SERCA) mRNA and
protein were shown (Figure 4).(75-81) This seems in contradiction with the situation in the
early-response phase. During the catecholamine mediated early-response phase the up-
regulation of SERCA is needed to maintain cardiac output. The assumption is that when
increased amounts of sarcomeric proteins start to stabilize cardiac function, SERCA is
downregulated. Within 72-96 hours the SERCA-levels already return to base-line and they
will decline even further in the progress of the hypertrophic process.(82) The consequence is a
downregulated sarcoplasmic reticulum calcium uptake in the hypertrophic cardiomyocyte,
resulting in a smaller amplitude and slower decline of the cellular [Ca2+]i transient.(75-81) In
dilated and failing human hearts, no differences in protein levels of SERCA, phospholamban
and calsequestrin have been detected compared to non-failing controls.(83-87) Although no
reduction in protein levels was detected, there were alterations found in the calcium handling,
i.e. an attenuation in the sensitivity of SERCA develops.(87) A possible explanation for the
alterations in calcium handling is provided by the phospholamban-sarcoplasmic reticulum
calcium pump interaction.(59,88-92) The protein phospholamban is the inhibitor of SERCA
in the reticular membrane.(93-99) SERCA functions at the end of contraction of the heart. It
pumps calcium out of the cytosol into the sarcoplasmic reticulum. During contraction
phospholamban is bound to SERCA thereby decreasing the SERCA affinity for Ca2+.(93) In
this manner phospholamban inhibits the function of SERCA. It is also possible to improve
cardiac function by inhibiting phospholamban interaction with SERCA.(98) An alternative
mechanism was proposed by Esposito et al(59), stating that the calcium homeostasis in the
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myocytes of diseased murine hearts is altered, leading to decreased intracellular [Ca2+]
transients and contractile responses caused by a dysfunctional excitation-contraction coupling,
identified as a decreased sensitivity of the SR Ca2+ release mechanism to triggering Ca2+. The
question remains, which molecular process essential is in the transition from hypertrophy to
failure. Nevertheless, the importance of the intracellular calcium milieu has been proven
unequivocally.
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Apoptosis
The programmed cell death process (apoptosis) can be divided in several biochemical
and morphological distinct phases.(100) In the initiation phase pro-apoptotic stimuli trigger
the onset of molecular changes leading to apoptosis. The apoptotic process is working on its
full capacity during the effector phase, in which nucleic degradation takes place. In the
degradation phase the hallmarks of apoptosis, such as membrane markers and morphologic
changes, become evident. However, the point of no return occurs several hours before the
appearance of the morphologic features.(101) Some morphologic features are the shrinkage of
the cell at the onset of apoptosis accompanied by nuclear chromatin condensation. The
nucleus eventually breaks up, a process called karyorrhexis. The apoptotic cell detaches from
neighboring cells and surrounding extracellular matrix and forms extensions on its membrane.
The extensions detach from the apoptotic cell (i.e. budding) and form apoptotic bodies. The
bodies are rapidly phagocytosed by all sorts of neighboring cells without associated
inflammation, which could be the consequence of releasing intracellular contents in cardiac
tissue.
The chronic exposure to catecholamines can exert a toxic effect on the myocardium,
by increasing the number of apoptotic myocytes mediated by the beta1-adrenergic receptor.
Furthermore, angiotensin II type 1 receptor pathways, nitric oxide and natriuretic peptides are
involved in the induction of apoptosis in these cells, while alpha1- and beta2- adrenergic
receptors, endothelin-1 receptor type A pathways and gp130- activating cytokines are anti-
apoptotic. The myocardial protection of the latter is mediated, at least in part, through MAPK-
dependent pathways (especially ERK MAPK), compatible with the findings in other cell
types.(57,102,103) In contrast, in some cases signaling pathways leading to apoptosis in
cardiac myocytes are distinct from those in other cell types. The cAMP/PKA pathway induces
apoptosis in cardiac myocytes and blocks apoptosis in other cell types. The p300 protein, a
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co-activator of p53, mediates apoptosis in fibroblasts, but appears to play a protective role in
differentiated cardiac myocytes.(104)
Fig. 5: Apoptosis pathways in cardiomyocytes. Several pathways leading to apoptosis have
been identified in cardiomyocytes. Cell shrinkage, membrane blebbing and DNA degradation
are followed upon stimulation by death receptors, for instance Fas-receptors, or mitochondrial
proteins, such as cytochrome-C and apoptosis inducing factor (AIF). Fas-receptor activation
leading to caspase 8 activation which induces the translation of procaspase-3 to caspase-3, the
critical caspase. Caspase can also be activated by cytochrome-C. Cytochrome C is normally
present in the outerlayer of the mitochondrial membranes in an inactive state. Upon
stimulation it travels through protein-pores into the sarcoplasm and simultaneously gets
activated. In the sarcoplasm cytochrome-C induces the activation of caspase-3, while AIF
directly translocates to the nucleus and degradates the present DNA.
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Initiation of apoptosis is associated with activation of different cascades, including the release
of cytochrome C and the apoptosis inducing factor (AIF) from mitochondria into the
cytoplasm and the processing of proteolytic caspases.(105-108) The activation of the caspases
leads to fragmentation of various proteins, including cytoplasmic structural proteins,
contractile proteins, proteins at the cell-to-cell and cell-to-matrix attachment sites and nuclear
envelope proteins. At this time-point apoptotic cells can be visualized by labeled Annexin-V
in vivo.(109,110) AIF, in contrast, translocates to the nucleus and initiates the fragmentation
of nuclear DNA. This process results in the cleavage of chromatin into oligonucleosome-
length DNA fragments, which is supported by endogenous DNA caspases, DNases like DNA
fragmentation factor (DFF40) and caspase activated DNase (CAD). Caspases are cysteine
proteases that cleave their substrate proteins specifically behind an aspartate residue.(111)
They are formed constitutively in the non-apoptotic cell and remain inactive by dimerization
with inhibitory proteins DFF45 and Inhibitor of CAD until stimulation by one of two major
pathways. The first pathway is initiated by ligation of the death receptors, Fas and TNF
receptors.(112) The mitochondrial pathway is the other and integrates apoptotic signals. This
pathway is regulated by the Bcl-2 protein family.(113,114) When the mitochondrial pathway
is activated permeability transition associated pores in the outermembrane of the mitochondria
are opened, and this enables cytochrome C and AIF to be released from the mitochondrial
transmembrane space.(115,116) In its turn cytochrome C activates apoptosis protease-
activating factor (Apaf-1) and dATP, which lead to caspase activation. DNases cut the
internucleosomal regions into double-stranded DNA fragments of 180-200 base pairs
(bp).(100,117,118) This DNA fragmentation can be demonstrated by a characteristic
laddering pattern on DNA agarose gel electrophoresis (DNA laddering) and terminal
deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) assay. Formation of
Chapter 2.  Molecular aspects of cardiac failure
23
large size (50-300 Kilobp) DNA fragments precedes internucleosomal fragmentation, which is
dependent of AIF activity (Figure 5).(106-108)
Apoptosis plays a role in the pathophysiology of several cardiac diseases such as
maladaptive hypertrophy and heart failure.(105,119,120) Apoptosis is found to be increased in
the remote myocardium after MI in animals and humans. Also, significantly more apoptotic
cells are found in end-stage cardiomyopathy compared to control hearts. It has been proposed
that ventricular dilatation and neurohumoral activation during heart failure lead to
upregulation of transcription factors and prepare the cell for re-entry into the cell cycle, which
fails and induces apoptosis.(105) The functional relevance of apoptosis though, is still
obscure.
The question remains, if the frequency of apoptosis found in failing hearts is sufficient
to explain a deterioration of cardiac function. Moreover, the question remains if apoptosis
precedes the transition towards heart failure or only accompanies this process. Interpretation
of the rate of apoptosis in diseased hearts is hampered by the fact that the time course of the
apoptotic cascade in adult cardiomyocytes is unknown.(121) Results from animal studies
indicate tight regulation of the different steps of the apoptotic cascade, which are time-
dependent.(121) Furthermore, apoptosis seems to be a general muscular phenomenon.(122)
Myocyte apoptosis occurs also in the skeletal muscle of patients with chronic heart failure,
and its magnitude is associated with the severity of exercise capacity limitation and the degree
of muscle atrophy. Muscle atrophy contributes to the limitation of exercise capacity, together
with the increased synthesis of fast, more fatigable myosin heavy chains.(122)
If apoptosis accompanies heart failure and could lead to deterioration of cardiac
function, beneficial effects could be expected from blockade of the process. Although studies
in rats revealed a reduction of apoptosis after caspase blockade, the rate of necrosis
subsequently increased.(121) This suggests that the cells are destined to die once the caspases
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are activated, for example by mitochondrial damage. Blockade of apoptosis would therefore
not be beneficial, because necrosis is accompanied with secondary morbidity, i.e.
inflammation and extensive fibrosis.
Myocyte replacement could explain the discrepancy between extensive collagen
accumulation and the modest reduction in the number of ventricular myocytes and the
occasional detection of nuclear mitotic divisions in the pathologic heart.  These findings led to
the suggestion that myocytes are not terminally differentiated and cell proliferation may be
stimulated in cardiomyopathies. Recent data indicated an increase in myocytes in the diseased
and decompensated human heart by myocyte division.(123,124) Although these results appear
very convincing, many cardiovascular researchers remain skeptic towards the rate and
therefore the importance of cardiomyocyte division.
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Fibrosis
Extracellular fibrillar collagen functions as scaffolding tissue to maintain cardiac
structure and stiffness. An adverse accumulation of extracellular matrix structural protein
compromises tissue stiffness and adversely affects myocardial viscoelasticity.(125)
Accumulation of fibrillar collagen leads to diastolic and systolic ventricular dysfunction. The
increased amounts of myocardial fibrillar collagen in the setting of hypertrophy and heart
failure are accompanied by elevated levels of circulating Ang II and aldosteron.(125) There is
sufficient evidence for a major role of the RAAS-system with autocrine and paracrine actions
in the process mentioned. Augmented systemic and tissue angiotensin formation are observed
in hypertrophy and heart failure as already stated. These augmented hormone levels influence
the progressive nature of heart failure. Normal cardiac tissue contains mineralocorticoid
receptors (MR) and high affinity MRs are localized on cardiomyocytes.(126) High levels of
aldosterone promote accumulation of interstitial collagen in the heart. This process is
dependent on the salt status. (126) Aldosterone promotes the reabsorption of sodium in the
distal tubule of the nephrons, mostly in exchange for potassium and hydrogen excretion. The
secretion of aldosterone in response to Ang II is negatively controlled by salt-losing hormones
as atrial natriuretic peptide and dopamine. Also, the adrenal response is enhanced following
poor dietary sodium and potassium intake. The involvement of upregulated AT-1 receptors
for Ang II, which are targets for aldosterone, is proposed.(126,127) Ang II induces cardiac
fibroblast proliferation, synthesis and secretion of adhesion molecules and extracellular matrix
proteins, and expression of integrin adhesion receptors.(127,128) Ang II stimulates cardiac
fibroblasts also to adhere more vigorously to defined matrixes.(128) The ability of Ang II to
induce collagen synthesis may be mediated by increased TGF-β1 production, from which the
expression is markedly increased in infarcted hearts and has shown to induce myocardial
fibrosis.(127,129) Either type I or type II Ang II receptor antagonists or the competitive
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aldosterone antagonist spironolactone completely abolish the increased collagen deposition.
(130)
The increased cardiac fibrosis in heart failure is not related to the augmented rates of
apoptotic cell death, because dying myocytes are removed from neighboring cells in the
absence of an inflammatory reaction and responsive fibrosis.(131)
The maladaptive fibrosis could be the target of pharmacologic intervention. Such
cardioprotective strategies could be based on inhibiting the generation of these hormones or
interfering with their receptor-ligand binding.(125)
Arrhythmias are common in heart failure and related to extensive cardiac fibrosis. In
one half of heart failure patients tachyarrhythmias lead to sudden death.(132) Re-entrance
mechanisms around scar tissue, afterdepolarizations, and triggered activity due to changes in
calcium metabolism significantly contribute to the etiology of arrhythmias.(132)
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Conclusion
Causal factors for the transition from hypertrophy to heart failure are detected in animal and
human studies:1 the changes in cellular signaling molecules; 2 the increased degree of
myocyte apoptosis; 3 the accelerated deposition of collagen; 4 and arrhythmogenicity and the
alterations in intracellular calcium handling and excitation contraction coupling are all
contributing to this transition. However, the relative importance of the processes remains to be
resolved. Certain is their relevance for the transition form hypertrophy to failure and they
explain largely the distinction between beneficial and maladaptive hypertrophy. Contributors
to maladaptive hypertrophy lead to heart failure and eventually death. Our future challenge
will be to allow compensatory hypertrophy and block maladaptive processes in the human
heart.
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Abstract
Genetically engineered mice are used in experiments in cardiovascular research. The
in vivo assessment of cardiac performance demands accurate methods. Overall cardiac
performance can be acquired by simultaneous and continuous left ventricular pressure and
volume (PV) measurements through the use of an intraventricular 1.4 F ultraminiature
conductance-micromanometer catheter positioned in the left ventricular cavity of intact mice.
Cardiac performance is represented in the two-dimensional graph plotting pressure and
volume into PV-loops. PV-loops adequately represent cardiac function and provide load and
heart rate independent parameters of intrinsic myocardial contractility and relaxation. All
sorts of cardiopathological situations can be investigated thoroughly with the use of PV-
measurements.
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Introduction
The use of murine transgenic and gene-targeted models in the field of cardiovascular
research has shown an exponential growth, since this approach provides essential genetic and
molecular insight into human congenital and acquired heart disease. By manipulating and
investigating cardiac gene expression by means of accurate techniques to analyze the resultant
phenotype, the molecular basis for cardiac dysfunction may be uncovered.
To date, multiple techniques allow assessment of murine left ventricular hemodynamic
behavior(1,2), such as MRI (3), transthoracic ultrasonography (4), Langendorff perfusion
systems (5), aortic flow probes (6), micromanometers (7) and, more recently, conductance-
micromanometers (8). The use of conductance-micromanometers allows generation of
instantaneous pressure and volume signals to create pressure-volume (PV) relations for highly
accurate assessment of left ventricular performance. The PV-loop method is regarded as the
golden standard for assessment of intrinsic myocardial function in large animals (9) and
humans (10). Recently, the development of miniaturized PV-catheters has made this
methodology applicable to small animals such as mice. (8)
The method of PV-loop assessment will be discussed in the following paragraphs.
More detailed information about the acquisition of left ventricular volume will be provided,
and the concepts of parallel conductance and volume correction factors are introduced. The
surgical protocols for open-chest and closed-chest PV measurements and the difference in
cardiac performance between these two protocols are part of the discussion. How to read PV-
loops completes the chapter.
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Fig. 1: Presentation of the size of the Millar conductance-micromanometer. The catheter is
placed in the left ventricle from a longitudinal sliced murine heart. The tip of the catheter is
placed in the apex of the heart, while the proximal part runs through the aortic valves. From
top to bottom are seen two volume electrodes, the pressure sensor and at the bottom two
volume electrodes. An index finger indicates the miniature size of the catheter.
Figure 1
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The assessment of pressure-volume loops
  PV loops are obtained by the conductance-micromanometer, miniaturized for invasive
use in rodents (figure 1). (11) The volume-signal is derived in accordance with Ohm’s Law:
“The amount of current flowing in a circuit made up of pure resistances is directly
proportional to the electromotive forces impressed on the circuit and inversely proportional to
the total resistance of the circuit”. In the setting of a mouse heart is the circuit of pure
resistances an analogue for ventricular bloodvolume, the electromotive forces for the applied
voltage and the amount of current for plain current. Voltage and current are constant during
bloodvolume measurements in the heart. Bloodvolume itself, however, is not. It varies
according to the cardiac cycle. The varying ventricular bloodvolume of the mouse heart is
inversely proportional with the measured resistance/impedance. Or, ventricular bloodvolume
is direct proportional with the measured electrical conductance of the blood (figure 2).
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Figure 2
Chapter 3. Murine left ventricular pressure-volume loops  
6
Fig. 2: The concept of conductance derived left ventricular volume. Left ventricular
bloodvolume is linear proportional with the time-varying conductance signal, which correlates
with the level of resistance/impedance of the bloodvolume on the electric current produced by
the catheter. The conductance-catheter underestimates the volume-signal due to inhomogenity
of the electrical field. The slope factor α corrects for this underestimation. The offset volume
that arises from the protrusion of the electrical current in tissues besides blood (parallel
conductance), is corrected by the correction volume Vc.
The conductance catheter is equipped with four electrodes (figure 3): two current
electrodes and two sensor electrodes. The current electrodes produce an electric field with a
magnitude of 30 µA.
Fig. 3: Position of the conductance catheter in the left ventricle. The catheter is retrogradely
inserted in the left ventricle. The catheter consists of one pressure sensor and four volume
Figure 3
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electrodes: two current electrodes and two sensor electrodes. The height of the measured
volume segment depends on the distance between the sensing electrodes, i.e. 4.5 mm. The
mean length of the longitudinal axis of the heart from adult mice is approximately 4.9 mm.
CE indicates current electrode, SE sensing electrode and PS pressure sensor.
This specific current is chosen to prevent interaction with the murine endogenous
conduction system of the heart. The catheter measures conductance, which is translated into
left ventricular volume by a software program. Cycle-varying conductance correlates with
time-varying ventricular volume V(t) according to the following formula:
V(t) = ρ L2 [G(t) – Gp]
where ρ (rho) is the mouse specific blood resistivity, L indicates the distance between the
sensor electrodes (i.e. 4.5 mm), G(t) the instantaneous conductance and Gp parallel
conductance. The mouse specific blood resistance is determined using a Rho-cuvette, with a
length of 0.5 cm and a diameter of 0.2 cm resulting in a content of 150 µl. Gp is the offset in
the volume signal that originates from an additional conductance signal. Shortly, an electric
field broadens theoretically without end and protrudes through the ventricular wall into other
intrathoracic structures and organs. Therefore, the ventricular-derived conductance signal
originates partly from lungs, mediastinum, and most notably from the left ventricular
myocardium. All have a relative contribution to the addition in ventricular-derived
conductance signal. This offset-volume is referred to as the correction volume Vc (figure 2).
Several methods are used to acquire Gp and subsequent Vc. One method calculates Gp from
the differences between myocardial and blood conductances at catheter excitation frequencies
of 2 and 10 kHz. (12) The second method estimates Gp by exploiting the differential
frequency-induced conductivity of myocardium and blood. (13) In our experiments we used
the hypertonic saline injection (HSI) method. The method comprises of the infusion of 4 µl
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hypertonic (30% NaCl) saline solution into the external jugular vein (~ 15% of left ventricular
absolute end-diastolic volume). The saline mixes with the murine blood and increases
conductance of blood through its high content of electrolytes. The result is a volume increase
as shown by figure 4, a representative figure of a common HSI procedure. The amount of
saline infusion is limited to 4 µl to prevent hemodynamic changes due to the fluid injection.
As shown in figure 4 there is no influence on pressure. The correction volume Vc is derived
via computerized algorithms.
Fig. 4: Conductance and pressure signals during hypertonic saline injection. The total
acquired time period was 5.84 seconds. Ventilation was stopped at the mark (*), after which 4
µL of 30% saline was injected (arrow) into the external jugular vein. The conductivity of
blood was increased by the hypertonic saline infusion as demonstrated by the increase in the
conductance signal. Parallel conductance is calculated by analyzing the conductance signal
Vo
lu
m
e 
(R
VU
) Volume signal
30
35
40
45
50
Pressure signal
-20
0
20
40
60
80
100
Time (s)
*
Pr
es
su
re
 (m
m
Hg
)
Vo
lu
m
e 
(R
VU
)
Pr
es
su
re
 (m
m
Hg
)
Figure 4
Chapter 3. Murine left ventricular pressure-volume loops  
9
obtained during wash-in of the saline. The unchanged pressure indicates that hemodynamics
are stable.
In practice the conductance-catheter tends to constantly underestimate the left
ventricular bloodvolume. The slope factor α should be calculated to correct for this
discrepancy (figure 2). For this purpose an independent volume measurement is needed,
obtained in mice by blood flow measurements or echocardiography. The slope factor α then
follows from the ratio conductance volume/independent measured volume. Table 1 shows the
results of α determination by echocardiography. Slope factor α varied from 0.3 - 0.5,
depending on the moment of measurement within the cardiac cycle. The variance could be
due to the relative inaccuracy of ultrasonographic analyses. It could also be inherent to
conductance measurements in the manner as performed. Slope factor α deviates from 1
primarily due to the dependency of Gp on left ventricular volume. (14) Gp should therefore be
measured continuously within the cardiac cycle to be able to correct adequately for the
variance of α. However, as the result of technical limitations continuous Gp acquisition is not
yet possible. Whenever echocardiography is used, end-diastolic volume EDV should be used
for α determination. The variance of this calculated α is minor (SEM = 0.02) and the
correlation relatively high (adjusted R2 = 0.65).
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Surgical protocols for PV-loops acquisition
The Sigma SA (CDLeycom, Zoetermeer, the Netherlands) single segment data
acquisition module was used for assessment of PV-loops. The system operated on a constant
excitation current of 30µA to prevent interaction with the murine cardiac conduction system.
determined by hypertonic saline injection and subtracted offline. CONDUCT 2000 software
(CDLeycom, Zoetermeer, The Netherlands) was used for data acquisition and Circlab
software (LUMC, Leiden, The Netherlands) was used for offline data analysis.
Invasive hemodynamic measurements of the murine left ventricle can theoretically be
performed by several ways for. To date, the most frequently reported method is an open-chest
(OC) approach. (8) In brief, mice are anaesthetized and the anterior thorax and the neck of the
mouse are shaved. The animals are fixed on a warming plate. Care is taken to maintain body
temperature constant at 37° Celsius. The neck skin of the mouse is opened by a saggital
incision. The trachea is exposed to visually guide the intratracheal cannula (20-Gauge), where
after the cannula is connected to a mouse ventilator, Minivent type 845 (Hugo Sachs
Electronics, Germany), set at 150 strokes per minute and a tidal volume of 250 µl. The
external jugular veins are cannulated with a flame-stretched PE-50 catheter for infusion of
saline and drugs. The abdomen is opened subcostally. The diaphragm is incised by a
transverse substernal approach leaving the pericardium intact. The micromanometer is
calibrated with a mercury manometer by placing the sensor in 37° Celsius normal saline. The
left ventricle is entered through an apical stab with a 25 1/2 G needle, immediately followed
by the Millar conductance-micromanometer. The catheter is positioned correctly in the left
ventricle under guidance of the online pressure and volume signals. The combination of
pressure and volume signals allows accurate positioning of the catheter in the left ventricle.
Ventilation is stopped during data acquisition to avoid influence from ventilation of the lungs
on the pressure and volume signals. The acquisition protocol consists of measurements of
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baseline cardiac function, hypertonic saline injection (3x), inferior caval vein occlusions with
and without β-adrenergic stimulation (isoproterenol, 1000 pg).
This method is theoretically disadvantageous, since collaps of the lungs and
destruction of myocardial integrity are induced through the relatively large surgical trauma.
Furthermore, in myocardial infarction studies the open-chest approach is hampered by
extensive left ventricular remodeling, since the scar tissue is not accessible for the
conductance catheter and fails to provide a stable position.
A closed-chest (CC) approach would theoretically circumvent several of these
disadvantages. Firstly, in a closed-chest the lungs remain untouched. Secondly, the cardiac
position and myocardial structures remain intact. Thirdly, surgical trauma and hemodynamic
stress would be reduced to a minimum. Finally, a closed-chest approach would allow accurate
assessment of left ventricular (LV) hemodynamic behavior in mice which underwent transient
or permanent occlusion of the left anterior descending coronary artery. The surgical procedure
is similar to the open-chest approach, except for the insertion of the conductance catheter into
the left ventricle. In brief, mice are anaesthetized and the neck and abdomen are shaved. Care
is taken to maintain body temperature and ventilation support is provided as above. Venous
catheters are placed, after which the right common carotid is prepared for insertion of the
ultraminiature conductance-micromanometer. The catheter is calibrated and subsequently
inserted into the left ventricle under guidance of the online pressure signal. A transverse
abdominal incision without opening the thorax is performed to expose the inferior caval vein.
The acquisition protocol is similar as in the open-chest approach.
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Explanation of the pressure-volume loop
The left ventricular PV loop is a two-dimensional representation of a single cardiac
cycle (figure 5). Beginning at end-diastole, when the mitral valve closes, the ejection phase
starts with pressure build up without actual volume ejection, i.e. the isovolumic contraction
phase. Blood is ejected out of the ventricle into the aorta upon opening of the aortic valve and,
subsequently, left ventricular volume decreases. The end of ejection is defined by aortic valve
closure and followed by myocardial relaxation characterized by pressure decrease without
volume change, i.e. the isovolumic relaxation phase. The filling phase is initiated with
opening of the mitral valve and rise of ventricular volume. The technique of simultaneous left
ventricular pressure and volume measurements provides continuous assessment of cardiac
function.
Fig. 5: The cardiac cycle in a single pressure-volume loop. End-diastole is marked by the
closure of the mitral valves. The hearts starts to build up pressure while all valves are closed
(isovolumetric contraction phase), before actual ejection begins following the opening of the
aortic valve. Volume decreases while ejection progresses until the aortic valves close (end-
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systole) and relaxation starts. Aortic and mitral valves are closed during relaxation
(isovolumic relaxation phase). The filling phase follows upon the opening of the mitral valve
and volume increase while pressure build up is minor.
PV loops reveal in first instance the standard functional parameters (figure 6).
Fig. 6: Cardiac performance parameters in the pressure-volume loop. ED indicates end-
diastole; ES: end-systole; Ved: end-diastolic volume; Ves: end-systolic volume; Ped: end-
diastolic pressure; Pes: end-systolic pressure. The area of the PV loop resembles stroke work
(SW). Stroke volume SV can be derived by subtracting Ves from Ved.
However, specific PV relationships are acquired too (table 2, figure 7). These
relationships describe the contractile and relaxative capabilities of the heart independent of
preload, afterload or heart rate. Transient occlusion of the inferior caval vein in mice is
performed to obtain these relationships. Caval vein occlusion leads to a decrease in venous
return and thereby in preload of the left ventricle. The response of the heart is typical, as
Figure 6
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presented in figure 7, and shows the PV correlations. Contractile parameters derived from PV-
correlations best detect small alterations in contractility in mice. (15)
Fig. 7: Pressure-volume relationships. Variably loaded PV loops are used to define several PV
relationships. The variable loading is derived by occluding the inferior caval vein and thereby
reducing venous return. The end-systolic PV relationship (ESPVR) describes the contractile
performance of the left ventricle. Contractility is linear correlated with the steepness of the
ESPVR slope, i.e. Ees. The end-diastolic PV relationship (EDPVR) describes diastolic
performance, for instance diastolic distensibility. The slope of the EDPVR (β) indicates the
passive chamber stiffness.
The end-systolic PV relationship (ESPVR) describes the relation between volume and
pressure changes in systole. Within the physiological range, this relationship approximates a
straight line. The relationship can be described in terms of its slope, which reflects myocardial
contractility, and its volume axis intercept V0. The volume intercept from the ESPVR line
Figure 7
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could better be taken at a constant pressure level in the physiological range, for example
between 50 and 100 mm Hg. (16) The volume intercept at a constant pressure (e.g. V75)
reflects myocardial contractility as it indicates the extent of contraction. Increased myocardial
contractility, for instance during beta-adrenergic stimulation with isoprenaline, results in a
steeper ESPVR-slope and a leftward shift on the volume axis, while attenuated contractility,
for example during clinical heart failure, results in a concomitantly plain slope and a
rightward shift on the volume axis. The slope of the ESPVR (Ees) is used to describe the left
ventricular elastance. Arterial elastance (Ea), a measure for ventricular afterload, is described
by the slope of the relationship between stroke volume and end-systolic pressure (figure 8).
Fig. 8: Arterial-ventricular coupling. Ventricular elastance is estimated from the end-
systolic PV relationship (ESPVR) slope, Ees. Arterial elastance (Ea) is approximated by the
stroke volume/end-systolic pressure ratio (Ao Pes-SV relationship). The between Ea and Ees
reflects the coupling between the left ventricle and the arterial circulation. The production of
stroke work is maximal when the Ea and Ees are approximately equal.
Figure 8
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The production of stroke work is maximal when the Ees and Ea are approximately
equal. Stroke work attenuates substantially in relation to its maximal value, whenever Ea and
Ees differ markedly. (17,18) The preload-recruitable stroke work (PRSW) is the relationship
between end-diastolic volume and performed stroke work by the ventricle. It is a load-
independent measure of contractility related to preload. The contractile state of the heart is
resembled by the steepness of the PRSW-slope. In a high contractile state the heart is able to
perform more stroke work at a constant end-diastolic volume, for instance by augmenting the
ejection fraction.
Diastolic function is derived from the end-diastolic PV relationship (EDPVR), which
correlates with the compliance of the ventricular myocardium. Diastolic dysfunctioning or
failure is observed by an inappropriate upward shift of the ESPVR. The slope of the EDPVR
(β) increases during augmented stiffness of the ventricular wall, when pressure rises
progressively more during ventricular filling. The opposite occurs in case of increased
compliance. Certain cardiac diseases and remodeling processes are correlated with increased
stiffness of the ventricular wall by collagen deposition, resulting in an increase of the
EDPVR-slope. (19)
Numerous other relationships can be assessed. The limits are determined by the
interests and the creativity of the investigator.
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Results of PV-measurements with the open- (OC) and closed-chest (CC) approach
A comparative study was performed to determine scientifically based arguments for
the choice between open- (OC) or closed-chest (CC) PV measurements to examine murine
cardiac function. Comparing cardiac performance between OC and CC protocols revealed
overall relatively similar values for the investigated parameters (table 3). The values for LV
volumes were corrected for ρ, determined at 124 Ω·cm in the used setup (N = 10, 123.52 ±
0.88 Ω·cm), α (N = 13, 0.30) and Vc. Vc was determined during all PV experiments by the
hypertonic saline injection method. No significant differences could be detected between CC
and OC instrumentation (94.69 ± 4.83 µl versus 92.72 ± 2.05 µl, respectively; N.S.). The 4 µl
30% saline demonstrated to be sufficient to change blood conductivity. Moreover, as this
volume encompasses only 15% of the normal murine end-diastolic volume, it proved to be too
small to influence LV end-diastolic and end-systolic pressures (figure 4) in either OC or CC
mice.
Several differences were found between the OC and CC approaches (table 3). Cardiac
function in the OC approach was characterized by higher ejection fractions (EF 69 versus
48% respectively), larger stroke volume (19.98 versus 14.70 µl, respectively) and a leftward
shift in ventricular volume. On the contrary, measuring cardiac function with an intact thorax
resulted in higher end-systolic pressures (ESP OC 52 versus CC 65 mmHg, with urethane
anesthesia) and a higher rate of relaxation as indicated by the dP/dtmin. No differences were
found in the PV relationships, i.e. the ESPVR, EDPVR or PRSW. Interestingly, the OC
approach did result in a mismatch between arterial afterload and ventricular work. The
arterial-ventricular elastance ratio (Ea/Ees) was significantly depressed following opening of
the chest. In contrast, Ea/Ees ratios were normal (i.e. ~ 1.0) in the CC approach under both
regimens. This finding is consistently found in open-chest instrumented mice. (8) The arterial-
ventricular coupling mismatch was depending on arterial resistance: the slope of the ESPVR
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Table 1. Comparison of volume derived by ultrasonography and conductance.
                  Descriptive statistics of alpha
N Min Max Mean SEM
EDV 13 0.18 0.45 0.30 0.02
ESV 13 0.16 0.94 0.51 0.07
SV 13 0.09 0.58 0.26 0.04
                 Regression analysis
N
R
R2
Adjusted R2
SEE
EDV
13
0.82
0.68
0.65
1.79
ESV
13
0.83
0.69
0.66
1.72
SV
13
0.41
0.17
0.09
1.17
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Left ventricular volume was measured by both ultrasonography
and conductance in adult C57Bl/6 mice. End-diastolic, end-
systolic and stroke volume were used to obtain alpha (α).
Descriptive analysis shows that α determination at the end-
diastolic moment results in the most consistent mean α. Also,
the correlation of LV volume values between ultrasonography
and conductance is high, as shown by the regression analysis.
SEM indicates standard error of the mean; SEE standard error
of the estimate.
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Table 2. Parameters derived by pressure-volume loops
Abbreviations Definitions
General parameters
CI (CI = CO/body wt) 
CO 
HR
Card iac index
Card iac output
Heart rate
Pressure
dP/dtmax
dP/dtmin
Ped
Pes
τ
Maximum derivative of change in systolic pressure in 
time
Maximum derivative of change in diastolic pressure in 
time
End-diastolic pressure
End-systolic pressure
Time constant of isovolumic relaxation
Volume
EF
SI (SI = SV/body wt)
SV
Ved
Ves
Ejection fraction
Stroke index 
Stroke volume
End-diastolic pressure
End-systolic pressure
Pressure-volume relationships
β
Ea (Ea = Pes/SV)
EDPVR
Ees
Slope of the end-diastolic pressure-volume relat ionship
Arterial elastance
End-diastolic pressure-volume relat ionship
End-systolic ventricular elastance
Emax
ESPVR
(slope of the end-systolic pressure-volume 
relationship)
Maximum chamber elasticity (∆P/∆V)
End-systolic pressure-volume relat ionship
Pressure-volume area
Efficiency
EW
PE
PRSW
PVA
SW
SWI (SWI = SW/body wt)
EW/PVA
External work = SW
Potential energy
Preload-recruitable stroke work
Pressure-volume area = EW + PE
Stroke work
Stroke work index 
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(Ees) proved to be equal in OC and CC instrumented mice. The combination of enlarged
stroke volume with attenuated systolic pressures leads to a decrease in arterial elastance. The
altered arterial elastance could be explained by the opening of the thorax. A drop in overall
peripheral vascular resistance from baseline values has been described during thoracoscopy.
(20)
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Fig. 9: Left ventricular pressure-volume loops. Pressure presented in mmHg and volume µl.
A. Representative figure of PV loops acquired during urethane anesthesia in closed chest
(CC) and open chest (OC) instrumented mice. B. Representative figure of PV loops acquired
during pentobarbital anesthesia in CC and OC instrumented mice. Loops are acquired during
an occlusion of the inferior caval vein. Venous returns decreases, which is represented in the
loops by attenuation of both pressure and volume. The differences in ESP, SW and ESPVR
between urethane and pentobarbital anesthesia can be observed by analyzing the loops in A
and B. The loops show also the larger stroke volume and depressed systolic pressure in OC
instrumented mice.
Figure 9 shows representative PV-loops while venous return was attenuated following
inferior caval vein occlusion. Typical pressure and volume effects are depicted, showing the
absence of apparent differences in PV relationships. The mentioned differences in ESP, SV
and EF are evident in the presented loops, though.
ECG recordings were made during both surgical protocols to detect possible heart rate
alterations and arrhythmias. Murine left ventricular PV measurements could be distorted by
physiological responses to the catheterization. Heart rate alterations could be anticipated,
especially in relation to carotid sinus stimulation while cannulating of the carotid artery.
However, neither bradycardia nor other arrhythmias were observed during either CC or OC
procedures (figure 10). This finding indicates that cannulation of the right common carotid
artery does not alter heart rate by carotid sinus stimulation.
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Table 3. Functional parameters to determine baseline LV functioning in open- and closed-
chest protocols during steady-state measurement.
URETHANE PENTOBARBITAL
OC CC OC CC
N = 5 N = 5 N = 10 N = 10
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM
HR* 583 ± 20 658 ± 21 493 ± 25 481 ± 36
SV† 19.58 ± 3.51 15.57 ± 2.54 20.18 ± 1.83 14.26 ± 1.03
CO 12 ± 2 10 ± 2 10 ± 1 7 ± 0
Vmax*† 17.61 ± 0.53 23.61 ± 2.23 30.89 ± 2.89 38.83 ± 2.30
Vmin*† 2.15 ± 1.33 6.79 ± 1.80 10.29 ± 1.89 23.73 ± 1.99
EF*† 79 ± 6 66 ± 8 66 ± 4 39 ± 2
ESP*† 52 ± 4 65 ± 5 42 ± 3 47 ± 4
EDP* 1 ± 1 -1 ± 1 -6 ± 2 1 ± 1
dP/dtmax* 7200 ± 1349 8252 ± 1685 4004 ± 629 3718 ± 684
dP/dtmin*† -4233 ± 531 -7577 ± 750 -3631 ± 424 -3348 ± 653
Tau* 10 ± 0 7 ± 0 12 ± 1 14 ± 2
SW 1066 ± 245 1147 ± 213 1076 ± 176 666 ± 116
Ea/Ees† 0.65 ± 0.20 0.84 ± 0.16 0.60 ± 0.05 1.03 ± 0.15
ESPVR* 5.70 ± 0.94 5.89 ± 0.74 3.47 ± 0.27 3.18 ± 0.52
EDPVR 0.09 ± 0.09 -0.08 ± 0.15 -0.15 ± 0.14 -0.05 ± 0.15
PRSW 79 ± 14 64 ± 6 68 ± 10 53 ± 3
Results from LV pressure-volume measurements in C57Bl/6 mice anesthetized by urethane or
pentobarbital. * Urethane versus pentobarbital P < 0.05. † OC versus CC P < 0.05. ρ Valued
124 Ω·cm, α 0.30. Open- (OC) and closed-chest (CC) protocols. HR indicates heart rate in
bpm; SV left ventricular stroke volume in µl; CO cardiac output ml/min; Vmin minimal left
ventricular volume in µl; Vmax maximal left ventricular volume in µl; EF ejection fraction in
%; ESP left ventricular end-systolic pressure in mmHg; EDP left ventricular end-diastolic
pressure in mmHg; dP/dtmax maximal first derivative of left ventricular pressure in mmHg/s;
dP/dtmin minimal first derivative of left ventricular pressure in mmHg/s; Tau time constant of
left ventricular relaxation in ms; SW stroke work in mmHg·µl; Ea arterial elastance / Ees
ventricular end-systolic elastance; ESPVR left ventricular end-systolic PV relationship in
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mmHg/µl; EDPVR left ventricular end-diastolic PV relationship in mmHg/µl; PRSW left
ventricular preload-recruitable stroke work in mmHg.
The steady-state functional parameters from OC and CC instrumented mice during
either urethane or pentobarbital are also depicted in Table 2. The use of pentobarbital
anesthesia had a cardiodepressive effect that was represented by significant function decline
in most parameters. EF, dP/dtMAX and ESPVR decreased respectively with 24, 57 and 41%
upon pentobarbital use compared to urethane anesthesia. Pentobarbital, therefore, had strong
negative chronotropic and inotropic effects.
He
ar
tr
at
e
(b
pm
)
Heart rate trace in closed-chest animal
0
100
200
300
400
500
600
700
Time (minutes)
arterial canulation
A.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Heart rate trace in open-chest animal
0
100
200
300
400
500
600
700
Time (minutes)
He
ar
tr
at
e
(b
pm
)
Ventricular catheterisation
B.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Figure 10
Chapter 3. Murine left ventricular pressure-volume loops  
25
Fig. 10: Heart rate tracings in closed chest and open chest instrumented mice.
A. Representative figure of a heart rate tracing in a closed-chest instrumented mouse. The
moment of arterial cannulation is indicated. Some arrhythmias are seen in response to
introduction of the catheter into the left ventricle. Arrhythmias are only present in a short
time-period that is part of the stabilization period following catheter introduction. Heart rate
remains unchanged during the measurements. B. Representative figure of a heart rate tracing
in an open-chest instrumented mouse. Somewhat more pronounced chronotropic arrhythmias
are seen in response to ventricular introduction of the catheter by apical stab. However, no
significant brady- or tachycardias are present during the measurements.
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Discussion
In this chapter OC and CC protocols for in vivo left ventricular PV relationship
measurement are described and discussed. Murine cardiac function determination via these
methods is sensitive, reproducible and comparable. The choice for open- or closed-chest PV
measurements in mice depends on the aim of the study with regards to the specific cardiac
pathology. The OC approach is technically less complicated and less time consuming. Main
characteristics of the OC model itself are low systolic pressures and arterial resistance. The
OC approach could best be used in studies where myocardial integrity is not at stake.
Particularly ischemia/reperfusion studies regarding myocardial integrity are probably better
done using the CC approach.
Assessment of cardiac performance in genetically engineered mice is indispensable to
understand human cardiovascular pathologies. In general the synergistic features of cardiac
diseases, such as hypertrophy and cell death, affect cardiac function negatively. The
contractile performance of the heart deteriorates, which is reflected in the attenuation of
systolic parameters as ejection fraction, stroke work and PV-relationships. Furthermore,
ventricular relaxation prolongs and diastolic filling becomes impaired. The progression of
cardiac disease ultimately results in clinical heart failure, which is defined by the inability of
the heart to meet hemodynamic demands of the body and is characterized by specific signs
and symptoms. (21) The most important parameter of cardiac performance which defines
heart failure is cardiac output.
The influence on cardiac performance of specific genes and proteins in the
development of cardiac diseases ought to be investigated extensively to assess their clinical
relevance. Various techniques have been used to assess cardiac performance in mice. The
main techniques will be discussed in brief.
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Echocardiography is the most widely used noninvasive technique to determine cardiac
performance in mice. High-frequency transthoracic and transesophageal transducers are used
as effective tools for two-dimensional and Doppler imaging of ventricular wall structures,
dimensions and volumes of cavum, and cardiac function. (22,23) Full-conscious or gas-
anesthesia experiments are preferred for echocardiographic assessment of cardiac function in
mice. (24,25) There is no limit to the diversity of murine models investigated by this general
accepted method of cardiac performance assessment. However, the most questionable aspect
of these measurements is the significant inter- and intraobservator variance in the
measurements.
Isolated working mouse heart measurements in a Langendorf perfusion setup are a
technique for ex vivo cardiac function measurements approximating the in vivo function level.
(5) Cardiac output, developed left ventricular pressure and first derivates of maximal and
minimal pressures are some of the parameters that can be derived. Isolated working heart
measurements are especially useful to study the acute effects of ischemic preconditioning and
ischemia-induced apoptosis.(26,27) Metabolites of interest can be measured accurately in the
perfusion fluid. Disadvantages are the impossibility of chronic studies and the
unphysiological situation of ex vivo cardiac function measurements.
Aortic flow measurements by means of a flow-probe have been used in several
studies. (28,29) Aortic flow acquisition is a validated technique and reveals functional
parameters as cardiac output, stroke volume and blood flow velocity. However, several
disadvantages oppose against this technique. Firstly, aortic flow measurements are invasive
(i.e. thoracotomy or laparotomy) and result solely in aortic derived volume parameters.
Integrated ventricular function cannot be assessed. More importantly, the exact localization of
the flow probe around the aorta is the critical determinant of the systematic error made by
these measurements. Flow probes have been placed around the ascending and descending
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thoracic aorta, and the abdominal aorta. The percentage of total cardiac output passing the
flow probe on the specific location has to be estimated. Flow probes located at the ascending
aorta correct for coronary circulation, and, for instance, bloodvolume passing the descending
thoracic aorta has been estimated to be around 75% of total cardiac output. (30) The estimated
correction factor provides ‘absolute’ stroke volume instead of absolute LV cavum volumes,
and does not correct for cardiophysiological changes. Altered cardiophysiological situations
could theoretically influence the relative amount of bloodvolume passing the flow probe. On
the other hand, major advances are the possibility of chronic cardiac function measurements
and the relative facile manner of data acquirement.(29) Moreover, aortic flow probe
measurements are not hampered by deleterious cardiac remodeling in myocardial ischemia or
hypertrophy studies.(28,29)
The newly developed method of cardiac performance assessment by in vivo left
ventricular PV measurements in the CC model is introduced here. Left ventricular PV
measurements in vivo provide an accurate assessment of murine cardiac function. The method
is highly sensitive during open- and closed-chest approaches in determining alterations in left
ventricular function as result of cardiac disease or altered hemodynamic stress. The
characteristics of simultaneous left ventricular pressure and volume measurements enable the
researcher to directly investigate pressure-related cardiac diseases, as cardiac hypertrophy and
restrictive cardiomyopathy (31), or volume-related diseases, as dilated cardiomyopathy (32).
Moreover, the effective influence of both aspects of cardiac disease on each other can be
observed in detail. For instance, ventricular dilation and subsequent decrease in ventricular
systolic pressure is mapped accurately in PV-loops. Continuous measurements provide
possibilities to investigate the complete cardiac cycle. Basic aspects of cardiac physiology can
be visualized using PV-loops in mice. (8,15,33-35) For instance, increase in ventricular filling
is followed by an increase in ejection fraction according to the Frank-Starling mechanism.
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The opposite is seen as a result of gradual venous return decrease in the case of transient caval
vein occlusion (figure 7 & 9). Moreover, the distinction between systolic and diastolic failure
can be made through continuous PV-measurements. (19) Systolic heart failure encompasses
mainly an ejection dysfunction with impaired contractility. Both aspects are obtained by and
directly visualized through PV-loops. Additionally, the definite diagnosis of diastolic failure
is dependent on the observation of an inappropriate upward shift of the (end-)diastolic PV
relationship, requiring cardiac catheterization for continuous volume determinations using
impedance measurements and high-fidelity measurements of ventricular pressure with a
micromanometer. (19) PV-loops are useful determining cardiac performance within the
complete continuum of healthy and diseased hearts.
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Conclusion
In vivo PV measurements provide an essential tool in the assessment of cardiac
function in genetically modified mice. Open- and closed-chest surgical protocols for murine
cardiac function determination are sensitive, reproducible and comparable. PV-loops enable
the researcher to accurately investigate diverse murine models of cardiac pathology by
adequately visualizing the cause-and-effect relationship between genetic modification and
their functional outcome. Changes in ventricular contractility are best detected by PV derived
parameters in comparison to other methods of cardiac function determination.
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Abstract.
Myocardial infarction causes a rapid and largely irreversible loss of cardiac myocytes that
can lead to sudden death, ventricular dilation, and heart failure. Recent investigation has sought to
elucidate the underlying molecular pathways that protect cardiac myocytes from ischemic insults.
Members of the mitogen-activated protein kinase (MAPK) signaling cascade have been implicated
as important effectors of cardiac myocyte cell death in response to diverse stimuli, including
ischemia-reperfusion injury.  Specifically, activation of the extracellular signal-regulated kinases
1/2 (ERK1/2) have been associated with cardioprotection, likely through antagonism of apoptotic
regulatory pathways. To determine a direct causal relationship between ERK1/2 signaling and
cardioprotection, here we analyzed Erk1 nullizygous gene targeted mice, Erk2 heterozygous gene
targeted mice, and transgenic mice with activated MEK1-ERK1/2 signaling in the heart. This gain-
and loss-of-function approach demonstrated a direct cardioprotective role for ERK signaling in the
heart following ischemia-reperfusion injury. While MEK1 transgenic mice were largely resistant to
myocardial infarction, Erk2+/- gene-targeted mice showed enhanced infarction areas, DNA
laddering, and TUNEL labeling compared to littermate controls.  Enhanced MEK1-ERK1/2
signaling protected hearts from DNA laddering, TUNEL labeling, and preserved hemodynamic
function assessed by pressure-volume loop recordings following ischemia reperfusion injury.
Collectively, these data are the first to demonstrate that ERK signaling directly participates in
mediating cellular protection following ischemic injury in the heart.
Chapter 4. MEK1-ERK1/2 signaling is cardioprotective.
3
Introduction
The mitogen-activated protein kinases (MAPK) constitute an essential signal transduction
cascade that occupies a central position in cell growth, differentiation, apoptosis, and transformation
(reviewed in Garrington and Johnson, (1)). While it is somewhat oversimplified, the MAPK
signaling pathway consists of a sequence of successively acting kinases that ultimately result in the
dual phosphorylation and activation of terminal kinases p38, c-Jun N-terminal kinases (JNKs), and
extracellular signal-regulated kinases (ERKs) (2). The MAPK signaling cascade is initiated in
cardiac myocytes by G-protein coupled receptors, receptor tyrosine kinases, cardiotrophin-1 (gp130
receptor), and by stress stimuli (3). The major upstream activators of ERK1/2 are two MAP kinase
kinases (MAPKK), MEK1, and MEK2 which directly phosphorylate the dual site in ERK kinases
(Thr-Glu-Tyr) (2). Once activated, p38, JNKs, and ERKs each phosphorylate a wide array of
intracellular targets that directly influence cell growth, acute alterations in cellular physiology, or
cellular apoptosis.
Within the heart, members of the MAPK cascade have been implicated in regulating
myocyte survival following ischemia-reperfusion injury, oxidative stress, and anthracycline
exposure. A number of studies support the hypothesis that the MEK-ERK branch of the MAPK
pathway is cardioprotective by directly antagonizing myocyte apoptosis. For example, Insulin-like
growth factor 1 (IGF-1), catecholamines and cardiotrophin 1 (CT-1) each induce ERK signaling,
which is an essential effector of anti-apoptosis in cultured myocytes (4-6). Inhibition of ERK
signaling also enhanced daunomycin-induced apoptosis in cultured cardiomyocytes (7) and ERK1/2
activation was associated with reduced apoptosis in a model of ischemia-reperfusion injury (8).
More recently, transgenic mice expressing an activated MEK1 protein in the heart were also shown
to be partially resistant to ischemia-reperfusion-induced DNA laddering, suggesting a
cardioprotective function for ERK1/2 signaling in vivo (9).
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While each of the studies discussed above supports the hypothesis that ERK1/2 activation is
anti-apoptotic in cardiac myocytes, the direct mechanism of protection is less certain. One potential
mechanism involves cyclooxygenase-2 (COX-2) enzyme, which has been implicated as a
cardioprotective downstream ERK effector in cardiomyocytes (10). In lymphocytes, ERK1/2
activation enhances expression of FLICE (FADD-like interleukin 1ß-converting enzyme) inhibitory
protein, a known inhibitor of the caspase cascade (11). More recently, non-genomic signaling
through estrogen was shown to have a myocyte protective effect in association with nitric oxide
(NO), ANF, and ERK1/2 signaling (12-16). Finally, ERK1/2 signaling may regulate
cardioprotection through a mechanism involving direct interaction with PKC in the mitochondria
(17).
While MEK1-ERK1/2 signaling is thought to protect the myocardium from apoptotic
insults, definitive genetic data demonstrating a necessary function for MEK1-ERK1/2 signaling
have not been reported. Here we analyzed Erk1-/- and Erk2+/- gene targeted mice, as well as MEK1
transgenic mice to evaluate both gain- and loss-of-function phenotypes associated with this
signaling pathway and cardiomyocyte cell survival. Erk2 heterozygote mice showed enhanced
apoptosis following ischemia reperfusion injury, while transgenic mice expressing activated MEK1
in the heart were significantly protected. These results provide definitive genetic data implicating
ERKs as beneficial effectors of myocyte survival following myocardial stress stimulation.
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Materials and Methods
Animals
For this study adult Erk1 nullizygous (Erk1-/-), Erk2 heterozygous (Erk2+/-), MEK1
transgenic mice (MEK1 TG) and their wild type littermates (resp. Erk+/+ and MEK1 wt) were
used. All animals were kept under standard housing conditions with an artificial 12h light cycle
with free access to standard rodent food and tap water. The animal studies were performed conform
the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996) and were approved by the animal ethical
committee of Cincinnati Children’s Hospital Medical Center.
Western Blotting and ERK Kinase Assay
Mice were subjected to in vivo PE stimulation to determine total ERK1/2 protein levels and
kinase activities. Wild-type, Erk1-/-, and Erk2+/- mice (average weight = 20 grams) were injected
subcutaneously with 10 mg kg-1 PE or PBS vehicle. Animals were sacrificed 15 minutes later, and
hearts were quickly excised, rinsed in PBS, and snap-frozen in liquid nitrogen. For all experiments,
one-quarter of each heart was homogenized in 400 mL Triton lysis buffer (TLB): Tris-HCl (pH 7.5)
40 mM, NaCl 137 mM, sodium b-phosphoglycerate 25 mM, sodium pyrophosphate 2 mM, EDTA 2
mM, sodium orthovanadate 1 mM, PMSF 1 mM, with 10% (v/v) glycerol, 1% (v/v) Triton X-100, 5
mg mL-1 leupeptin, and 5 mg mL-1 aprotinin. Lysates were cleared by centrifugation and stored at
–80 C until use.
For ERK immunoprecipitation (IP) kinase assays, total ERK protein was
immunoprecipitated from 100 mg of lysate by 1 mg each of agarose-conjugated anti-ERK1 and
anti-ERK2 antibodies (Santa Cruz Biotechnology). Samples were rocked overnight at 4° Celsius in
400 mL TLB; beads were then washed three times in TLB and twice with kinase buffer (KB):
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HEPES (pH 7.4) 25 mM, sodium b-phosphoglycerate 25 mM, MgCl2 25 mM, sodium
orthovanadate 0.1 mM, and DTT 0.5 mM. ERK kinase activity was determined by incubating beads
with 10 mg dephosphorylated myelin basic protein (MBP) (Upstate Biotechnology), 1.25 nmole
ATP, and 15 mCi [32P]  ATP in 25 mL KB at 30 C for 30 minutes. Samples were then mixed with
SDS loading buffer, boiled 5 minutes, and electrophoresed on 14% SDS-PAGE gels. Gels were
dried, exposed overnight to a PhosphorImager screen (Molecular Dynamics), and 32P-MBP levels
were quantitated using a Storm 820 scanner (Molecular Dynamics) and ImageQuant software
(v.1.2).
For Western blotting, 100 mg of lysate was electrophoresed by SDS-PAGE and transferred
to PVDF membranes. Membranes were blocked in 10% nonfat milk/TBS-T, washed in TBS-T, and
probed in 5% milk/TBS-T with antibodies against phospho-ERK1/2 (Cell Signaling) or ERK1/2
(Cell Signaling). Detection was accomplished using alkaline phosphatase-conjugated secondary
antibodies, ECF reagent, and a Storm 860 scanner.
Murine in vivo ischemia reperfusion
Adult mice (8-10 weeks) were anesthetized with isoflurane, 2% in O2 (500 ml/min). The
anterior thorax was shaved and disinfected with betadine solution. Mice were placed on a heating
plate and body temperature was kept constant. A 20-gauge tube was positioned in the trachea and
connected to a rodent ventilator (Minivent, Hugo Sachs Electronics, Germany) for mechanical
ventilation (200 µl, 200 strokes per minute). A left thoracotomy was performed to expose the heart
and the left anterior descending artery (LAD). The LAD was ligated with 8-0 prolene (Ethicon,
USA) using a slip knot placed approximately 2 mm distal from its origin. Mice were allowed to
wake up. The LAD ligation was removed following 60 or 90 min ischemia time (C57Bl/6 versus
FVB/N backgrounds, respectively), after which the mice were reperfused for 24 h or 7 d depending
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on the final analysis chosen. Sham-operations were performed in a similar manner, although actual
LAD ligation was not performed.
Left ventricular in vivo pressure-volume measurements
Following 7 days of reperfusion mice were instrumented and anesthetized as described
above. The right and left external jugular veins were cannulated with PE-50 catheters for saline and
drug infusion. A 1.4 French conductance-micromanometer (Millar Instruments, Houston, TX, USA)
was inserted into the right common carotid artery, advanced through the aorta and positioned in the
left ventricle (LV). Correct LV placement was controlled by the combination of the online pressure
and volume signal. For pressure and volume signal acquisition the MCPU-200 recording unit
(Millar Instruments, Houston, TX, USA) and 8S/P Powerlab control unit (AD instruments,
Australia) were used, in combination with Chart and Scope software (AD instruments, Australia).
Function data analysis was performed with Circlab software (LUMC, the Netherlands).
Staining for infarct size
Following 24 hours of reperfusion mice were anesthetized with 5% Avertin. Upon complete
anesthesia the thorax was quickly opened and the 8-0 prolene ligature was retied around the LAD.
A 0.5 cc insulin syringe was used to inject 0.3 ml of 2 % Evans Blue dye in the left ventricle,
thereby specifically staining the heart except for the LAD perfusion area. The heart was taken out,
washed in PBS to rinse off the excess dye and embedded in 2% agarose gel. Short-axis cross
sections were cut from the heart and placed in 2% 2,3,5-triphenyl-tetrazodium chloride (TTC)
solution (Sigma, St. Louis, USA) at 37° Celsius to stain for viable myocardium. Fifteen minutes
later the slices were taken out of the TTC solution. Slices were fixed in 10% buffered formalin
phosphate solution (Fisher Scientific, New Jersey, USA). Digital pictures of both sides of the
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sections were made and analyzed for infarct area (IA), area-at-risk (AAR) and left ventricular area
(LV) with ImageJ software (Wayne Rasband, National Institutes of Health, USA)
DNA laddering assays
For PCR-based DNA laddering assays samples of heart tissue were utilized following 24
hours of reperfusion.  Hearts were removed and rinsed quickly in ice-cold PBS. After removal of
the atria and great vessels, heart tissue was frozen in liquid nitrogen, and was stored at 70°C until
further analysis. Tissue was ground with a mortar and pestle immersed in liquid nitrogen, and was
digested in 1 ml lysis buffer (10 mM Tris [pH 8.0], 100 mM NaCl, 25 mM EDTA, 0.5% SDS, 1.0
mg/ml Proteinase K (Sigma Chemical Co., St. Louis, MO) overnight at 37°C. Protein was removed
by precipitation in NaCl at a final concentration of 1.2 M, followed by centrifugation at 10,000 g for
30 min. After extraction of supernatants with phenol-chloroform, genomic DNA was precipitated
with isopropanol, washed in 70% ethanol, resuspended in 10 mM Tris (pH 8.0), 1.0 mM EDTA,
and treated with RNase A for 30 min at 37°C. 0.5 µg of genomic DNA was mixed with Ligation
Buffer (Maxim Biotech Inc., San Francisco, CA), heated to 55°C for 10 min, cooled down to 10°C
over approximately 1 hour and incubated with T4 DNA ligase (Maxim Biotech Inc., San Francisco,
CA) at 16°C overnight. For PCR-reactions 100 ng of adaptor-ligated DNA was used for each
sample. PCR thermocycle profile was set according to manufacturers instructions, and 10 µl
samples of the reaction mixture were extracted at cycles 23, 25 and 28. Reaction samples were
loaded on a 1.5% agarose/EtBr gel for electrophoresis.
For DNA laddering of cultured cardiomyocytes, three 10 cm plates were utilized under each
experimental condition. To isolate genomic DNA cells were trypsinized for 5 min. and collected by
a 1 min. spin in a microfuge at 13,000 rpm.  Cells were lysed in 10 mM Tris (pH=8.0), 25 mM
EDTA, 100 mM NaCl, 0.5% SDS, and 1 mg/ml proteinase K overnight at 37ºC.  After incubation,
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proteins were precipitated by addition of an equal volume of 2.4 M NaCl and removed by
centrifugation. The supernatant was extracted once with phenol:chloroform, the DNA precipitated
with isopropanol, washed with 70% ethanol, and resuspended in 10 mM Tris (pH=8.0), 1 mM
EDTA, and treated with 100 mg/ml DNAse free RNAse (Boehringer Mannheim) for 30 min at
37ºC.  The genomic DNA was precipitated with isopropanol, rewashed with 70% ethanol and
dissolved in 10 mM Tris (pH=8.0), 1 mM EDTA and its concentration determined by
spectrophotometry.  Equal amounts of DNA were loaded on 1.5% agarose gels containing 1 µg/ml
ethidium bromide and visualized under UV light.
TUNEL labeling
In situ DNA fragmentation was detected using the terminal deoxyribonucleotide transferase
(TdT)-mediated dUTP nick-end labeling (TUNEL) in paraffin-embedded tissue sections. Hearts
were collected form genetically modified and wild type littermate mice 24 hours following I/R-
injury, rapidly fixed, paraffin embedded and sectioned cross-sectional in 6µm slices. TUNEL
labeling was performed using the In Situ Cell Death Detection kit (Roche, Penzberg, Germany)
using the manufacturer’s recommended conditions. Sections were dewaxed and rehydrated,
permeabilized with 0.1% Triton X-100, 0.1% sodium citrate solution. Subsequently sections were
incubated with TUNEL Labeling solution at 37°C in a humidified climate. Cardiac myofibers were
counterstained with 0.05% phalloidin and nuclei with 0.05% bis-benzamide solution. Digital
pictures of the sections were made with a fluorescence camera and stored accordingly. TUNEL
rates were determined solely in the ischemic area of the mid-myocardium of each heart at various
sections.
SDS PAGE and Immunoblot Analysis for PARP cleavage
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Protein samples were separated by SDS-PAGE according to the method described by
Laemmli (1970). (18) Protein extracts were prepared from heart tissue using extraction buffer (20
mM NaPO4, 150 mM NaCl, 2 mM MgCl2, 0.1% NP-40, 10% glycerol, 10 mM NaF, 0.1 mM
sodium orthovanadate, 10 mM sodium pyrophosphate, 10 µM phenylasine oxide, 10 nM okadaic
acid, 1 mM DTT, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml pepstatin, 10 µg/ml TPCK, and
10 µg/ml TLCK). Samples containing 50-100 µg were thawed on ice, diluted 1:1 with a 2X sample
buffer to a final concentration of 2% SDS, 62.5 mM Tris•HCl pH 6.8, 5% 2-mercaptoethanol, 10%
glycerol, 0.001% bromophenol blue, and heated at 95°C for 5 min. The samples were then loaded
onto 10% acrylamide gels and electrophoresed in the presence of 25 mM Tris pH 8.3, 2 mM glycine
and 0.1% SDS at room temperature. Following SDS-PAGE, proteins were transferred
electrophoretically onto Hybond-P membranes (Amersham Pharmacia Biotech, Buckinghamshire,
UK) with transfer buffer (25 mM Tris, 190 mM glycine, 20% methanol) for 12 hours at 4°C.
Membranes were then blocked for 2 hours at room temperature with Tris buffered saline containing
0.1% Tween 20, 10 mM Tris pH 7.5, 150 mM NaCl (TBS-T), 5% non-fat milk, and then incubated
either in antiserum (anti-[poly (ADP-ribose) polymerase] PARP) overnight at 4°C.  Membranes
were then washed three times 10 min each with TBST and incubated for 2 hours with secondary
antibody conjugated to horseradish peroxidase with either anti-mouse IgG (dilution 1:2500) or anti-
rabbit IgG (dilution 1:2500). After this incubation, membranes were washed three times with TBST
and immunoreactivity was detected using the enhanced chemiluminescence system (ECL)
(Amersham Pharmacia Biotech, Buckinghamshire, UK) according to kit instructions.
Immunoreactive bands on films were digitized and quantified for fluorescence with a Storm 860
PhosphoImager (Molecular Dynamics, Sunnyvale, CA).
Statistical Analysis
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Statistical analyses between the experimental groups were performed using a Student’s t-test
or one-way ANOVA when comparing multiple groups. Data are reported as mean ± SEM. P-values
< 0.05 were considered significant.
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Results
A gene targeting approach was employed to evaluate the necessary functions of ERK1 and
ERK2 gene products as regulators of cardiac homeostasis and stress responsiveness. Erk1 and Erk2
gene targeted mice were each previously described. (19,20) Erk1 null mice are fully viable as
adults, but Erk2 gene targeted mice could only be analyzed in the heterozygous state, since null
mice were not viable. Western blotting from cardiac protein extracts was performed to examine the
quantity of ERK1 and ERK2 proteins from each gene targeted mouse (figure 1) and the resulting
effect on total cardiac ERK kinase activity following stress stimulation (figure 2). In protein
quantification studies through Western blot techniques ERK1/2 proteins were detected using a pan-
ERK antibody. Equivalent antibody reactivity was demonstrated with bacterial-generated ERK1 and
ERK2 protein standards (GST fusion proteins), from which a standard curve was generated to
quantify endogenous ERK1 and ERK2 levels in the heart (figure 1A). Further quantification of
cardiomyocyte cellular protein content indicated ERK2 to represent approximately 60-70% of total
ERK protein in the heart in wildtype mice (figure 1B). ERK1 protein could not be detected in Erk1-
/-, while, importantly, ERK2 protein levels were not increased in the hearts of Erk1 deficient mice.
ERK2 protein levels in Erk2+/- mice were observed to be downregulated, while ERK1 protein
levels were unaffected in these mice. Cardiac ERK activation was assessed by immunoprecipitation
kinase assay from hearts of wildtype, Erk1-/- and Erk2+/- mice following an acute 30 min of
ischemia (figure 2B), or acute PE injection (figure 2A & C). The immune kinase assays showed a
consistent profile of inhibited total ERK activity from either Erk1-/- or Erk2+/- hearts by either
stimulation. For example, 30 minutes of ischemia induced a 2-fold increase in ERK activity in
wildtype hearts, but essentially no increase in Erk1-/- or Erk2+/- hearts (P < 0.05) (figure 2B).  In
response to PE stimulation, a similar percentage of reduction in ERK kinase activity was observed
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Fig. 1: Analysis of ERK protein expression in wildtype and Erk genetic modified mice. A. Western
blot with bacterium-generated ERK1- and ERK2-GST fusion protein standards to verify antibody
equivalence. Left panel shows actual Western blots ERK1/2-GST binding by the pan-ERK antibody
(Cell Signaling). Right panel shows the quantification of antibody binding affinity, demonstrating
equivalent antibody affinity (NS, N = 3). B. Western blot quantification for content of endogenous
ERK1 and ERK2 in the heart. Left panels show Western blots from tissue extracts from wild type,
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Erk1-/- and Erk2+/- mice. Quantification of ERK1/2 proteins in wild type mice is visualized in the
right panel, demonstrating ERK2 to be the predominant ERK protein in the heart.
Fig. 2: Analysis of kinase activity in Erk1 and Erk2 gene targeted mice.  A. Western blot analysis
for phosphorylated ERK1 and ERK2 proteins from cardiac tissue extracts from wild type (wt),
Erk1-/-, and Erk2+/- mice at baseline or after PE agonist stimulation. B. Total ERK immune kinase
activity against myelin basic protein (MBP) from hearts of wildtype (Wt), Erk1-/-, and Erk2+/-
Figure 2
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ERK 2 +/-
ERK wt ERK 1
ERK wt
ERK 2 +/-
ERK wt ERK 1
ERK wt
B. ERK wt
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mice after 30 min of ischemia in vivo, or after sham operation. C. Immune kinase assay for total
ERK1/2 activity from wild type, Erk1-/-, and Erk2+/- hearts at baseline line or 30 minutes after PE
stimulation. The kinase substrate was myelin basic protein (MBP). Similar results were observed in
2 independent experiments.
in both Erk1-/- or Erk2+/- hearts (P < 0.05).  These results indicate that both Erk1-/- and Erk2+/-
mice show a similar defect in ERK kinase activation in the heart (see discussion).
While previous studies using cell culture-based models have suggested an anti-apoptotic role
for ERK MAPK signaling, such results have yet to be definitively extended to an intact animal.
Here we analyzed both gain- and loss-of-function phenotypes associated ERK1/2 signaling in the
heart following an acute apoptosis provoking insult within the intact heart. Specifically, Erk1-/- and
Erk2+/- gene targeted mice underwent 60 minutes of left ventricular cardiac ischemia followed by
24 h of reperfusion to induce myocardial infarctions and cell death in vivo. Remarkably, Erk2+/-
mice showed a significant increase in total left ventricular infarct area normalized to area-at-risk
compared to wild type controls (identical strain) or Erk1-/- mice (P < 0.05)(figure 3A,C, infarct
areas are white, while viable myocardium stains red). No significant difference was measured in the
AAR normalized to left ventricular area, indicating that alterations in infarct size were not
influenced by variations in the perfused areas between each cohort (figure 3B). These data indicate
that a 50% reduction in Erk2 gene dosage renders the myocardium more susceptible in I/R.
However, loss of Erk1 did not significantly enhance myocardial infarction susceptibility (see
discussion).
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Fig. 3: Ischemia-reperfusion injury in Erk1-/-, Erk2+/- and MEK1 transgenic mice. A. Infarct area
(IA) was normalized to the area-at-risk (AAR) by histological analysis of TTC- and Evans blue-
stained heart sections form ischemia/reperfusion (I/R) injury. B. Each of the genetic models showed
equivalent AARs normalized to left ventricular (LV) areas. C. Representative TTC- and Evans blue
-stained heart cross-sections from each of the cohorts.
To extend the mechanistic implications between alterations in ERK activity and
susceptibility to myocardial infarction, cardiac specific transgenic mice with enhanced ERK1/2
activation were analyzed. Transgenic mice expressing an activated MEK1 mutant protein in the
Figure 3
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heart were previously shown to have enhanced ERK1/2 activities, which were associated with the
presentation of a mild hypertrophic response (9). MEK1 transgenic mice and non-transgenic
littermate controls (FVB strain) were also subjected to ischemia/reperfusion injury and
quantification of infarct area by histological staining. The data demonstrate that activated MEK1
transgenic mice, which have greater ERK1/2 activity, were significantly protected (figure 3A,C).
These results indicate that enhanced ERK1/2 signaling in the heart is associated with
cardioprotection following ischemia/reperfusion damage and are consistent with the observation of
greater infarct areas in Erk2+/- mice. To extend these analyses of cardiac myocyte cell death and
further determine the role of apoptosis in the cardioprotective effect seen, caspase activation was
also measured by direct quantification of poly (ADP-ribose) polymerase (PARP) cleavage from I/R
injured hearts (figure 4). The data demonstrate that MEK1 transgenic mice were largely protected
from PARP cleavage (33% less cleavage) following I/R injury, indicating less caspase activation (P
< 0.05) (figure 4, quantification was performed from 5 individual hearts in each cohort).
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Figure 4
Apoptosis determination in MEK1
transgenic mice by PARP cleavage.
Relative apoptosis amounts were
investigated by poly (ADP-ribose)
polymerase (PARP) cleavage determination
in I/R injured hearts. MEK1 transgenic
mice were largely protected from PARP
cleavage (33% less cleavage) following I/R
injury, indicating less caspase activation (*
P < 0.05).
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The role of myocardial cell apoptosis was further investigated using TUNEL and ligation-mediated
PCR laddering for DNA fragmentation studies in the infarct susceptibility region of the left
ventricle following ischemia and 24 hrs of reperfusion. The data demonstrate significantly reduced
TUNEL and DNA laddering in MEK1 transgenic hearts compared with strain-matched controls (P
< 0.05)(figure 6A,B; figure 8A), and significantly higher TUNEL and DNA laddering in Erk2+/-
hearts compared to strain-matched controls (P < 0.05) (figure 7A,B; figure 8A). These results were
extended through the use of neonatal myocytes infected with recombinant adenoviruses expressing
various MEK1-ERK1/2 effectors, which were subsequently treated with staurosporine (500 nM) for
18 hours to induce apoptosis. Staurosporine induced significant DNA laddering in control Adßgal-
infected myocytes, which was qualitatively antagonized by expression of activated MEK1 (figure
8B). More importantly, inhibition of endogenous ERK1/2 activity with recombinant adenoviruses
expressing either dominant negative MEK1 or the ERK-specific dual-specificity phosphatase MKP-
3, each noticeably enhanced staurosporine-induced DNA laddering (figure 8B). MEK1 transgenic
mice and their littermate controls were also subjected to thorough physiologic analysis following
myocardial ischemia-reperfusion injury to correlate infarct susceptibility with functional
performance. Each cohort was analyzed 7 days after ischemic injury by invasive hemodynamic
assessment of left ventricular pressure and volume collected in the anesthetized mouse (Table 1).
Using 90 minutes of ischemia time wild type FVB/N mice demonstrated a significant decrease in
physiologic performance (Table 1). For example, cardiac output and ejection fraction were
significantly depressed in non-transgenic mice compared to sham operated controls (P < 0.05)
(figure 8A, table 1). In dramatic contrast, MEK1 transgenic mice (FVB/N) did not show a
significant loss in functional performance (figure 9A, Table 1), consistent with the observed
reduction in myocardial infarct size assessed by histological methods. This cardioprotective
relationship is more dramatically visualized through individual pressure-volume loops collected in
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each of the cohorts (figure 9B). Specifically, wild type mice subjected to ischemia/reperfusion
damage show a rightward shift in the pressure-volume relationship during both diastole and systole
(figure 9B). However, MEK1 transgenic mice showed essentially no shift in this relationship.
Collectively, these data indicate that MEK1-ERK1/2 signaling protects myocardial function
following ischemia/reperfusion damage.
Erk1-/- and Erk2+/- gene targeted mice were also analyzed for cardioprotection following
ischemia/reperfusion injury and compared to C57Bl/6 strain-matched controls. In this series of
experiments we induced less ischemia/reperfusion injury to permit evaluation of increased
myocardial infarction from a given baseline level of damage.  Specifically, C57Bl/6 strain-matched
controls were subjected to 60 minutes of ischemia followed by 7 days of reperfusion, which induced
a more nominal level of injury and dysfunction compared to the conditions used in FVB/N mice
above (Table 1). Under these conditions, Erk1-/- mice (C57Bl/6) showed no difference in function
Figure 5
Detailed image of TUNEL labeling in the heart. A
representative image of cardiomyocyte apoptosis as detected
by TUNEL labeling (i.e. red staining) of myocyte nuclei in
myofibers from an Erk2+/- mouse.
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Figure 6 Fig. 6: Apoptosis detection by TUNEL labeling in
MEK1 transgenic mice. A. Representative overview
images of the apoptosis amount in the ischemic area
of the myocardium 24 hours following the ischemic
event. The images show the evident lower apoptosis
rate in MEK1 transgenic compared to wild type
littermate mice. B. Quantification of apoptosis
amount shows a significant reduction in MEK1
transgenic mice following I/R injury compared to
wild type littermates († P < 0.05). Baseline
apoptosis rates in non-ischemic hearts were not
different between genotypes.
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Figure 7 Fig. 7: Apoptosis detection by TUNEL labeling in ERK
gene targeted mice. A. Representative overview images
of the apoptosis amount in the ischemic area of the
myocardium 24 hours following the ischemic event. The
images show the evident higher apoptosis rate in
Erk2+/- compared to wild type littermates and Erk1-/-
mice. B. Quantification of apoptosis amount shows a
significant increase in Erk2+/- mice following I/R injury
compared to wild type littermates († P < 0.05), while
apoptosis amounts were not different between wild type
and Erk1-/- mice (# NS). Baseline apoptosis rates in
non-ischemic hearts were not different between
genotypes.
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Fig. 8: Assessment of ischemia-reperfusion-induced DNA laddering in Erk1-/-, Erk2+/-, and MEK1
transgenic mice or cultured cardiomyocytes. A. Representative DNA laddering analysis from the
left ventricle of sham mice or Erk1-/-, Erk2+/-, and MEK1 transgenic mice 24 h after
ischemia/reperfusion injury. MEK1 transgenic mice were largely protected against I/R-induced
DNA laddering, while Erk2+/- showed enhanced DNA laddering compared to wild type mice. B.
Representative DNA ladders from +/- staurosporine-treated neonatal cardiomyocytes infected with
the indicated adenoviruses. Adenoviral MEK1 overexpression inhibits DNA laddering in cultured
cardiomyocytes, while dominant-negative MEK1 overexpression (AdMEK1dn) pronounces
apoptotic cell death as demonstrated by DNA laddering. Adenoviral overexpression of the
endogenous inhibitor of MEK1 (AdMKP-3) even so pronounced DNA laddering.
Figure 8
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following ischemia/reperfusion injury compared to strain-matched controls (data not shown). In
dramatic contrast, Erk2+/- mice (C57Bl/6) showed significant functional deficits following
ischemia/reperfusion injury.  Specifically, Erk2+/- mice showed a greater decrease in ejection
fraction and dP/dtmax compared to strain-matched controls, consistent with the observed increase in
myocardial damage assessed by histological methods (P < 0.05) (figure 9A, Table 1). Analysis of
individual pressure-volume loops showed a greater rightward shift in Erk2+/- mice following
ischemia/reperfusion damage compared to sham operated mice (figure 9C).  Collectively, these
Figure 9
A.
B.
C.
ERK wt MEK1 wt
MEK1 wt
ERK wt
Fig. 9: MEK1 transgenic mice maintain
functional performance following I/R
injury. (A) Invasive hemodynamic
functional assessment of ejection fraction
was performed in wildtype versus Erk2
heterozygous and wild type versus MEK1
transgenic mice 7 days after sham
operation or ischemia/reperfusion injury
(*P < 0.05 versus sham control). (B)
Representative pressure-volume loops (PV
loops) measured from MEK1 wild type and
MEK1 transgenic mice 7 days after sham
operation or ischemia/reperfusion injury.
(C) Representative PV loops measured
from ERK wild type and Erk2
heterozygous mice.
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results support the hypothesis that ERK factors are normally cytoprotective in the heart and indicate
that MEK1-ERK2 signaling antagonizes cell death following acute stress stimulation in cardiac
myocytes.
Table.  Cardiac function measurements in sham and I/R injured mice.
MEK1 wt MEK1 TG
Sham I/R Sham I/R
n = 12 n = 13 n = 10 n = 13
HR 415 ± 19 416 ± 6 449 ± 43 492 ± 12
SV 4.70 ± 0.35 2.92 ± 0.19‡ 3.99 ± 0.49 3.40 ± 0.13
CO 1899 ± 115 1215 ± 81‡ 1688 ± 160 1667 ± 66
Vmax 7.88 ± 0.69 9.95 ± 0.54‡ 6.96 ± 0.63 5.59 ± 0.37
Vmin 3.22 ± 0.42 7.15 ± 0.47‡ 2.80 ± 0.42 2.79 ± 0.33
ESP 75 ± 2 74 ± 3 68 ± 5 59 ± 3
EDP 7 ± 2 10 ± 2 10 ± 2 2 ± 0§
dP/dtmax 7008 ± 497 4965 ± 329‡ 5726 ± 224 5660 ± 199
dP/dtmin -4816 ± 361 -3300 ± 348‡ -3567 ± 198 -4112 ± 160§
SW 305 ± 23 166 ± 15‡ 230 ± 30 163 ± 12
TAU 11 ± 1 16 ± 1‡ 13 ± 2 9 ± 0§
PHT 6 ± 0 9 ± 1‡ 6 ±1 4 ± 0§
EF 62 ± 2 31 ± 1‡ 60 ± 4 64 ± 5
ERK wt Erk2 +/-
Sham I/R Sham I/R
n = 10 n = 9 n = 4 n = 3
HR 650 ± 16 587 ± 28 691 ± 20 565 ± 9§
SV 3.26 ± 0.44 3.81 ± 0.23 2.30 ± 0.18 2.44 ± 0.75
CO 2121 ± 299 2227 ± 141 1595 ± 163 1390 ± 435
Vmax 5.98 ± 0.56 7.79 ± 0.58‡ 4.97 ± 0.31 7.25 ± 1.62
Vmin 2.19 ± 0.35 3.73 ± 0.58‡ 2.14 ± 0.05 4.49 ± 0.77§
ESP 71 ± 3 64 ± 3 76 ± 3 71 ± 8
EDP 2 ± 1 2 ± 0 1 ± 1 5 ± 2
dP/dtmax 8176 ± 455 7381 ± 453 9720 ± 447 6366 ± 556§
dP/dtmin -6767 ± 373 -5792 ± 519 -8397 ± 354 -5875 ± 1067
SW 240 ± 27 240 ± 23 195 ± 19 180 ± 78
TAU 7.7 ± 0.3 8.6 ± 0.5 7.3 ± 0.1 8.7 ± 0.5§
PHT 4.0 ± 0.2 4.4 ± 0.3 3.8 ± 0.1 4.8 ± 0.3§
EF 59 ± 4 52 ± 3 52 ± 2 34 ± 5§
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Invasive measurement of hemodynamic function in anesthetized MEK1 wild type mice versus
littermate MEK1 transgenic mice and ERK versus littermate Erk2+/-. Hemodynamic evaluation
performed 7 days after sham and I/R surgery. HR, heart rate per minute; SV, stroke volume in µl;
CO, cardiac output µl/min; Vmax, maximal left ventricular volume in µl; Vmin, minimal left
ventricular volume in µl; ESP, end systolic pressure in mmHg; EDP, end diastolic pressure in
mmHg; dP/dtmax, maximum derivative or pressure in mmHg/sec; dP/dtmin, minimum derivative or
pressure in mmHg/sec; SW, stroke work mmHg ⋅ µl; Tau, time constant of relaxation in msec; PHT,
pressure half time in msec; EF, ejection fraction (%). ‡P < 0.05, respective wt I/R vs wt sham. §P <
0.05, respective MEK1 TG sham or Erk2+/- I/R vs MEK1 TG or Erk2+/- sham.
Chapter 4. MEK1-ERK1/2 signaling is cardioprotective.
25
Discussion
Here we analyzed genetically altered mice with both enhanced and depressed ERK
activation to determine the function of this kinase effector pathway in regulating cardiomyocyte
apoptosis in vivo. While previous studies have suggested the hypothesis that ERK activation can
partially antagonize apoptosis, our present analysis simultaneously employed genetically altered
mouse models that both represent enhanced and depressed ERK signaling in vivo. For example,
although studies in cultured cardiomyocytes have shown that ERK activation is associated with
anti-apoptosis, a direct cause and effect relationship was not established (4-7). Here, a direct
relationship is suggested given the observation that Erk2+/- mice are more susceptible to
ischemia/reperfusion damage while activated MEK1 transgenic mice are protected. While
previously MEK1 transgenic mice were shown to be partially resistant to DNA laddering following
ischemia/reperfusion injury (9), here we extended these observations to show that MEK1 transgenic
have smaller infarcts and maintain cardiac function following ischemia/reperfusion injury. If this
analysis of MEK1 transgenic mice is considered in conjunction with the data obtained in Erk gene
targeted mice a unified hypothesis emerges: that ERK activation regulates myocyte viability
following stress stimulation.
An interesting aspect of the present study is that Erk2 heterozygote gene-targeted mice
showed enhanced myocardial injury following I/R stimulation, while Erk1 null mice showed a level
of injury equivalent to wildtype mice. This differential susceptibility to I/R injury documented
between Erk1 null and Erk2 heterozygote gene targeted mice suggests two possible mechanisms.
Quantitative western blotting indicated that ERK2 protein levels are higher than ERK1, as shown in
certain other cell-types. (21) However, Erk2 heterozygote mice showed somewhat similar reduction
in total kinase activity in the heart following acute ischemia or PE injection compared with Erk1
null mice (Fig 1C). Thus, the loss of one allele of Erk2 appears to alter the net amount of ERK1/2
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activity in the heart similar to loss of both Erk1 alleles.  Another more plausible mechanism is that
ERK1 and ERK2 have specific functions, as suggested by the lack of compensation by Erk1 in Erk2
null mice, the latter of which die during embryonic development. (19)
Even though ERK1 and ERK2 are highly related, precedent exists for each factor having its
own functional characteristics as a second potential mechanism underlying the observed differences
in ischemia/reperfusion susceptibility. Indeed, ERK1 and ERK2 can undergo differential activation
in response to specific stimuli or upstream effectors (22-27).  Moreover, ERK1 and ERK2 proteins
also prefer to homodimerize compared to cross dimerization, suggesting structural differences
between these two proteins (28). Collectively, these reports suggest that ERK1 and ERK2 proteins
could have slightly different intrinsic functions in the heart as an underlying mechanism of
regulating cardioprotection.
The contention that ERK1/2 activation promotes cellular protection in response to apoptotic
stimuli has been demonstrated in many, but not all cell types (For examples see refs (29-32)). ERK
signaling has also been directly associated with cell survival in cultured cardiomyocytes or the
intact heart subjected to apoptotic stimuli (7-9,33-35). A number of downstream ERK effectors
have been identified including other kinases, transcription factors, and diverse regulatory proteins
(21). With respect to potential anti-apoptotic regulatory factors, ERK signaling is associated with
cellular protection through the downstream effectors COX-2, FLICE, heat shock protein 27
(HSP27), p90 ribosomal S6 kinase (p90rsk, also referred to as MAPKAP kinase), and Bad
phosphorylation (10,11,36-39). For example, ERK1/2 can directly phosphorylate and activate
p90rsk which in turn phosphorylates the pro-apoptotic factor Bad in the mitochondria resulting in
cellular protection (37). ERK factors were also recently shown to interact with PKCε within the
mitochondria facilitating cellular protection within the context of the intact heart (17). While the
overall importance of each potential downstream protective mechanism was not evaluated in our
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study, we did observe a prominent increase in p90rsk phosphorylation in MEK1 adenoviral infected
cardiomyocytes (data not shown). Regardless of the exact downstream mechanism, this report is the
first to unequivocally demonstrate that MEK1-ERK signaling protects the heart from apoptotic
insults. A future challenge will be to develop strategies that exploit this function of ERK1/2
signaling in the heart by tightly controlling activation to potentially benefit the myocardium during
stress.
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Abstract
Cardiovascular disease is the leading cause of mortality and morbidity within the
industrialized nations of the world, with coronary heart disease (CHD) accounting for as
much as 66% of these deaths. Acute myocardial infarction is a typical sequelae associated
with long-standing coronary heart disease resulting in large scale loss of ventricular
myocardium through both apoptotic and necrotic cell death. In this study, we investigated the
role that the calcium calmodulin-activated protein phosphatase calcineurin (PP2B) plays in
modulating cardiac apoptosis after acute ischemia-reperfusion injury to the heart. Calcineurin
Aβ gene–targeted mice showed a greater loss of viable myocardium, enhanced DNA
laddering and TUNEL, and a greater loss in functional performance compared with strain-
matched wild-type control mice after ischemia-reperfusion injury. RNA expression profiling
was performed to uncover potential mechanisms associated with this loss of cardioprotection.
Interestingly, calcineurin Aβ -/- hearts were characterized by a generalized downregulation in
gene expression representing approximately 6% of all genes surveyed. Consistent with this
observation, nuclear factor of activated T cells (NFAT)-luciferase reporter transgenic mice
showed reduced expression in calcineurin Aβ -/- hearts at baseline and after ischemia-
reperfusion injury. Finally, expression of an activated NFAT mutant protected cardiac
myocytes from apoptotic stimuli, whereas directed inhibition of NFAT augmented cell death.
These results represent the first genetic loss-of-function data showing a prosurvival role or
calcineurin-NFAT signaling in the heart.
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Introduction
Cardiovascular disease is the leading cause of mortality in adults in the United States
where it is thought to account for approximately 12 million deaths annually. (1,2) Myocardial
infarction, as well as non-ischemic forms of heart failure, are thought to involve an
irreversible loss of cardiac myocytes through apoptosis or programmed cell death. (2-4) In
recent years, a great body of research has focused on identifying the signaling molecules
responsible for myocardial cell death or those molecules that might protect the myocardium
from ischemic insults. (5) For example, numerous studies have identified signaling molecules
that enhance cardiomyocyte apoptosis such as p38α, c-Jun N-terminal kinase, tumor necrosis
factor-α, p53, β-adrenergic receptors, and nitric oxide. (5-7) In contrast, other signaling
pathways have been shown to protect the heart from apoptosis such as cardiotrophin-1
through the gp130 receptor, p38β, insulin-like growth factor-1 (IGF-1), Akt/protein kinase B,
protein kinase Cε, nitric oxide, and extracellular signal-regulated kinases 1/2. (5,6,8-12)
Another potential regulator of cardiac apoptosis is the calcium-calmodulin–activated protein
phosphatase calcineurin (or PP2B). Calcineurin was identified as an important regulator of
cardiomyocyte hypertrophy in vivo and in vitro, while more recent investigation has
suggested a role for calcineurin in the modulation of cardiomyocyte apoptosis. (13,14) Studies
conducted in neurons, lymphocytes, and tumor cell lines have demonstrated either pro- or
antiapoptotic effects associated with calcineurin activation. (15-22) Similarly, both pro- and
antiapoptotic modulatory roles have been ascribed to calcineurin in cardiomyocytes. For
example, calcineurin activation in cultured cardiac myocytes confers protection to H2O2- or
2-deoxyglucose–induced apoptosis, suggesting that calcineurin is cytoprotective. (14,23)
Moreover, transgenic mice expressing an activated form of calcineurin in the heart are largely
protected from ischemia-reperfusion–induced DNA laddering, further suggesting that
calcineurin activation antagonizes cardiomyocyte apoptosis in vivo. (14) In contrast,
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isoproterenol stimulation of cardiac β-adrenergic receptors promoted myocyte apoptosis, in
part, by stimulating calcineurin activity. (24) Part of this disparity potentially stems from the
dichotomous actions of the often-employed inhibitory agent cyclosporine A. For example,
cyclosporine A not only inhibits calcineurin enzymatic activity, but also inhibits
mitochondrial permeability pore transition (MPTP) and apoptosis through its association with
cyclophilin D in the inner-mitochondrial membrane. (25) However, use of cyclosporine-
independent strategies have also revealed pro- and antiapoptotic regulatory roles for
calcineurin, suggesting multiple levels of complexity underlying the biology of calcineurin
and cell death. Given these issues, we pursued a genetic approach to evaluate the functional
significance of calcineurin as a potential modulator of ischemia-reperfusion–induced
apoptosis in vivo.
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Materials and Methods
Surgical Procedure and Animal Models
Mice were randomized to receive either ischemia-reperfusion injury or a sham
procedure. Mice were anesthetized and placed on a warming pad maintained at 37°C. The
trachea was cannulated with a polyethylene tube connected to a respirator (Harvard
Apparatus) with a tidal volume of 0.6 mL (110/min). A left lateral thoracotomy was
performed between the fourth and fifth ribs, pericardial tissue was removed, and the left
anterior descending artery (LAD) was visualized and ligated with a slipknot of 8-0 silk.
Reperfusion was initiated 60 minutes after the occlusion. The calcineurin Aβ (CnAβ)-/-
mouse and the NFAT-dependent luciferase reporter transgenic line (containing nine copies of
an NFAT binding site upstream of a minimal promoter) were described previously. (26,27)
Measurements of Ischemic Area at Risk (AAR) and Infarct Size
Twenty-four hours after reperfusion, mice were anesthetized, the individual LADs
were re-occluded, and 1 mL of 1.0% Evans blue was injected into the apex of each heart to
stain non-ischemic tissue. The hearts were then excised, washed with PBS, embedded in
agarose, and cut into five transverse slices for 15 minutes of incubation at room temperature
with 1.5% 2,3,5-triphenyltetrazolium chloride (TTC) to measure viable myocardium (red
staining). Slices were photo-graphed (each side) under a microscope and left ventricular area,
AAR, and infarct area were determined by digital planimetry.
Echocardiography and Working Heart Analyses
CnAβ -/- or wild-type mice were anesthetized with 2% isoflurane and hearts were
visualized using a Hewlett Packard Sonos 5500 instrument and a 15-MHZ transducer. Cardiac
ventricular dimensions were measured on M-mode three times for the number of animals
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indicated. The isolated ejecting mouse heart preparation has been described in detail
previously. (28)
DNA Laddering and TUNEL
CnAβ -/- mice or wild-type controls were subjected to 60 minutes LAD occlusion and
24 hours of reperfusion to induce cardiac apoptosis for DNA laddering and 3 weeks of
reperfusion for terminal deoxyribonucleotide transferase (TdT)–mediated dUTP nick-end
labeling (TUNEL) assessment as previously described. (14)
Assessment of Apoptosis in Cultured Cardiac Myocytes
Conditions for generating and culturing neonatal cardiac myocytes were described
previously. (14) The Ad∆CnA and Ad∆NFATc4 adenoviruses were described previously,
(14) whereas the AdVIVIT NFAT inhibitory adenovirus was composed of the green
florescent protein (GFP) fused to the VIVIT sequence as described previously(29) (gift of Dr
Susan D. Kraner and Chris Norris, University of Kentucky, Lexington). Cardiac myocytes
were treated with staurosporine (500 nmol/L) for 18 hours, and all manipulations were
performed 24 hours after adenoviral infection to allow adequate protein expression. (14) DNA
laddering and measurement of TUNEL were described previously. (14)
Affymetrix Gene Expression Profiling and Bioinformatics
Total RNA samples were prepared from four individual hearts from 8-week-old CnAβ
-/- or wild-type control mice. Biotin-labeled target cRNA was prepared from T7-transcribed
cDNA made from 10 µg of the total RNA using the Affymetrix-recommended
protocol(30,31) and hybridized for expression analysis to the Affymetrix U74Av2 Gene-Chip
using antibody-based fluorescence signal amplification. Data values used for filtering and
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clustering were Signal, Signal Confidence, Absolute Call (Absent/Present), and Change
(Increase, Decrease, and Unchanged) as implemented in MicroArray Suite 5.0.
Statistical Analysis
Statistical analyses between the experimental groups were performed using a Student’s
t-test or one-way ANOVA when comparing multiple groups. Data were reported as mean ±
SEM. Values of P < 0.05 were considered significant.
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Results
Although conclusive evidence has emerged implicating calcineurin as a pivotal
regulator of cardiac myocyte hypertrophy, its role in regulating cardiac myocyte survival or
apoptosis after ischemic or stress-related injury has engendered some controversy. To more
thoroughly evaluate the association between calcineurin signal transduction and cardiac
survival/apoptosis, we analyzed CnAβ -/- mice for susceptibility to ischemia-reperfusion
injury. Null mice and strain-matched wild-type (wt) controls were subjected to 60 minutes of
LAD coronary artery occlusion followed by 24 hours of reperfusion. After this 24-hour
reperfusion period, hearts were removed and perfused with Evans blue dye, sectioned, and
incubated in 1.5% TTC to quantify area at risk and area of infarct normalized to total left
ventricular area (AAR/LV). The area at risk normalized to ventricular area was not different
between the two groups (wt, 79.8 ± 3.3%; CnAβ -/- mice, 76.5 ± 2.9%; Figure 1A). These
results indicated that there were no genotype-dependent differences in the perfused areas
between the two groups. In contrast, loss of viable myocardium was increased by
approximately 30% in CnAβ -/- mice compared with wt mice (wt, 31.9 ± 3.6%; CnAβ
-/- mice, 46.19 ± 3.6%, N = 8; P < 0.05, Figures 1B and 2C).
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Fig. 1: CnAß-/- mice show greater myocardial
injury following ischemia-reperfusion injury. A.
Area at risk (AAR) to total left ventricular area
ratios. B. Infarcted area (IA) normalized to AAR
(N = 8; P < 0.05). C. Representative injured
hearts from wildtype (wt) and CnAß-/- mice
stained with Evans blue and TTC.
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DNA laddering was examined by agarose gel electrophoresis using hearts from sham
operated animals and mice subjected to ischemia-reperfusion injury. CnAβ -/- mice showed a
qualitative increase in the degree of DNA laddering compared with hearts from wt mice,
suggestive of more apoptotic damage (N = 6 hearts in each group, although only two each are
shown) (Figure 2A). These data were extended through along with independent assessment of
DNA fragmentation by ligation-mediated polymerase chain reaction, which also showed
significantly greater signal in the CnAβ -/- hearts after ischemia-reperfusion injury (Figure
2B). Histological analysis was performed using Masson’s trichrome staining (blue color
shows fibrosis and scar) on myocardial tissue from wt and CnAβ -/- mice subjected to
ischemia and 3 weeks of reperfusion. Analysis of six individual hearts in each group revealed
greater myocardial damage and increased interstitial fibrosis in CnAβ -/- mice compared with
wt animals (two representative hearts are shown for each group) (Figure 2C).
Figure 2a-d
wt wt wt
wt
wt wt
Figure 2
CnAß-/- mice show greater myocyte death
following ischemia-reperfusion. A.
Representative DNA ladder as an indication
of apoptosis from wildtype (wt) and CnAß-/-
hearts after ischemia-reperfusion injury (N =
6). B. Representative DNA fragmentation
detection assays by ligation-mediated PCR.
C. Representative histological sections
showing greater scarring in CnAß-/- hearts
after ischemia-reperfusion injury (N = 6). D.
TUNEL quantification of cardiomyocytes in
2 CnAß-/- and wildtype control hearts 3
weeks after ischemic injury expressed as a
percentage of total myocytes in the
remaining viable myocardium.
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As a more quantifiable measure of cell death, TUNEL was performed from histological
sections, 3 weeks after ischemia-reperfusion injury. Rates of TUNEL in cardiac myocytes
were assessed within the remaining region of viable left ventricle and septum, which
demonstrated approximately twice the rate in CnAβ -/- hearts compared with wt controls
(Figure 2D). Basal TUNEL rates did not vary between wt and CnAβ -/- hearts from sham
animals (data not shown). Collectively, these results indicate that CnAβ -/- mice undergo
enhanced cell death after ischemia-reperfusion injury, suggesting that calcineurin is normally
cytoprotective in the heart.
CnAβ -/- mice have a partially compromised immune response, (26) an effect that
might secondarily lessen the degree of myocardial injury, ventricular remodeling, and the
inflammatory response after ischemia-reperfusion injury. In attempt to control for such
E. Hematoxylin and eosin- and
chloroacetate esterase-stained
cardiac histological sections from
the indicated mice (24 hours of
reperfusion; arrows show mast
cells).
Figure 2e
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wt
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variables, cardiac histological sections were subjected to immunohistochemical analysis for
CD45 (total leukocytes), CD3 (T-lymphocytes), and B220 (B-lymphocytes), which showed
no differences in cellular recruitment 24 hours after ischemia-reperfusion in either group (data
not shown). Histological sections were also stained with hematoxylin and eosin (H&E) and
chloroacetate esterase (for mast cells) (Figure 2E). The data show similar degrees of
cellularity augmentation in both groups 24 hours after ischemia-reperfusion injury (H&E
sections), as well as equivalent levels of mast cells in the pericardium (Figure 2E).
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Figure 3 Figure 3
Cardiac morphology and function as
determined by echocardiography. A and
B. Left ventricular end-diastolic
dimensions (LVED) and left ventricular
end-systolic dimensions (LVES) in
CnAβ -/- mice compared to wildtype
(wt) mice (*, P < 0.05 versus baseline;
#, P < 0.05 versus wt after ischemia-
reperfusion).  Data are expressed in
millimeters, average ± SEM, N = 9. C.
Fractional shortening assessed by
echocardiography in CnAß-/- and wt
mice (*, P < 0.05 versus baseline; #, P
< 0.05 versus wt post-
ischemia/reperfusion, N = 9). Fractional
shortening was calculated as (LVED-
LVES)/LVED x 100 and expressed as
percentage, average ± SEM, N = 9.
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At baseline, hearts from CnAβ -/- mice functioned equivalent to wt control hearts with
respect to +dP/dt, maximal left ventricular pressure developed, and time to peak pressure,
each assessed by working heart preparation (Table). These results indicate that loss of
calcineurin Aβ does not obviously alter cardiac function in the unstimulated state. To further
evaluate the functional ramifications of enhanced cell death after ischemia-reperfusion injury,
transthoracic echocardiography was performed in CnAβ -/- mice and wt animals.
Echocardiography was performed at baseline and 1, 2, and 3 weeks after ischemia-reperfusion
injury to serially evaluate function non-invasively. As shown in Figures 3A and 3B, left
ventricular end-diastolic dimensions (LVED) and left ventricular end-systolic dimensions
(LVES) increased to a larger extent in CnAβ -/- mice compared with wt mice (P < 0.05).
These results indicate greater left ventricular dilation in the heart, presumably due to
enhanced cell death in the absence of CnAβ. More importantly, fractional shortening, which
approximates cardiac contractile performance, was reduced to a greater extent in CnAβ -/-
mice compared with wt mice 2 and 3 weeks after the ischemic event (P < 0.05, N = 9; Figure
3C). These results indicate that CnAβ -/- mice had reduced cardiac function after ischemia-
reperfusion injury compared with wt controls, consistent with the notion that CnAβ -/- hearts
are more susceptible to a cell death–promoting stimulus. However, it is possible that CnAβ -/-
mice could also show alterations in function due to differences in ventricular remodeling that
typifies post-infarction injury. To address this possibility, heart weight to body weight ratio
assessments were performed after the final 3-week echocardiographic measurement in both
groups. Neither wt nor CnAβ -/- mice underwent significant cardiac hypertrophy over this
time period under the conditions used, suggesting that the difference in functional
performance likely reflects the degree of injury (data not shown).
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Fig. 4: Relative expression ratios of selected functional gene groups assessed from microarray
screening. Cardiac RNA was collected from 2 CnAß-/- mice (KO) and two wildtype mice (wt)
and subjected to expression profiling using the Affymetrix U74Av2 array. The left panels
show a color scale representation of gene expression levels, with yellow equal to 1 (no
change), blue equal to 0.2 (reduced expression), and red equal to 5 (increased expression).
Absolute normalized expression data are shown for each sample in the right-hand columns
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expression in the array screen was subject to a confirmatory RT-PCR analysis of expression
levels at varying cycles (to show the most linear point in amplification).
The enhanced myocardial damage observed after ischemia-reperfusion injury in CnAβ -/-
mice suggested an alteration in one or more molecular pathway(s) that influences cell
survival. Given the vast number of effectors that might potentially influence the survival
versus apoptotic decision of myocardial cells after ischemia-reperfusion injury, we performed
a large scale, unbiased screen for altered gene expression. Specifically, hearts from 8-week-
old CnAβ -/- and strain-matched wt mice (2 each) were harvested and RNA was purified for
gene expression profiling using the Affymetrix U74Av2 array. This array contains all genes in
the murine Unigene database that have been functionally characterized (approximately 6000)
as well as an additional 6000 expressed sequence tags (ESTs). Duplicate heart samples were
cross-compared between wt and CnAβ -/- mice resulting in 5735 genes being significantly
detected in one or more groups after internal normalization. Of these genes, 437 were
significantly altered in expression between CnAβ -/- and wt hearts (P < 0.05). The raw data
shown in Figure 4 represent the 2n relationship of expression between wt and CnAβ -/- hearts.
For example, a wt value of 1.0 and a null value of 0.33 or 3.0 translates into an 8-fold change
in gene expression either way. The data are also depicted on a colorimetric scale for
simplicity (Figure 4A). Remarkably, 383 genes showed downregulated expression in CnAβ -/-
hearts, whereas only 54 genes showed upregulated expression. This general profile suggests
that the loss of CnAβ reduces the expression of a subset of cardiac genes, implicating
calcineurin as an important positive transcriptional effector pathway in the heart.
Expression signatures were further analyzed in CnAβ -/- hearts to potentially implicate
individual genes as phenotypic modulators. The most significantly altered genes within seven
functional categories were assembled and annotated; any one of which might affect the
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viability of cardiac myocytes after injury. An interesting alteration was identified in a select
group of genes that regulate sterol/cholesterol metabolism such as ATP-binding cassette
transporter ABC1, the low-density lipoprotein receptor-related protein 10, and the stearoyl-
coenzyme A desaturase 1 (Figure 4A). Also of interest, four cell cycle regulatory genes were
significantly altered in CnAβ -/- hearts, as well as five genes encoding mitochondrial-
localized proteins (Figure 4A). Within the transcription category, the DNA binding factors
Nkx2.5, Hand2, YB-1, and ATF-3 were each downregulated in CnAβ -/- hearts, whereas
ATF4 and DBP were upregulated. The observed reduction in Nkx2.5 and Hand2 expression,
which themselves are important regulators of cardiac gene expression, is consistent with the
proposed paradigm whereby calcineurin-NFAT signaling directly and indirectly augments
expression of a subset of cardiac genes. Another intriguing pathway alteration was observed
in structural genes that facilitate cellular adhesion and/or intracellular support. For example,
four and a half LIM domains 1, γ-sarcoglycan, α-sarcoglycan, desmoglein-2, α-6-integrin,
and α-4-tubulin each showed altered expression in the CnAβ -/- heart (Figure 4A). A large
number of genes that participate in cellular signaling, apoptosis signaling, or stress-responsive
signaling were also identified as significantly altered in the absence of CnAβ. Finally, a group
of genes showing altered expression in the array screen were selected for reverse transcriptase
polymerase chain reaction (RT-PCR) analysis at varying cycles to confirm the observed
relationships (Figure 4B). The data obtained by RT-PCR showed the same profile of
increased or decrease expression, confirming the reliability of the array screen (normalized to
L7 expression) (Figure 4B).
The large number of candidate genes showing altered expression made it difficult to
mechanistically establish which factors or pathways might ultimately underlie the observed
profile of greater stress-induced cell death in the absence of CnAβ. Despite this qualification,
the overall observation that large subsets of genes are reduced in expression suggests that
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calcineurin functions as a general transcriptional regulator in the heart, which might
predispose the heart to cell death. Indeed, NFAT transcription factors are primary effectors of
calcineurin signaling that could fulfill such a role (see next section).
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Fig. 6: Relative luciferase activity from the
hearts of NFAT-luciferase reporter transgenic
mice at baseline or after ischemia-reperfusion
injury. These reporter mice were crossed into
the CnAß-/- or CnAß+/+ background (N = 6
and 5, respectively). Activity is shown from
the whole heart (control), right ventricle (RV),
non-ischemic region of the LV and septum
(LV-non), and the LAD-perfused area of the
LV subject to ischemia (LV-injured).
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To determine the potential involvement of NFAT factors as regulators of cardiac
myocyte cell survival, a neonatal cardiac myocyte culture–based model was employed.
Whereas we have previously shown that calcineurin activation protects cultured myocytes
from staurosporine- or 2-deoxyglucose–induced apoptosis, the necessity of NFAT factors as
downstream mediators was not determined.14 To this end an NFAT-specific inhibitory
adenovirus was used that expresses the VIVIT peptide as a GFP fusion. (28) The specificity
of this inhibitory virus was demonstrated by co-infection with an NFAT-dependent reporter
adenovirus in cultured neonatal myocytes (Figure 5A). AdVIVIT dramatically inhibited
Ad∆CnA-induced activation of the NFAT-dependent luciferase reporter. More importantly,
AdVIVIT infection in neonatal cardiac myocytes augmented staurosporine-induced TUNEL,
whereas expression of an activated NFATc4 truncation mutant antagonized TUNEL (P <
0.05; Figure 5B). Moreover, Ad∆NFATc4 partially reduced enhanced TUNEL associated
with calcineurin inhibition through Adcain infection (also see De Windt et al(14))(P < 0.05,
Figure 5B). Expression of Ad∆NFATc4 infection also antagonized staurosporine-induced
DNA laddering, further implicating NFAT factors as modulators of apoptosis itself in cardiac
myocytes (Figure 5C).
The results discussed above indicate that NFAT factors can function as regulators of
apoptosis in cultured cardiac myocytes. However, it was uncertain whether NFAT factors
might play a similar role within the intact adult heart, downstream of calcineurin signaling. To
address this issue, NFAT-luciferase reporter transgenic mice were crossed into the CnAβ -/-
background and subjected to ischemia-reperfusion injury. NFAT-luciferase transgenic mice,
wt for CnAβ, were also generated from the same parental cross for direct comparison. Six
CnAβ -/- and five wt controls were subjected to 60 minutes of ischemia followed by 48 hours
of reperfusion injury, at which time the hearts were removed and parsed into three
components for measurement of luciferase activity: right ventricle (RV), non-ischemic left
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ventricle and septum (LV-non), and the injured area of the LV (LV-injured). The RV was
analyzed to measure NFAT activity as a secondary consequence of ischemia-reperfusion
injury–induced remodeling/hypertrophy. Ischemia-reperfusion injury dramatically enhanced
NFAT luciferase activity in each of the assayed ventricular compartments in wt controls
(Figure 6). More importantly, CnAβ -/- mice consistently showed less NFAT activation after
injury (Figure 6). These results suggest an association between reduced NFAT transcriptional
activity and diminished cardioprotection in CnAβ -/- mice.
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Discussion
In this study, we investigated the association between the calcineurin-NFAT signaling
pathway and cell death in the myocardium after stress stimulation. Loss of CnAβ rendered the
myocardium more susceptible to ischemia-reperfusion injury, suggesting that calcineurin
signaling helps maintain myocyte viability in vivo. Part of the mechanism responsible for
increased ischemic damage in CnAβ -/- mice is likely a secondary consequence of altered
gene expression due to reduced NFAT activity.
Although calcineurin has been recognized as a central regulator of the hypertrophic
growth of the myocardium, its role as an effector of myocardial cell death is more
controversial. In other tissues or cell-types, calcineurin has been shown to either agonize or
antagonize apoptosis after stress stimulation. Studies conducted in neurons, lymphocytes, and
tumor cell lines have shown both pro- and antiapoptotic effects of calcineurin activation. (15-
22) The exact decision of cytoprotection versus apoptosis is likely regulated by coordinated
signals from other co-stimulated signaling pathways or depends on cell-type specific
calcineurin effector/docking proteins. Indeed, calcineurin activation was shown to either
induce apoptosis or to antagonize apoptosis depending on the status of p38 activation. (32)
More recently, calcineurin was shown to localize to the mitochondria in fibroblasts through
docking with the inhibitory protein FKBP38, resulting in Bcl-2 and Bcl-xl redistribution. (33)
Calcineurin has also been implicated as a direct inducer of apoptosis in primary hippocampal
neurons through dephosphorylating the proapoptotic factor Bad. (15) In addition to cell-type
specific regulatory considerations, the pro- or antiapoptotic effects attributed to calcineurin
have been obscured by the use of cyclosporine A, which can modulate apoptosis independent
of calcineurin through direct effects on mitochondrial permeability transition pore (MPTP)
formation within the inner mitochondrial membrane. (25) Given the calcineurin-independent
effects associated with cyclosporine A and FK506, the use of calcineurin gene-targeted mice
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and/or null cells derived from these mice should help elucidate the direct role that calcineurin
plays in modulating cellular apoptosis in diverse tissues.
In the present study, we demonstrated that genetic disruption of the CnAβ gene in the
mouse enhanced cardiac damage induced by ischemia-reperfusion injury. This result indicates
that calcineurin signaling imparts a degree of protection against cell death in the heart.
Consistent with this notion, we have previously shown that transgenic mice expressing a
constitutively active mutant of calcineurin in the heart are significantly protected from
ischemia-reperfusion-induced cell death. (14) In cultured cardiomyocytes, adenoviral-
mediated gene transfer of activated calcineurin reduced 2-deoxyglucose-induced TUNEL,
whereas calcineurin inhibition with a Cain-expressing adenovirus increased TUNEL. (14) In
contrast, a subsequent study reported that isoproterenol stimulation of neonatal
cardiomyocytes promoted apoptosis, in part, by stimulating calcineurin activity. (24) These
authors demonstrated that cyclosporine A and FK506 blocked the increase in cardiomyocyte
apoptosis induced by isoproterenol stimulation and, more significantly, that transgenic mice
expressing dominant-negative calcineurin in the heart were refractory to isoproterenol-
induced TUNEL reactivity in vivo. These results suggest that calcineurin activation is
associated with enhanced apoptosis in cardiomyocytes, in contrast to our original and
subsequent observations. It is likely that the nature of the stimulus (isoproterenol) partially
underlies the disparity between the two studies discussed above. For example, isoproterenol
induces a prominent elevation in cAMP, which induces protein kinase A signaling and
secondary alterations in inotropy, events not typically associated with ischemic injury or
staurosporine stimulation.
By comparison, Kakita et al(23) recently identified an anti-apoptotic role for
calcineurin activation in cardiomyocytes after endothelin-1 stimulation. Specifically,
endothelin-1 stimulation protected cardiac myocytes in culture from H2O2-induced TUNEL
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reactivity, DNA laddering, caspase-3 cleavage, and loss of mitochondrial membrane potential.
This endothelin-1–mediated cytoprotection from H2O2-induced apoptosis was blocked by
inhibition of calcineurin with either cyclosporine A or FK506. Collectively, these disparate
accounts underscore the complexity of intracellular signaling networks within mammalian
cells, such that seemingly related stress stimuli can elicit fundamentally different responses
depending on the nature of the stimulus (mitochondrial- versus death receptor–mediated), the
status of other parallel signaling pathways, and the context of cell-type specific calcineurin
modulatory factors.
Although a large number of studies have implicated calcineurin as a modulator of cell
death in varied cell types, only a few downstream mechanisms responsible for death or
protection have been identified. As discussed above, calcineurin was reported to directly
dephosphorylate Bad in neurons, thus enhancing apoptosis. (15) Careful evaluation of Bad
phosphorylation at serine 112, 136, and 128 from the hearts of calcineurin transgenic mice or
CnAβ -/- mice failed to show any difference from controls (data not shown). Kakita et al(23)
reported that calcineurin-mediated protection from H2O2-induced apoptosis was associated
with an increase in Bcl-2 expression in cultured neonatal cardiac myocytes. However,
expression levels of Bcl-2 did not change in the hearts of either calcineurin TG mice or CnAβ
-/- mice, nor was expression altered for Bcl-xl, Bad, caspase-1, -3, -8, -9, or FKBP38 (data not
shown). Previously, we identified a minor but significant increase in Akt phosphorylation in
the hearts of calcineurin transgenic mice. (14) However, CnAβ -/- mice showed no difference
in basal or stimulated Akt phosphorylation in the heart, ruling out this potential mechanism
(data not shown). Collectively, these negative findings suggest that the classical effectors of
the apoptotic response are not directly linked to calcineurin signaling in the heart.
To investigate other potential mechanisms, an unbiased array screen was performed
from the hearts of CnAβ -/- and matched wt mice. Although a number of potential regulatory
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proteins were altered in expression, the most significant observation was the dramatic
downregulation in expression of large subsets of unrelated genes (about 6% of detectable
genes in the heart). This observation suggested a defect in the transcriptional potency
underlying a group of genes in the hearts of CnAβ -/- mice. This interpretation is consistent
with known role of NFAT transcription factors as important effectors of calcineurin-regulated
gene expression in most cell types. (34) Indeed, the full potency of calcineurin-induced
hypertrophy in the heart was shown to require NFATc3 using gene-targeted mice. (35)
With respect to apoptosis signaling, we previously observed that overexpression of an
activated NFATc4 in cultured neonatal cardiomyocytes partially antagonized 2-deoxyglucose-
induced apoptosis. (14) Furthermore, Kakita et al (23) showed that endothelin-1–mediated
protection from H2O2-induced apoptosis also promoted NFAT dephosphorylation. In this
study, we showed that specific inhibition of NFAT with AdVIVIT augmented cardiomyocyte
cell death after staurosporine treatment. More importantly, CnAβ -/- mice showed reduced
NFAT transcriptional activity in vivo after ischemia-reperfusion injury. These results are also
consistent with a recent report by Izumo and colleagues (36) in which NFAT inhibition
augmented cardiac myocyte apoptosis after phenylephrine stimulation in culture.
Collectively, these results discussed suggest that the homeostatic transcriptional
activity of NFAT provides the necessary framework of basal gene expression that affords
cardiac “health” and resistance to apoptotic stimuli. However, the exact array of downstream
effectors that are regulated by NFAT factors in providing protection is not known. Despite
this, the results of this study provide the first genetic data indicating that calcineurin signaling
is necessary for cardiac protection and suggests that strategies to acutely agonize calcineurin
might be of therapeutic benefit during or after myocardial infarction. However, this notion is
in dramatic contrast to the function of calcineurin as a mediator of cardiac hypertrophy, which
itself can lead to cardiomyopathy and heart failure if constitutively activated (although it is
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apoptosis-independent). These observations suggest that calcineurin may function as a
“double-edge sword,” such that transient activation antagonizes myocyte apoptosis, but long-
standing activation induces cardiac hypertrophy and deleterious ventricular remodeling
associated with heart failure.
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 Abstract
GSK-3β acts as an anti-hypertrophic kinase that can interfere with calcineurin
mediated signaling pathways evoked by diverse hypertrophic stimuli in vivo. Previously,
transgenic mice overexpressing a signal resistant form of GSK-3β (serine 9 mutated to
alanine) in the heart have been generated and characterized to have a blunted hypertrophic
response in response to calcineurin activation, adrenergic stimulation and pressure overload,
suggesting that GSK-3β functions as an inhibitor of hypertrophy in vivo. The present study
was designed to elucidate the role of GSK-3β following ischemia-reperfusion. Ischemia-
reperfusion induces immediate cardiac damage through apoptotic and necrotic processes,
followed by hypertrophic remodeling of the non-infarcted, viable myocardium. In transgenic
animals, ischemia led to a significantly larger infarct area and subsequent worsened cardiac
performance, while post-ischemic hypertrophic remodeling was blunted. Conclusively, these
findings point towards a role for GSK-3β as a dualistic signal molecule transducing both anti-
hypertrophic as well as cell death promoting pathways.
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Introduction
The adult myocardium responds to a variety of pathologic stimuli by hypertrophic
growth that frequently progresses to heart failure. (1) In contrast to other kinases, glycogen
synthase kinase-3β (GSK-3β) is highly active in unstimulated cells and becomes inactivated
in response to mitogenic stimulation. (2,3) The activity of GSK-3 is controlled by the
phosphorylation status of serine-9. Phosphorylation of this residue leads to inactivation of
GSK-3β activity by creating an inhibitory pseudosubstrate for the enzyme. (4) Conversely,
dephosphorylation of this site, or mutations that prevent phosphorylation, result in activation
of the kinase. Several protein kinases, including Akt/protein kinase B (PKB), have been
shown to phosphorylate serine-9 of GSK-3β in response to mitogenic signaling, thereby
inactivating the enzyme. (5) GSK-3β is also inhibited by Wingless/Wnt signaling through a
mechanism independent of serine-9 phosphorylation. (6)
Cardiac-specific expression of a signal resistant form of GSK-3β (GSK-3β S9A)
diminished hypertrophy in response to chronic β-adrenergic stimulation and pressure
overload. (7) The calcium/calmodulin-dependent protein phosphatase calcineurin is a potent
transducer of hypertrophic stimuli. (8) Calcineurin dephosphorylates members of the nuclear
factor of activated T cell (NFAT) family of transcription factors, which results in their
translocation to the nucleus and activation of calcium-dependent genes. GSK-3β
phosphorylates NFAT proteins and stimulates NFAT nuclear export leading to a diminished
DNA binding ability and prevention of transcription activation (figure 1). (9) Cross-breeding
of transgenic mouse lines with cardiac specific α-myosin-heavy-chain (MHC) driven
overexpression of constitutively active calcineurin and GSK-3β S9A gave significant
reductions in cardiac size, prevented β- MHC expression and reduced immunostaining for
nuclear NFAT. Moreover, left ventricular failure did not arise following surgical constriction
of the thoracic aorta in GSK-3β transgenic mice.
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Several molecules involved in cardiac hypertrophic signaling have been implicated to
promote cell survival. For instance, the MEK1-ERK1/2 signaling pathway stimulates cardiac
hypertrophic growth associated with augmented cardiac function (i.e. beneficial adaptive
hypertrophy) combined with partial resistance to apoptosis.(10,11) Another potent cardiac
survival factor, cardiotrophin-1 (CT-1) initiates cardiac hypertrophy and is capable of
inhibiting cardiomyocyte apoptosis too.(12,13) To date, the role of the calcineurin-NFAT
pathway in pro- or anti-apoptotic responses is not clear. For instance, adrenergic stimulation
led to calcineurin-mediated cardiomyocyte apoptosis (14), while other in vitro and in vivo
studies found calcineurin mediated myocardial protection against ischemia-induced apoptosis.
(15,16) It seems that NFAT nuclear import is the critical component in the regulation whether
calcineurin stimulation results in the activation of pro- or antiapoptotic pathways in
cardiomyocytes. (16,17) Selective NFAT inhibition during phenylephrine stimulation
prevented calcineurin mediated hypertrophy but resulted in increased cardiomyocyte
apoptosis. (17)
Figure 1
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Fig. 1: Inhibition of NFAT nuclear transport by
GSK-3β. GSK-3β is an endogenous inhibitor of
the calcineurin pathway. In unstimulated cells
active GSK-3β is present. GSK-3β phosphorylates
NFAT thereby inhibiting its nuclear transport.
During ischemia GSK-3β is inactivated, and is the
transcription factor NFAT able to exert its effects
in the nucleus.
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Previous studies have demonstrated that GSK-3β can act as an anti-hypertrophic
kinase capable of interfering with calcineurin mediated hypertrophic signals in vivo. (7) The
present study addressed whether GSK-3β is also involved in the acute cell death process and
later hypertrophic remodeling associated with ischemia-reperfusion-induced damage of the
myocardium. In addition, cardiac function was monitored by non-invasive echocardiography
and invasive pressure-volume determinations. It was observed that, ischemia led to a
significantly larger infarct area and subsequent worsened cardiac performance, while post-
ischemic hypertrophic remodeling was blunted.
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Materials and methods
Animals
For this study adult transgenic mice (GSK-3β TG) that expressed a signal resistant
form of GSK-3β (GSK-3βS9A) under control of the α-MHC promoter (7) and their wild type
littermates (GSK-3β wt) were used. All animals were kept under standard housing conditions
with an artificial 12h light cycle with free access to standard rodent food and tap water. The
animal studies were performed conform the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996) and were approved by the animal ethical committee of the University of Texas
Southwestern Medical Center.
Murine heart ischemia- reperfusion in vivo
Adult mice (8-10 weeks) were anesthetized with isoflurane, 2% in O2 (500 ml/min).
The anterior thorax was shaved and disinfected with betadine solution. Mice were placed on a
heating pad and body temperature was kept constant at 37° Celsius. A 20-gauge tube was
positioned in the trachea and connected to a rodent ventilator (Minivent, Hugo Sachs
Electronics, Germany) for mechanical ventilation (200 µl, 150 strokes per minute). A left
thoracotomy was performed to expose the heart and the left anterior descending artery (LAD).
The LAD was ligated with 8-0 prolene (Ethicon, USA) using a slip knot placed approximately
2 mm distal from its origin. Mice were allowed to wake up. The LAD ligation was removed
following 45 minutes of ischemia time, after which the hearts were allowed to reperfuse for
either 24 hours or 4 weeks. Sham-operations were performed in a similar manner, but the
LAD was not ligated. Myocardial infarction (MI) operation comprised of an irreversible LAD
ligation.
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Staining for infarct size
Following 24 hours of reperfusion mice were anesthetized with 2% isoflurane. Upon
complete anesthesia the thorax was quickly opened and the 8-0 prolene ligature was retied
around the LAD. A 0.5 cc insulin syringe was used to inject 0.3 ml of 2 % Evans Blue dye in
the left ventricle, thereby specifically staining all of the myocardial regions except for the
perfusion area distal to the LAD. The heart was removed, washed in PBS to rinse off the
excess dye and embedded in 2% agarose gel. Short-axis cross sections were cut from the heart
and placed in 2% 2,3,5-triphenyl-tetrazodium chloride (TTC) solution (Sigma, St. Louis,
USA) at 37° Celsius for 15 minutes to stain for viable myocardium. Slices were fixed in 10%
buffered formalin phosphate solution (Fisher Scientific, New Jersey, USA). The infarct area
(IA) is marked by a white color and represents the actual infarcted (i.e. dead) myocardial
tissue. The area-at risk (AAR) is the total area of the myocardium perfused by the LAD,
which was ischemic upon LAD occlusion. The AAR has a red color in the TTC/Evans blue
staining. The AAR is normalized for left ventricular area (LV) to control for measurement
localization. The LV area is colored blue. Digital pictures of both sides of the sections were
made and analyzed by computerized planimetry for infarct area (IA), area-at-risk (AAR) and
left ventricular area (LV) with ImageJ software (Wayne Rasband, National Institutes of
Health, USA).
Echocardiographic measurements
Left ventricular short-axis measurements were made with a Hewlett Packard Sonos
5500 ultra-sound machine and a 13 MHz transducer (Hewlett Packard Company, Palo Alto,
USA) 3 weeks following surgery. A standoff of 0.5-1.0 cm through the use of gel-filled glove
finger was used for recordings. Mice were anaesthetized with ketamine (100 mg/kg,
intramuscular) and xylazine (5 mg/kg, subcutaneous). The anterior thorax was shaved
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following complete anesthesia. Body temperature was maintained constant at 37° Celsius with
a heating lamp.
Left ventricular in vivo pressure-volume measurements
Following 4 weeks of reperfusion mice were instrumented and anesthetized according
to the ischemia-reperfusion procedure described above. The right and left external jugular
veins were cannulated with PE-50 catheters for saline and drug infusion. A 1.4 French
conductance-micromanometer (Millar Instruments, Houston, TX, USA) was inserted into the
right common carotid artery, advanced through the aorta and positioned in the left ventricle.
Correct LV placement was controlled by the combination of the online pressure and volume
signal. For pressure and volume signal acquisition the MCPU-200 recording unit (Millar
Instruments, Houston, TX, USA) and 8S/P Powerlab control unit (AD instruments, Australia)
were used, in combination with Chart and Scope software (AD instruments, Australia).
Function data analysis was performed with Circlab software (LUMC, the Netherlands).
 Statistical analysis
Results are presented as means ± SEM. Data were statistically analyzed by two-way
ANOVA using SPSS 8 software (SPSS Inc., Chicago, Illinois, USA). A P-value < 0.05 was
considered statistically significant.
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Results
The amount of cell death, either necrosis or apoptosis, was assessed by the TTC/Evans
Blue staining, where viable and dead tissue are distinguished (figure 2). GSK-3β wt mice (N =
3) showed a mean IA/AAR ration of 35 ± 9%, while GSK-3β TG mice (N = 3) had an infarct
area of 65 ± 19% following ischemia-reperfusion injury (figure 2). The AAR/LV ratios for
both groups were similar, meaning that the localization of the area measurements could not
account for differences detected. These findings indicate that GSK-3β activity exaggerates
cardiac damage following acute I/R injury.
Fig. 2: Cell death following ischemia-reperfusion injury. (A) Infarct area (IA) normalized to
the area-at-risk (AAR) by histological analysis of TTC- and Evans blue-stained heart sections
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from ischemia-reperfusion (I/R) injury. The IA/AAR for the GSK-3β wt (N = 3) and TG (N =
3) mice was respectively 35 and 65% (P = 0.28).(B) AAR was normalized to the area of the
left ventricle (LV) to control for localization of measurement. Each of the genetic models
showed equivalent AAR to LV ratios (wt vs TG, resp. 72 vs 56 %, not significant). (C)
Representative picture of a TTC- and Evans blue -stained heart from a GSK-3β wt mouse. (D)
Representative picture of a stained heart from a GSK-3β TG mouse.
GSK-3β TG mice showed blunted hypertrophic growth in response to several
hypertrophic stimuli in previous investigations. (7) In the present study the GSK-3β TG mice
showed attenuated hypertrophic growth compared to wildtype littermates two weeks
following I/R (figure 3). Both ischemia-reperfusion (*) and myocardial infarction (†)
stimulated cardiomyocyte hypertrophic growth in wildtype animals (resp. 26 and 19% growth
vs sham; P < 0.05). GSK-3β transgenic animals showed diminished growth (resp. 8 and 12%).
No significant differences were found between sham operated GSK-3β wt and TG animals
however.
Figure 3
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Fig. 3: GSK-3β transgenic mice are resistant to
hypertrophy induced by ischemia. (A) Heart weight-to-
body weight analysis showed in the wildtype mice ratios
for sham, ischemia-reperfusion and myocardial infarction
groups of 4.2 ± 0.1, 5.3 ± 0.5 and 5.2 ± 0.3 mg/g,
respectively.  In the transgenic animals values were 3.7 ±
0.2, 4.0 ± 0.2 and 4.2 ± 0.2 mg/g. * Indicates I/R vs sham
P < 0.05. † Indicates MI vs sham P < 0.05. (B) The
hypertrophic growth in percentages is larger in wildtype
compared to transgenic animals following both ischemia-
reperfusion (26 vs 8%) and myocardial infarction (19 vs
12%).
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Echocardiography was used at 2-3 weeks following the ischemic event to investigate
cardiac geometry and function (figure 4). GSK-3β overexpression was characterized by a HR
depression in TG animals, averaging 678 ± 14 beats per minute (bpm) in the wildtype group
compared to 620 ± 11 bpm in the transgenic group (P < 0.05). Cardiac function, defined by
fractional shortening (FS) was significantly different between wt and TG mice (resp., wt 48 ±
4% vs TG 39 ± 3%; P < 0.05). Ischemia induced several geometrical and functional
alterations. Wall diameters were thicker in wildtype compared to transgenic mice (anterior
wall diameter, wt 0.85 ± 0.00 mm vs TG 0.75 ± 0.00 mm; P < 0.05). I/R led to the most
pronounced hypertrophic response as indicated by wall thickness in both wt and TG mice
(posterior wall diameter, sham 0.89 ± 0.00 mm vs I/R 0.98 ± 0.00 mm vs MI 0.78 ± 0.00 mm;
P < 0.05). In addition, the performed procedure resulted in significant differences in FS (resp.,
sham 53 ± 2% vs I/R 47 ± 4% vs MI 31 ± 3%; P < 0.05). Transgenic GSK-3β mice subjected
to MI showed the most deteriorated cardiac function as assessed by FS, i.e. 28 ± 4%.
Cardiac function by in vivo pressure-volume measurements was performed 4 weeks
following the ischemic event (table 1). The depression in HR was also evident with this
technique: HR averaged 628 ± 13 bpm in wildtype mice and 562 ± 14 bpm in transgenic
GSK-3β mice (P < 0.05). Several other statistical differences between the two genotypes were
found. Cardiac output was lower in GSK-3β transgenic mice (wt 1657 ± 166 rvu/min vs TG
1210 ± 88 rvu/min; P < 0.05), without significant differences in stroke volume (figure 5). Left
ventricular relaxation was prolonged in GSK-3β transgenic mice as shown by the time
constant of left ventricular relaxation (Tau, τ, wt 8.9 ± 0.4 ms vs TG 10.7 ± 0.6 ms; P < 0.05)
and pressure halftime (PHT, wt 4.7 ± 0.2 ms vs TG 6.0 ± 0.4 ms; P < 0.05).  Analysis of the
pressure-volume relationships did not reveal striking differences between genotypes (table 2).
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Figure 4
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Fig. 4: Echocardiographic analysis three weeks following the ischemic event. (A)
Heart rate in beats per minute (bpm). Heart rate averaged 687 bpm within the
wildtype group versus 620 bpm in the transgenic group (P < 0.05). No
differences were found between sham, I/R or MI procedures. (B) Fractional
shortening in percentage. Fractional shortening averaged 48% in the wildtype
group versus 39% in the transgenic group, which was statistically different (P <
0.05). A decline in fractional shortening is seen depending on the severity of the
ischemic event (resp., sham 53% vs I/R 47% vs MI 31%; P < 0.05). (C) Anterior
wall diameter in millimeters. Differences were seen in left ventricular anterior
wall diameter three weeks after the ischemic event by echocardiographic analysis
between the wildtype and transgenic groups (resp., wt 0.85 mm vs 0.75; P <
0.05). (D) Posterior wall diameter in centimeters. No differences were seen
between the wildtype and transgenic mice groups. Statistically significant
differences were found between procedures, with the largest wall diameters in
I/R mice (0.98 mm) compared to the smallest diameters in MI mice (0.78 mm; P
< 0.05).
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Several parameters of cardiac function were significantly altered depending on the performed
surgical procedure (table 1, figure 5). Stroke volume (SV) and cardiac output (CO), for
instance, were highest in sham animals and lowest in I/R mice (sham 3.18 ± 0.29 rvu vs I/R
Figure 5
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Fig. 5.: Deterioration in cardiac function following ischemia. (A) Cardiac
output in relative volume units (RVU) per minute. Cardiac output
decreased significantly following ischemia as determined by the in vivo
catheterization method. # P < 0.05 GSK-3β wt sham versus I/R. Also,
cardiac output was lower in GSK-3β transgenic compared to wildtype
mice (resp., 1210 RVU/min vs 1657 RVU/min. (B) Ejection fraction in
percentage. Ejection fraction deteriorated following ischemia. # P < 0.05
GSK-3β wt sham versus MI, * P < 0.05 GSK-3β TG sham versus I/R. (C)
Minimal first derivative of left ventricular pressure in mm Hg/s. The
functional parameter dP/dtMIN deteriorated significantly depending on the
severity of the ischemic event. # P < 0.05 GSK-3β wt sham versus MI, *
P < 0.05 GSK-3β TG sham versus MI.
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1.87 ± 0.20 rvu vs MI 2.39 ± 0.20 rvu; P < 0.05). Moreover, ischemia-reperfusion groups
consistently showed low cardiac performance as assessed by stroke work, ejection fraction
and pressure-volume area. Pressure-volume analysis revealed similar differences in preload-
recruitable stroke work (PRSW, sham 59 ± 5 mm Hg/rvu vs 36 ± 3 mm Hg/rvu vs 37 ± 4 mm
Hg/rvu; P < 0.05). The minimal first derivative of left ventricular pressure (dP/dtMIN) was the
only parameter completely depending on the severity of the ischemic event (sham -7635 ±
533 mm Hg/s vs I/R -6432 ± 416 mm Hg/s vs MI -4981 ± 373 mm Hg/s; P < 0.05; figure 5).
The arterial-ventricular coupling ratios (Ea/Ees) equaled 1 in both sham groups reflecting
maximal performed left ventricular stroke work (SW). However, upon ischemic damage the
coupling ratios deviated from 1, rising up to 1.70 (figure 6). The rise of the coupling ratios
depended on the increase of arterial elastance (Ea) in the ischemia study groups, because the
slope of the ESPVR lines remained on sham level. Left ventricular mechanical efficiency was
found to be depressed also upon ischemia. Left ventricular mechanical efficiency, defined by
the ratio between SW and pressure-volume area (PVA), was 0.74 ± 0.02 in sham, 0.61 ± 0.02
in ischemia-reperfusion and 0.71 ± 0.02 in MI mice (P < 0.05).
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Fig. 6: Arterial-ventricular coupling mismatch
following ischemia. The Ea/Ees ratio deviates
from 1 following ischemia, indicating a
mismatch between arterial and ventricular
elastance which results in submaximal left
ventricular stroke work. In contrast to the GSK-
3β transgenic mice, the Ea/Ees ratio is
significantly augmented between sham and I/R
GSK-3β wildtype mice. The myocardial
infarction groups are not incorporated in the
analysis because of the low number of animals
(N = 2) in the studygroups. * P < 0.05 GSK-3β
wt sham versus I/R.
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Representative pressure-volume loops for all experimental groups are depicted in
figure 7. Ischemia led to a decline in cardiac function reflected by a rightward shift of the PV-
loops, decreased stroke volume and ejection fraction, and attenuated pressure in both
genotypes.
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Figure 7 Fig. 7: Cardiac function expressed by pressure-
volume loops. (A) PV-loops measured in sham
(black line), ischemia-reperfusion (red line) and
myocardial infarction (blue line) GSK-3β
wildtype mice. Ischemia leads to a rightward
shift of the PV-loops, decreased stroke volume
and ejection fraction, and diminished pressure.
(B) PV-loops measured in GSK-3β transgenic
mice.  Function decline following ischemia is
detected by the rightward shift on the volume-
axis, the decreased stroke volume and ejection
fraction, and lower pressure.
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Discussion
In GSK-3β mice ischemia-reperfusion led to an 85% enlargement of the infarct areas
compared to wildtype littermates. Hypertrophic growth was attenuated in transgenic animals
following I/R. Finally, following ischemia cardiac functional deterioration was more
pronounced in GSK-3β transgenic mice than in wildtype mice.
GSK-3β acts as an antihypertrophic kinase known to interfere with hypertrophic
stimuli, such as chronic β-adrenergic stimulation and pressure-overload. The present paper
demonstrates the antihypertrophic effect of GSK-3β overexpression following myocardial
ischemia. Several cellular targets of GSK-3β have been associated with hypertrophic growth.
For instance, GSK-3β is capable of inhibiting c-jun, a prohypertrophic transcription factor and
target of the mitogen-activated protein kinase JNK. (18,19) Other targets as c-myc, cyclin D1,
glycogen synthase and eukaryotic initiation factor 2B could all be involved in the process of
cardiomyocyte hypertrophy. (20,21) However, GSK-3β prevents hypertrophic growth
predominantly by inhibiting NFAT nuclear transport, as NFAT nuclear transport is sufficient
to provoke hypertrophic cell growth. (7,8)
The pro-apoptotic effect of GSK-3β in response to ischemia-reperfusion injury could
be explained by the inhibitory effect of GSK-3β on the cell-survival calcineurin-NFAT
pathway.  NFAT nuclear transport appears to be the critical determinant in the anti-apoptotic
effect of the calcineurin pathway. (16,17) The direct effect of GSK-3β overexpression on
NFAT activity could be the explanation for the myocardial infarction enlargement following
ischemia in the studied transgenic mice. However, as shown by the study of De Windt et al. is
the calcineurin-NFAT pathway only partly capable of inhibiting apoptosis. (15)
The mechanism whereby calcineurin affords protection from apoptosis is partially
mediated by calcineurin-NFAT signaling and partially by phosphatidylinositol 3-kinase
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(PI3K) signaling. (15)  PIK3 is involved in both hypertrophic (22,23) and anti-apoptotic
processes (24,25). Downstream target for PI3K is Akt/protein kinase B (PKB.) Akt/PKB is
capable of phosphorylating BAD and thereby inhibiting the cytochrome C mediated apoptosis
pathway. (26,27) Another downstream target of Akt/PKB is GSK-3β. Many stimuli that
activate PI3K inhibit GSK-3β through Akt/PKB. (3,28) GSK-3β is inactivated by Akt/PKB
through phosphorylation. Inhibition of Akt/PKB and subsequent activation of GSK-3β leads
to the promotion of apoptosis (29), while on the other hand activation of Akt/PKB prevents
GSK-3β mediated apoptosis (30).
Another cellular target of Akt/PKB and active GSK-3β is NF-κB. (31) Activation of
the transcription factor NF-κB induces gene transcription programs involved in the
myocardial protection against ischemia. (32) GSK-3β acts as a negative regulator of NF-κB
activity during apoptosis suggesting that the pro-apoptotic effects of active GSK-3β may be
mediated at least in part through the inhibition of NF-κB pathway. (33,34) Interestingly, NF-
κB activity is partly under the control of calcineurin. Stress-induced activation of NF-κB
involves inactivation of I-κBβ through calcineurin-mediated dephosphorylation. (35,36)
Most other transcription factors that are negatively regulated by active GSK-3β,
thoroughly reviewed by Hardt (3), are involved in processes of apoptosis prevention and cell
proliferation.
Overexpression of a constitutively active GSK-3β protein would theoretically result in
the stimulation of apoptosis because of the fact that the protein is catalytically active in cells
even under unstimulated conditions as was found in astrocytes. (34) However, unstimulated
rates of apoptosis were not found to be augmented in the hearts of the GSK-3β transgenic
mice.
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Until now, a hemodynamic assessment to elucidate the effects of GSK-3β activity on
plain cardiac function had not been performed. Cardiac performance was assessed by
echocardiography and in vivo pressure-volume measurements to evaluate the differences in
genotype. Cardiac function in the GSK-3β transgenic mice was characterized by attenuated
heart rate and cardiac output in comparison to wildtype mice at baseline in both
echocardiographic and pressure-volume measurements without a known cause. Although a
decrease in cardiac output could reflect the pathological state of heart failure, the survival
curve of unstimulated GSK-3β transgenic mice is not significantly different compared to their
wildtype littermates. Mice overexpressing Akt specifically in the heart demonstrated
enhanced contractile parameters. (37) Those mice showed heightened levels of inactive
phosphorylated GSK-3β. Left ventricular catheterization revealed furthermore a relatively
slower diastolic relaxation in unstimulated transgenic animals as assessed by the time constant
τ and pressure halftime. Ischemia or other causes of myocardial depression are frequently the
cause of attenuation in the rate of left ventricular pressure decline. However, without the
presence of other indications of cardiac dysfunction at baseline, for instance within the
pressure-volume relationships, the prolongation of τ is probably purely depending on the low
heart rate in GSK-3β transgenic mice.
Cardiac performance was also analyzed for the effects of ischemia-reperfusion and
myocardial infarction on specific parameters. Comparable functional decrements were seen in
wildtype and transgenic animals. Ischemia-reperfusion and myocardial infarction showed
alternatively the worst attenuation in cardiac performance. Cardiac output and left ventricular
ejection fraction decreased significantly indicating worsening of cardiac performance. No
differences were seen in the pressure-volume relationships. However, ischemia led to an
arterial-ventricular coupling mismatch and attenuation of left ventricular mechanical
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efficiency. Augmented vascular resistance associated with altered arterial compliance is the
consequence of these effects. (38)
The present study evidently showed the ischemia-induced proapoptotic effect of GSK-
3β in cardiomyocytes. Ischemia led to an enlargement of the infarct area and subsequent
decrease in cardiac performance in transgenic animals, while the hypertrophic response
following ischemia was blunted. GSK-3β acts as a central modifier in antihypertrophic and
proapoptotic signaling pathways. Future research should be performed to elucidate the
possible clinical value of GSK-3β in cardiac hypertrophy and ischemia.
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Fig. 8: Proposed mechanisms of the pro-apoptotic effects of
GSK-3β. Active GSK-3β inhibits the anti-apoptotic effects
of the transcription factors NFAT and NF-κB (dashed lines).
Upon stimulation of PI3K by an ischemic stimulus GSK-3β
is inactivated through phosphorylation by Akt/PKB (straight
lines). Akt/PKB itself stimulates NF-κB activity and
concomitantly cell survival gene programs. Inactive GSK-
3β has no inhibitory effect on the calcineurin-NFAT
pathway, also promoting cell survival.
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Table 1. LV cardiac function derived by in vivo pressure-volume analysis in wildtype and GSK3-β transgenic mice four weeks following the
initial ischemic insult.
GSK3-β wt GSK3-β TG
Sham I/R MI Sham I/R MI
MEAN SEM MEAN SEM MEAN SEM MEAN SEM MEAN SEM MEAN SEM
 N = 9 N = 10 N = 6 N = 7 N = 9 N = 10
HR* 624 ± 22 627 ± 21 638 ± 25 609 ± 17 550 ± 28 540 ± 21
SV† 3.77 ± 0.30 1.66 ± 0.27 2.64 ± 0.37 2.30 ± 0.33 2.13 ± 0.30 2.17 ± 0.19
CO*† 2348 ± 237 1032 ± 180 1662 ± 214 1429 ± 223 1091 ± 106 1159 ± 130
VMAX 7.56 ± 0.60 4.13 ± 0.54 6.91 ± 0.78 5.38 ± 0.81 5.82 ± 0.60 5.03 ± 0.39
VMIN 3.42 ± 0.45 2.07 ± 0.29 4.08 ± 0.51 2.72 ± 0.49 3.26 ± 0.41 2.63 ± 0.27
ESP 86 ± 6 80 ± 5 71 ± 4 78 ± 6 78 ± 7 72 ± 5
EDP 4 ± 1 5 ± 1 6 ± 2 7 ± 3 6 ± 1 10 ± 1
dP/dtMAX 10263 ± 1055 8205 ± 999 6828 ± 705 7916 ± 714 8340  ± 1430 6470 ± 659
dP/dtMIN† -8253 ± 753 -6826 ± 635 -5419 ± 442 -6840 ± 683 -5994 ± 523 -4719 ± 535
SW*† 321 ± 37 135 ± 27 167 ± 19 175 ± 27 153 ± 28 149 ± 12
Tau* 8.33 ± 0.43 9.13 ± 0.72 9.41 ± 1.04 9.99 ± 1.08 9.29 ± 0.50 12.51 ± 1.08
PHT* 4.49 ± 0.35 4.74 ± 0.36 5.03 ± 0.48 5.40 ± 0.74 5.18 ± 0.30 7.04 ± 0.65
EF† 54 ± 3 45 ± 6 39 ± 3 50 ± 2 40 ± 2 47 ± 4
PVA*† 432 ± 46 217 ± 40 235 ± 23 237 ± 35 223 ± 37 211 ± 21
* Genotype P < 0.05 wt vs TG. † Procedure P < 0.05 sham vs I/R vs MI. HR indicates heart rate; SV stroke volume; CO cardiac output; VMAX
maximal left ventricular volume; VMIN minimal left ventricular volume; ESP end-systolic pressure; EDP end-diastolic pressure; dP/dtMAX
maximal first derivative of left ventricular pressure; dP/dtMIN minimal first derivative of left ventricular pressure; SW stroke work; Tau time
constant of relaxation; PHT pressure halftime; EF ejection fraction; PVA pressure-volume area.
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. Table 2. Pressure-volume relationships at baseline cardiac function
GSK3-β wt GSK3-β TG
Sham I/R MI Sham I/R MI
MEAN SEM MEAN SEM MEAN SEM MEAN SEM MEAN SEM MEAN SEM
N = 6 N = 6 N = 2 N = 6 N = 6 N = 7
ESPVR 19 ± 5 20 ± 1 24 ± 9 25 ± 4 18 ± 2 24 ± 4
PRSW† 65 ± 9 31 ± 3 43 ± 0 52 ± 6 40 ± 5 35 ± 5
dP/dtMAX – Ved 1352 ± 221 1187 ± 274 1152 ± 224 1420 ± 331 1015 ± 136 1049 ± 192
EDPVR 1.26 ± 0.59 3.43 ± 0.79 2.39 ± 0.74 3.14 ± 0.56 3.16 ± 0.30 2.89 ± 0.82
Ea 15 ± 2 35 ± 7 27 ± 10 27 ± 6 30 ± 5 39 ± 7
Ea/Ees 1.01 ± 0.23 1.76 ± 0.23 1.11 ± 0.03 1.11 ± 0.23 1.75 ± 0.38 1.84 ± 0.36
† Procedure P < 0.05 sham vs I/R vs MI. ESPVR indicates end-systolic pressure-volume relationship; PRSW preload-recruitable stroke work;
dP/dtMAX-Ved maximal first derivative of left ventricular pressure-to-end – diastolic volume relationship; EDPVR end-diastolic pressure-volume
relationship; Ea arterial elastance; Ea/Ees arterial-ventricular coupling.
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The concept of cardiomyocyte resuscitative survival pathways
Intracellular signaling pathways mediate cellular adaptation upon stimulation by
external or internal factors. These intracellular signaling pathways are cascades of enzymes,
kinases, phosphatases and/or peptides. They (in)activate the target protein downstream from
itself, thereby forming communication-chains of molecular switches between stimulus and
cellular response. Specific stimuli or situations induce (in)activation of specific signaling
pathways. The eventual cellular response could be of non-genomic or genomic character.
Non-genomic effects develop within seconds and circumvent DNA transcription. The direct
modulation by estrogens of L-type Ca2+-channels via cardiac guanine monophosphate
(cGMP)-pathways decreasing the cellular Ca2+-influx is one example of a non-genomic
cellular response. (1) Initiation of the caspase-cascade by ischemia-injury leading to apoptotic
cell death is another non-genomic cellular response. In contrast, genomic effects constitute
changes in gene expression, requiring DNA transcription and RNA translation leading to the
formation of new or additional proteins. Genomic effects have a delay in the range of minutes
to hours. The well-known estrogen-induced expression of atrial natriuretic factor (ANF),
which is known to possess anti-hypertrophic effects, is one example of a genomic cellular
response. (1) Another example of genomic cellular responses characterizes pressure-induced
hypertrophic growth. The mechanical stress induces a fetal-like gene-expression profile that
promotes the assembly of additional motor units and cytoplasmic protein content to alleviate
the heart from its hemodynamic burden. The adaptation of cells via genomic and non-
genomic responses upon stimulation is tightly controlled by multiple signaling pathways in
close relationship with each other (Figure 1).
Cardiomyocyte resuscitative survival pathways mediate the response of the
cardiomyocyte upon stimulation by deleterious situations as ischemia-reperfusion or pressure-
overload. The viability of cells and organs are mainly maintained through the well-conserved
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processes of hypertrophy and anti-apoptosis. In general cardiomyocyte hypertrophy augments
the capacity of the cell to cope with hemodynamic stress. There is reasonable consensus
assuming the cardiomyocyte in the adult heart to be terminally differentiated, although
interesting concepts and experimental findings surmise otherwise. (2) Being terminally
differentiated the cardiomyocyte is incapable of counteracting augmented wall stress or
increased cell loss by cellular self renewal, i.e. regenerating myocardial tissue. It is through
the formation of additional sarcomeric motor units and volume-expansion, characteristics of
hypertrophy, that cardiomyocytes withstand the hemodynamic burden. Through another
mechanism the heart is protected against inefficient, unviable or potentially malignant cells,
i.e. by the phenomenon of programmed cell death (apoptosis). Cellular injury, as occurs
subsequently to ischemia, negatively influences intracellular activity of structural and
functional proteins, and thereby initiates apoptosis. The time- and energy-requiring process of
Figure 1
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Fig. 1: Intracellular signaling
pathways. This figure presents a
scheme of some of the signaling
pathways involved in cellular
hypertrophy and apoptosis. It
indicates the multiplicity of signaling
pathways involved and their
numerous interconnections, making
the understanding of precise signaling
difficult.
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apoptosis destructs the cells without secondary inflammation and prevents functional
deterioration of the heart in time. Both hypertrophy and apoptosis-inhibition provide adequate
adaptation of the cardiomyocyte towards detrimental situations, thereby warranting prolonged
cellular livelihood.
Cardiomyocyte resuscitative survival pathways can be defined in detail by several
characteristics. Firstly, survival pathways are those signaling cascades that simultaneously
mediate hypertrophic and anti-apoptotic responses in the same response. Another
characteristic is their indispensable presence in cellular physiology throughout life.
Hypertrophy and apoptosis inhibition are well-conserved cellular adaptation processes that
promote cell survival in different situations at distinct life-stages of the organism. Already in
the first phase of life, where the struggle for survival begins, the processes of
hypertrophy/(proliferation) and apoptosis are crucial for normal development. The region-
specific balance between cardiomyocyte proliferation, differentiation and apoptosis sculptures
the heart during embryogenesis (Figure 2A). MEK1-ERK1/2 and calcineurin-NFAT pathways
are already determining at this time-point in the development of normal cardiogenesis. (3-6)
Later in life, in the adult cardiomyocyte, MEK1-ERK1/2 and calcineurin-NFAT pathways
promote cellular hypertrophy and protect against apoptosis in response to adverse situations
like ischemia. (7-11) Additionally, and interestingly, in an attempt to regain proliferative
capacity cardiomyocytes express fetal gene-transcription programs in case of hypertrophic
growth.
And finally, the balance between the combination hypertrophy/apoptosis determines
the clinical outcome of the heart under pathological conditions (Figure 2). Molecular research
in cardiomyocyte hypertrophy led to the concept that specific intracellular signaling could
predict the clinical outcome, i.e. beneficial or maladaptive hypertrophy, which is not
depending on the degree of hypertrophy or functional efficiency of the affected
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cardiomyocytes. Instead, maladaptive hypertrophy proved to coincide with increased cell
death, eventually resulting in the development of heart failure (Figure 2D). (12-16) Heart
failure does not develop at a similar rate or to a similar degree, when the occurrence of
apoptosis is prevented. (17,18) Interestingly, beneficial hypertrophy is, on the other hand,
related to lower degrees of cardiomyocyte apoptosis (Figure 2C). (7) Apparently combined
signaling promoting hypertrophy and inhibiting apoptosis simultaneously influences
positively the clinical outcome, while the combination of hypertrophy with apoptosis is
associated with deterioration of cardiac function.
Fig. 2: The balance between hypertrophy and apoptosis. A. During embryogenesis the
proliferation/hypertrophy versus apoptosis balance is region-specific. This determines the
eventual form of organs and limbs in the growing fetus. In general augmented apoptosis rates
coincide with attenuated hypertrophy or proliferation levels (straight arrows). The opposite is
true for attenuated apoptosis rates (dotted arrows).  B. In normal adult mammal tissue are
proliferation/hypertrophy and cell death/apoptosis in balance. C. In the heart the combination
of cellular hypertrophy with attenuated apoptosis rates is beneficial for cardiac function and
Figure 2
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clinical outcome. This combination is designated beneficial hypertrophy. D. Whenever
hypertrophy is in dysbalance with augmented apoptosis rates, the functional status of the heart
progresses towards clinical heart failure. This form of hypertrophy is therefore named
maladaptive hypertrophy.
The present thesis investigated the MEK1-ERK1/2 and calcineurin-NFAT pathways in
their role as cardiomyocyte survival pathways in acute ischemic heart disease.
Several studies proved their role to be essential in endogenous cardiomyocyte hypertrophy
through genetic engineering. (7,8) Numerous other studies proved their necessary presence in
exogenous stimulated hypertrophic growth through pressure-overload and catecholamines.
(19-26) In this thesis their protective role against ischemia-reperfusion injury within the
myocardium was shown (Chapter 4-6). The anti-apoptotic effect of MEK1-ERK1/2 activation
has been observed by others in the past. For instance, MEK1-ERK1/2 activation enhances
expression of FLICE (FADD-like interleukin 1ß-converting enzyme) inhibitory protein, a
known inhibitor of the caspase cascade. (27) Alternatively, MEK1-ERK1/2 activation confers
cellular protection by preventing mitochondrial membrane permeability. (28) MEK1-ERK1/2
activation directly activates p90rsk resulting in inactivity of the pro-apoptotic factor Bad. 
The cytoprotective role of calcineurin has been more controversial, because of
contradicting results between several cell types (discussed in Chapter 5). However, the
genetic loss-of-function study discussed in Chapter 5 clearly showed the detrimental effect of
calcineurin loss in the heart during ischemia-reperfusion injury. The cell-survival effect of
calcineurin signaling could partially be mediated by NFAT signaling and partially by
phosphatidylinositol 3-kinase (PI3K) signaling, and their respective downstream targets.
(11,29) The precise role of NFAT molecules in ischemia-induced apoptosis has not been
determined yet, but will be elucidated through future research. The role of PI3K in apoptosis,
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though, has been better delineated. In pathological situations such as ischemia PIK3 activates
Akt/protein kinase B (PKB). Akt/PKB itself is capable of phosphorylating Bad and thereby
inhibiting cytochrome C release and apoptosis. (30,31)  Furthermore, Akt/PKB prevents
apoptosis by inhibition of GSK-3β, of which the numerous downstream targets are generally
disadvantageous for cell survival. (32,33) As in addition, Akt/PKB has been proven to be
involved in cardiomyocyte hypertrophy (34-36), it certainly complies with the definition of a
cardiomyocyte survival pathway.
The future challenge will be to develop strategies that exploit cardiomyocyte
resuscitative survival signaling in the heart by tightly controlling activation of potentially
beneficial mechanisms in the myocardium during ischemic stress in human patients.
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Expanding research in cardiomyocyte resuscitative survival pathways
Research into cardiomyocyte resuscitative survival pathways demands explicit
conditions. In vitro experiments in cultured cardiomyocytes clarify interactions between
molecules and provide indications for the direction of signaling pathways. However,
reproducibility of in vitro results in the living mammal is not guaranteed. Better evidence is
provided by in vivo experiments in genetically modified animals, most notably transgenic and
gene-targeted mice. Frequently used knockout and overexpression techniques give rise to a
genetic modification of the cellular response on pathological situations, as the engineered
gene-expression alteration is permanently and irreversibly present since conception. This
genetic predisposition very often does not match with human disease. New techniques as
tamoxifen-induced cardiac-specific and temporally regulated gene-expression approximate
reality better, as the confounder genetic predisposition is evaded. (37,38)
As has been described earlier, heart disease occurs whenever survival pathways have
been corrupted or disadvantageous signaling patterns predominate. As signaling pathways
constitute of proteins it is essential to look at temporal and spatial changes in protein
modulation. The method for molecular analysis is proteomics. Some considerations of
proteomic studies have to be mentioned as proteins are more difficult to work with than DNA
or RNA. Proteins cannot be amplified like DNA; proteins have secondary and tertiary
structure; proteins can be denatured or otherwise altered during the process of purification of
intracellular proteins. Purification demands excessive processing and some proteins are
difficult to analyze due to their poor solubility. Proteomic studies are performed at the level of
protein-protein interactions, frequently using molecular imaging as the investigative tool.
Multiple techniques have been developed in the past for in vitro molecular imaging, like mass
spectrometry and two-hybrid assays. However, in vitro investigations miss the theoretic
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systemic influences of pathology on cellular processes. New imaging techniques have been
developed equipped for studies in the living animal.
Initial reports of real-time molecular imaging were reported by Dumont et al. (39)
Fluorescent labeled proteins were infused for visualization of apoptotic membrane changes of
single cardiomyocytes during myocardial ischemia in the living mouse. The authors state that
this technology could enhance knowledge of intracellular signaling pathways in the process of
apoptosis and strategies to manipulate these pathways for therapeutic effect in humans.
Human in vivo visualization and quantification of apoptotic signaling following myocardial
ischemia has been reported using similar techniques. (40) The fluorescence labeling of
binding molecules as performed in these studies is feasible for a multitude of target proteins
and DNA molecules and results in temporal and spatial information of the various processes
involved. Other molecular techniques in development include for instance two-hybrid systems
for positron-emission tomography (microPET) and fluorescence imaging in the living animal,
involving the creation and intracorporeal implementation of hybrid proteins (i.e. fusion of
proteins of interest with DNA binding or transcription activation domains) and resulting
expression of a reporter gene. (41,42) Another in vivo noninvasive visualization technique
uses magnetic resonance molecular imaging combined with exogenous contrast agents
directed towards specific molecular entities of most notably the cellular outer membrane. (43)
(44) This is not a detailed enumeration of all techniques in development, but does delineate
the process of in vivo molecular imaging. As the examples from above show, at this moment
molecular imaging is confined to the visualization of single molecules in extensive signaling
cascades. Focusing on single molecules blindfolds the investigator for the role of other
proteins, peptides and signaling cascades. Making molecular imaging more dynamic through
incorporating the possibility for visualization of single pathways at distinct levels within the
cascade, or simultaneously multiple pathways, would increase its value in molecular
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biological research: dynamic molecular imaging (DMI). Powerful data would arise from
detailed exploration of real-time intracellular signal transduction in different heart disease
conditions. DMI derived information could clarify and visualize intracellular signaling
activity (ISA) patterns in the course of disease development like hypertrophy and heart failure
in a temporal and spatial manner. Moreover, changes in ISA patterns could be adequately
followed. Detailed knowledge about the relationship between ISA patterns and concurrent
disease condition enables scientists and clinicians to predict prognosis. Moreover, therapy
could be provided in a tailored manner. As DMI could prove to be indispensable in
cardiovascular research and clinical practice and current techniques are not yet insufficient,
new developments have to be initiated.
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Clinical relevance
This thesis points to the anti-apoptotic effect of genetic activation of MEK1-ERK1/2
and calcineurin-NFAT pathways in ischemia-reperfusion injury. The extent of ischemia-
induced apoptotic injury in cardiomyocytes is diminished compared to normal protein
activation. In addition, attenuated ischemia-induced injury form a risk for the maintenance of
cardiac function, a determinant of clinical prognosis.
The results reported in this thesis provide in the first place valuable additive basic
scientific knowledge about intracellular signaling pathways in ischemia-induced apoptosis.
They provide important handles for future therapeutic options in clinical care for mainly acute
ischemic heart diseases. Main limitation is the fact that the presented experiments were
performed in genetically modified mice. Results derived from murine studies are not
necessarily suited for direct translation to the human population, despite the major
comparability in DNA composition between the two species. Another important limitation is
the use of genetically modified mice, as genetic engineering is not an option in human
patients. Nevertheless, the derived results concerning cardiomyocyte survival pathways could
have implications for clinical practice.
Activation of MEK1-ERK1/2 and/or calcineurin-NFAT pathways in acute myocardial
infarction could protect affected cardiomyocytes against apoptotic cell death resulting in
favorably diminished infarction-lesions. Development of methods to inhibit apoptotic cell
death could result in a realistic alternative for exogenous tissue engineering. Exogenous tissue
engineering using skeletal myoblasts and embryonic or bone marrow stem cells has
undergone promising substantial progress, but did not yet reach clinical practice. (45) The
treatment procedure with survival pathway activation in acute myocardial ischemia requires
specific considerations. The therapeutic signaling activation needs to be cardiac-specific
targeted, most preferably cardiomyocyte-specific. As MEK1-ERK1/2 and calcineurin-NFAT
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pathways mediate important processes in other cell types, systemic infusion of a signaling
active substance could result in important side effects. (46) Moreover, both pathways have
been implicated in carcinogenesis. (47,48) Cardiac-specific targeting could be accomplished
by linking the therapeutic agent to smart-binding molecules. These smart-binding molecules,
for example cardiomyocyte anti-lineage-specific antibodies or cytokines, are able to target
cardiomyocytes specifically and concomitantly deliver the therapeutic agent at the site where
it is needed. However, during continuing ischemia the target cells for therapeutic signaling
activation cannot be reached through systemic administration unless the coronary occlusion is
removed by an intracoronary intervention. Retrograde administration is a possible option, but
it constitutes more risks for the patient. Another important aspect of therapy is the timing of
administration. With regard to the most optimal clinical outcome therapeutic signaling
activation is preferably accomplished before myocardial ischemia occurs. Theoretically that
would involve large-scale primary prevention studies, which are costly and not without
danger. Most practical would be therapy administration subsequent to myocardial reperfusion.
Clinical trials are needed to reveal the range of gain that can be obtained concerning infarct
size and maintenance of cardiac function. Another possible moment for therapeutic
administration could be during recovery after an acute myocardial infarction, as deleterious
cardiac remodeling and heart failure development could be prevented by apoptosis inhibition.
As murine studies have been performed, a new step in the near future concerning the
study of cardiomyocyte survival pathways in apoptotic cell death protection could be pig or
canine models of acute myocardial ischemia. In these large mammals different therapeutic
agents in distinct administration modalities and varying infusion time-schemes could be the
subject of investigation. Infarct size, apoptosis rates and cardiac remodeling could be relevant
parameters. This step could be a bridge to clinical trials in patients.
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Conclusion  
Closed-chest left ventricular pressure-volume acquisition is a sensitive, reproducible
and adequate method for in vivo cardiac function assessment in mice.
MEK1-ERK1/2 activation regulates cardiomyocyte viability following stress
stimulation in vivo. Calcineurin signaling helps to maintain cardiomyocyte viability in vivo,
mediated by specific NFAT activity. GSK-3β sensitizes the cardiomyocyte for stress-induced
apoptosis and antagonizes hypertrophic growth in vivo.
Cardiomyocyte survival pathways, such as the MEK-ERK1/2 and calcineurin-NFAT
pathways, protect the cardiomyocyte against deleterious stimuli by antagonizing apoptosis
and promoting hypertrophic growth through (in)activation of specific pathways.
MEK1-ERK1/2 and calcineurin-NFAT activation is cardioprotective in acute
myocardial ischemia-reperfusion injury as apoptotic cell death is prevented and follow-up
cardiac function maintained. These pathways are part of the concept of well-preserved
cardiomyocyte resuscitative survival pathways. New investigative strategies like dynamic
molecular imaging could significantly increase our knowledge about intracellular signaling
activation patterns in the course of disease. Therapeutic options with regard to intracellular
signaling activation in acute myocardial ischemia are at an early stage of investigation. The
next step would be the systemic administration of signaling specific therapeutic agents in
large mammal models to assess therapeutic potential and important side effects of treatment.
This interesting challenge in molecular cardiovascular science lies ahead of us.   
Chapter 7; General discussion. Molecular survival pathways in cardiomyocytes
References
1. Babiker FA, De Windt LJ, van Eickels M, Grohe C, Meyer R, Doevendans PA.
Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc
Res 2002;53:709-719.
2. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl
J Med 2002;346:5-15.
3. Corson LB, Yamanaka Y, Lai KM, Rossant J. Spatial and temporal patterns of ERK
signaling during mouse embryogenesis. Development 2003;130:4527-37.
4. de la Pompa JL, Timmerman LA, Takimoto H, et al. Role of the NF-ATc transcription
factor in morphogenesis of cardiac valves and septum. Nature 1998;392:182-6.
5. Ranger AM, Grusby MJ, Hodge MR, et al. The transcription factor NF-ATc is
essential for cardiac valve formation. Nature 1998;392:186-90.
6. Bennett AM, Tonks NK. Regulation of distinct stages of skeletal muscle
differentiation by mitogen-activated protein kinases. Science 1997;278:1288-91.
7. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway
promotes compensated cardiac hypertrophy in transgenic mice. Embo J 2000;19:6341-
50.
8. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional
pathway for cardiac hypertrophy. Cell 1998;93:215-28.
9. Lips DJ, Antos CL, Hassink RJ, De Windt LJ, Doevendans PA, Olson EN. GSK-3beta
overexpression attenuates hypertrophy and sensitizes the heart to ischemic damage and
dysfunction. In preparation 2003.
10. Lips DJ, Bueno OF, Wilkins BJ, et al. The MEK1-ERK2 signaling pathway protects
the myocardium from ischemic damage in vivo. Submitted 2003.
11. Bueno OF, Lips DJ, Kaiser RA, et al. Calcineurin Abeta gene targeting predisposes
the myocardium to stress-induced apoptosis and dysfunction. Circ Res. 2003 Nov 13
[Epub ahead of print] 2003.
12. Anversa P, Kajstura J, Olivetti G. Myocyte death in heart failure. Curr Opin Cardiol
1996;11:245-51.
13. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure
in the pressure-overloaded human heart: structural deterioration and compensatory
mechanisms. Circulation 2003;107:984-91.
14. Leri A, Franco S, Zacheo A, et al. Ablation of telomerase and telomere loss leads to
cardiac dilatation and heart failure associated with p53 upregulation. EMBO J
2003;22:131-9.
15. Oh H, Wang SC, Prahash A, et al. Telomere attrition and Chk2 activation in human
heart failure. Proc Natl Acad Sci U S A 2003;100:5378-83.
16. Lips DJ, Van Kraaij DL, De Windt LJ, Doevendans PA. Molecular determinants of
myocardial hypertrophy and failure: alternative pathways for beneficial and
maladaptive hypertrophy. Eur Heart J 2003;24:883-896.
17. Wencker D, Chandra M, Nguyen K, et al. A mechanistic role for cardiac myocyte
apoptosis in heart failure. J Clin Invest 2003;111:1497-504.
18. Abbate A, Biondi-Zoccai GG, Bussani R, et al. Increased myocardial apoptosis in
patients with unfavorable left ventricular remodeling and early symptomatic post-
infarction heart failure. J Am Coll Cardiol 2003;41:753-60.
19. Esposito G, Prasad SV, Rapacciuolo A, Mao L, Koch WJ, Rockman HA. Cardiac
overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated
kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload.
Circulation 2001;103:1453-8.
Chapter 7; General discussion. Molecular survival pathways in cardiomyocytes
20. Wilkins BJ, De Windt LJ, Bueno OF, et al. Targeted disruption of NFATc3, but not
NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic
growth. Mol Cell Biol 2002;22:7603-13.
21. De Windt LJ, Lim HW, Bueno OF, et al. Targeted inhibition of calcineurin attenuates
cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2001;98:3322-7.
22. Zou Y, Hiroi Y, Uozumi H, et al. Calcineurin plays a critical role in the development
of pressure overload-induced cardiac hypertrophy. Circulation 2001;104:97-101.
23. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3 beta
suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2002;99:907-12.
24. Hill JA, Rothermel B, Yoo KD, et al. Targeted inhibition of calcineurin in pressure-
overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem
2002;277:10251-5.
25. Bueno OF, Wilkins BJ, Tymitz KM, et al. Impaired cardiac hypertrophic response in
Calcineurin Abeta -deficient mice. Proc Natl Acad Sci U S A 2002;99:4586-91.
26. Bueno OF, De Windt LJ, Lim HW, et al. The dual-specificity phosphatase MKP-1
limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 2001;88:88-96.
27. Yeh JH, Hsu SC, Han SH, Lai MZ. Mitogen-activated protein kinase kinase
antagonized fas-associated death domain protein-mediated apoptosis by induced
FLICE-inhibitory protein expression. J Exp Med 1998;188:1795-802.
28. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival
promoted by the Ras-MAPK signaling pathway by transcription-dependent and -
independent mechanisms. Science 1999;286:1358-62.
29. De Windt LJ, Lim HW, Taigen T, et al. Calcineurin-mediated hypertrophy protects
cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model
of dilated heart failure. Circ Res 2000;86:255-63.
30. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival
signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
31. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced
phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-9.
32. Zhang HM, Yuan J, Cheung P, et al. Over-expression of interferon-gamma -inducible
GTPase inhibits coxsackievirus B3-induced apoptosis through the activation of the
PI3-K/Akt pathway and inhibition of viral replication. J Biol Chem 2003;Epub ahead
of print.
33. Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac
hypertrophy and development. Circ Res 2002;90:1055-63.
34. Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic
overexpression of activated Akt in the heart. J Biol Chem 2002;277:22896-901.
35. Condorelli G, Drusco A, Stassi G, et al. Akt induces enhanced myocardial contractility
and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A 2002;99:12333-8.
36. Shioi T, McMullen JR, Kang PM, et al. Akt/protein kinase B promotes organ growth
in transgenic mice. Mol Cell Biol 2002;22:2799-809.
37. Rajewsky K, Gu H, Kühn R, et al. Conditional gene targeting. J Clin Invest
1996;98:600-3.
38. Petrich BG, Molkentin JD, Wang Y. Temporal activation of c-Jun N-terminal kinase
in adult transgenic heart via cre-loxP-mediated DNA recombination. FASEB J
2003;17:749-51.
39. Dumont E, Reutelingsperger CP, Smits JF, et al. Real-time imaging of apoptotic cell-
membrane changes at the single-cell level in the beating murine heart. Nat Med
2001;7:1352-5.
Chapter 7; General discussion. Molecular survival pathways in cardiomyocytes
40. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients
with acute myocardial infarction. Lancet 2000;356:209-12.
41. Luker GD, Sharma V, Pica CM, Prior JL, Li W, Piwnica-Worms D. Molecular
imaging of protein-protein interactions: controlled expression of p53 and large T-
antigen fusion proteins in vivo. Cancer Res 2003;63:1780-8.
42. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome
activity and inhibition in living mice. Nat Med 2003;9:969-73.
43. Artemov D. Molecular magnetic resonance imaging with targeted contrast agents. J
Cell Biochem 2003;90:518-24.
44. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging
of the HER-2/neu receptor. Cancer Res 2003;63:2723-7.
45. Hassink RJ, Brutel de la Riviere A, Mummery CL, Doevendans PA. Transplantation
of cells for cardiac repair. J Am Coll Cardiol 2003;41:711-7.
46. Bueno OF, Brandt EB, Rothenberg ME, Molkentin JD. Defective T cell development
and function in calcineurin A beta -deficient mice. Proc Natl Acad Sci U S A
2002;99:9398-403.
47. Goto S, Matsukado Y, Mihara Y, Inoue N, Miyamoto E. An immunocytochemical
demonstration of calcineurin in human nerve cell tumors. A comparison with neuron-
specific enolase and glial fibrillary acidic protein. Cancer 1987;60:2948-57.
48. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated
protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7.
Cardiomyocyte survival pathways Summary
Summary
The use of genetically engineered mice renders vital information about the precise
roles proteins play in the diversity of intracellular signaling pathways associated with the
events of cardiomyocyte hypertrophy or apoptosis. In the present thesis, the link between the
genotype of the mouse and the concurrent phenotype is investigated employing sophisticated
molecular and cellular techniques combined with in vivo cardiac performance measurements.
In chapter 1 we focus on the characteristics of cardiac remodeling following an ischemic
event in man. The characteristics of remodeling - such as cell death, deposition of collagen
and myocardial hypertrophy - are thoroughly discussed through the results solely derived
from studies in genetically modified mice. The use of genetically modified murine models in
ischemia (-reperfusion) studies has led to a wealth of knowledge about the molecular
pathways involved in these processes. Despite the data available, intracellular signaling is still
a mystery as we lack the tools to study several pathways simultaneously and maybe even
more important the temporal changes in signaling cascade interactions.
In chapter 2 the molecular processes involved in cardiac hypertrophy are discussed.
The concept of beneficial and maladaptive pathways is introduced and related to the
detrimental transition of hypertrophy towards heart failure.   
Open-chest and closed-chest protocols for in vivo left ventricular pressure-volume
measurement are illustrated in chapter 3. Murine cardiac function determination via both
methods is sensitive, reproducible and comparable. We have chosen for closed-chest cardiac
function assessment protocol in our ischemia-reperfusion studies, because of better systolic
and diastolic performance, normal arterial-ventricular coupling and preservation of
myocardial integrity.
To unravel the importance of specific signaling pathways (e.g. MEK1-ERK1/2 and
calcineurin-NFAT) in ischemia-reperfusion-induced cell death techniques of transgenesis (e.g.
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MEK1 and GSK-3β transgenic mice) and gene targeting (e.g. ERK1 homozygous, ERK2
heterozygous and CnAβ homozygous knockout mice) have been used. Because single genes
were targeted, it was possible to elucidate the specific functions of the corresponding protein
in intracellular signaling pathways. In chapter 4 we analyzed ERK1 homozygous knockout
mice, ERK2 heterozygous knockout mice, and transgenic mice with activated MEK1-ERK1/2
signaling in the heart to determine a direct causal relationship between ERK1/2 signaling and
cardioprotection. A direct cardioprotective role for ERK signaling in the heart following
ischemia-reperfusion injury was demonstrated. While MEK1 transgenic mice were largely
resistant to myocardial infarction, ERK2+/- gene targeted mice showed enhanced infarction
and cardiomyocyte apoptosis when compared to littermate controls, resulting in concomitant
deterioration of cardiac function. Collectively, these data are the first to demonstrate that ERK
signaling directly participates in mediating cellular protection following ischemic injury in the
heart. In chapter 5 we investigate the role the calcium/calmodulin-activated protein
phosphatase calcineurin plays in modulating cardiac apoptosis following acute ischemia-
reperfusion injury in the heart. Calcineurin Aß (CnAβ) gene targeted mice showed a greater
loss of viable myocardium, more apoptosis, and a greater loss in functional performance
following ischemia-reperfusion injury when compared to strain-matched wildtype control
mice. Increased cell death was associated with a reduction of NFAT activity. Indeed, NFAT
activation protected cardiac myocytes from apoptotic stimuli, while directed inhibition of
NFAT augmented cell death. Collectively, these results represent the first genetic loss-of-
function data showing a pro-survival role for calcineurin-NFAT signaling in the heart. The
study presented in chapter 6 is designed to elucidate the role of GSK-3β following ischemia-
reperfusion. In GSK-3β transgenic mice, ischemia led to a larger infarct area and subsequent
worsened cardiac performance, while post-ischemic hypertrophic remodeling was blunted.
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Conclusively, these findings point towards a role for GSK-3β as a dualistic signaling
molecule transducing both anti-hypertrophic as well as pro-apoptotic pathways.
In previous studies activation of both MEK1-ERK1/2 and calcineurin-NFAT signaling
pathways were associated with hypertrophic cellular growth. The present thesis proves their
involvement in anti-apoptotic protection against ischemia-reperfusion injury. The dualistic
role of both resuscitative survival pathways in distinct pathogenic conditions as
cardiomyocyte hypertrophy and apoptosis, is a fascinating observation. To further delineate
the specific roles of individual survival pathways and investigate their potential use in clinical
practice, future research should focus on studying multiple signaling cascades simultaneously
and their interplay. A possible option is to cross-breed different genetically modified mice,
thereby creating double knockout or knockout/transgenic mice. Another possibility could
come from dynamic molecular imaging, through which protein function and interaction could
be visualized. The treatment of cardiac ischemia will eventually be improved significantly
through new developments in molecular science.
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In de cardiologie worden genetisch gemodificeerde muizenstammen gebruikt voor het
wetenschappelijk onderzoek naar pathofysiologische processen zoals hypertrofie en apoptose
van de cardiomyocyt. Met deze proefdiermodellen worden de precieze functies van specifieke
eiwitten in de diverse intracellulaire processen ontrafeld. Dit proefschrift beschrijft de link
tussen het genotype van de muis en het daarbij behorende fenotype door middel van
moleculaire en cellulaire laboratoriumtechnieken in combinatie met hartfunctiemetingen in de
levende muis.
Hoofdstuk 1 gaat dieper in op de cellulaire en orgaanrespons van het hart op ischemie,
een variëteit aan processen die gedefinieerd wordt door de term remodeling. Al deze
processen worden besproken en verduidelijkt aan de hand van onderzoeksresultaten
uitsluitend verkregen in genetisch gemodificeerde muizenstammen. Uit dit hoofdstuk blijkt
dat het gebruik van genetisch gemodificeerde muizen onmiskenbaar zijn waarde heeft
bewezen in de zoektocht naar determinerende stappen in het remodeleringsproces.
Hoofdstuk 2 bespreekt de moleculaire en cellulaire mechanismen in hypertrofie van
het hart. Daarnaast wordt ingegaan op die mechanismen, die de transitie van hypertrofie naar
hartfalen lijken te bepalen en versnellen. Het concept van gunstige (beneficial) en ongunstige
(maladaptive) signaalwegen wordt geïntroduceerd en de relevantie besproken voor de
dagelijkse klinische praktijk.
In hoofdstuk 3 worden de onderzoeksprotocollen voor drukvolume metingen bij open
en gesloten muizenthorax gedetailleerd beschreven en besproken. Hartfunctie metingen in de
muis, uitgevoerd volgens deze protocollen, zijn sensitief, reproduceerbaar en vergelijkbaar. In
ischemie-reperfusie vervolgstudies werd gekozen voor hartfunctiemeting bij gesloten thorax,
vanwege de betere hartfunctie tijdens de systole en diastole, een normale arterial-ventricular
coupling  en behoud van integriteit van het myocard. De betekenis van specifieke
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signaalwegen (MEK1-ERK1/2 en calcineurin-NFAT) in de reactie van de cardiomyocyt  op
ischemie-reperfusie stress werd onderzocht door middel van transgene (MEK1 en GSK-3β)
en (ERK1 homozygote, ERK2 heterozygote en CnAβ homozygote) knockout muizen.
Aangezien deze technieken leiden tot verandering in het enkelvoudige gen is het mogelijk de
specifieke functies van het enkelvoudig corresponderend eiwit in de intracellulaire
signaalwegen te onderzoeken.
Het onderzoek naar de betekenis van MEK1-ERK1/2 signaalactivatie bij de respons
van de cardiomyocyt  op schade ten gevolge van ischemie-reperfusie  wordt  beschreven in
hoofdstuk 4. Hierbij werden ERK1 homozygote, ERK2 heterozygote en MEK1 transgene
muizen gebruikt. ERK1/2 signaalactivatie blijkt direct gecorreleerd te zijn met bescherming
van de cardiomyocyt tegen celdood ten gevolge van myocardischemie. MEK1 transgene
muizen blijken vrijwel resistent te zijn voor de ischemische stimulus. ERK2 heterozygote
knockout muizen vertonen een groter myocardinfarct met meer apoptose in vergelijking met
controle muizen. De hartfunctie blijkt daarbij navenant verslechterd te zijn. Dit zijn de eerste
gepubliceerde onderzoeksresultaten waarin bescherming van de cardiomyocyt tegen
ischemie-reperfusie schade door MEK1-ERK1/2 signaalactivatie wordt aangetoond.
De rol van het calcium/calmoduline-geactiveerde eiwit fosfatase calcineurine in
cardiomyocyt apoptose in respons op ischemie-reperfusie schade is het onderwerp van
hoofdstuk 5. Calcineurine Aβ (CnAβ) knockout muizen vertonen een groter myocardinfarct
met meer apoptose na myocardischemie dan controle muizen. Het verlies van hartfunctie is
lineair degressief in deze muizen in vergelijking met controle muizen. De verhoogde mate van
apoptotische celdood is geassocieerd met een reductie in NFAT activiteit. Activatie van
NFAT beschermt de cardiomyocyten tegen apoptotische stimuli, terwijl directe inhibitie van
NFAT activatie leidt tot meer apoptotische celdood. Deze resultaten leiden tot de conclusie
dat de calcineurine-NFAT as bescherming biedt tegen de gevolgen van ischemie.
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Het in hoofdstuk 6 beschreven onderzoek is  opgezet om de rol van GSK-3β bij de
respons op ischemie-reperfusie te verklaren. Myocardischemie resulteert in grotere
myocardinfarcten en verslechtering van de hartfunctie in GSK-3β transgene muizen, terwijl
postischemische hypertrofe remodeling verminderd blijkt. Uit beide observaties komt de
duale rol van GSK-3β naar voren: zowel inhibitie van hypertrofie als promotie van apoptose
in de cardiomyocyt.
 Eerdere publicaties gingen in op activatie van MEK1-ERK1/2 en calcineurine-NFAT
signaalwegen ten tijde van hypertrofe groei van de cardiomyocyt in respons op diverse
pathologische situaties. Dit proefschrift beschrijft de rol van beide signaalwegen bij de
bescherming van de cardiomyocyt tegen apoptotische celdood in respons op schade door
ischemie-reperfusie. De observatie dat beide signaalwegen afzonderlijk een rol van betekenis
spelen in zowel prohypertrofe als anti-apoptotische cellulaire processen biedt een fascinerend
uitgangspunt voor toekomstig onderzoek. Hierin heeft het simultaan bestuderen van meerdere
signaalwegen en de onderlinge interactie prioriteit. Dit kan worden verwezenlijkt door het
kruisen van genetisch gemodificeerde muizenstammen  waardoor dubbelknockouts of
knockout/transgene muizenstammen ontstaan. Ook het bestuderen van meer specifiek
proteïne-proteïne interacties is van essentieel belang. Een mogelijkheid zou dynamic
molecular imaging zijn, dat veranderingen in eiwitfuncties in de tijd visualiseert. De
behandeling van myocardischemie in de patiënt zal in de toekomst door moleculaire
ontwikkelingen in ieder geval significante verbeteringen ondergaan.
Curriculum vitae
The author of this thesis, Daniel Jozef Lips, was born October 15th, 1978 in Hwidiem
BA, Ghana. From 1991 he attended Zwijsen College in Veghel, the Netherlands, where he
obtained the year prize for Roman language and culture at his graduation in 1997.
Subsequently he started his academic career at the Faculty of Health Sciences at Maastricht
University. After graduating his first year (i.e. Propedeuse, cf. B.Sc) in Health Sciences, he
started in 1998 his medical training at the Faculty of Medicine at Maastricht University. He
was founding member of the fraternity Onafhankelijk Heerendispuut Hyperion Maastricht, in
which he served several years as board member and chairman. During his first year of
medical training he began to serve as a research assistant at the Department of Cardiology of
the University Hospital Maastricht under supervision of Dr. P.A. Doevendans and Prof. Dr.
H.J.J. Wellens. In 2000 he was trained for six weeks at the laboratory of Dr. Howard D.
Rockman, Department of Cardiology, Duke University Medical Center, Durham, North
Carolina, USA. In 2001 he was awarded the international Journal of Experimental Biology
Travelling Fellowship Award for his study proposal Cardiac function in murine genotypes of
beneficial and maladaptive myocardial hypertrophy. In the same year he won the students-
science prize at the Maastricht Medical Students Research Conference for the best poster
presentation. From 2001 to 2004 he worked with grants from the Hein J.J. Wellens foundation
and foundation De Drie Lichten during several periods as a Ph.D. student at the laboratories
of Dr. Jeffery D. Molkentin, Children’s Hospital Medical Center, Cincinnati, Ohio, USA, and
Prof. Dr. Eric N. Olson, University of Texas Southwestern Medical Center, Dallas, Texas,
USA. His clinical elective internship was performed at the Department of Cardio-Thoracic
Surgery of the University Medical Center Utrecht under supervision of Prof. Dr. A. Brutel de
la Rivière in 2003. Currently he is in the last year of medical training and expects to graduate
in August 2004.
Full papers
1. Van den Bosch BJC, Doevendans PA, Lips DJ, Geurts JMW, Smeets HJM. Towards
elucidation of genetic pathways in cardiac hypertrophy: technique to develop microarrays.
In: Doevendans PA, Kaäb S. Cardiovascular genomics: new pathophysiological concepts.
Dordrecht: Kluwer Academic Publishers, 2002:97-105.
2. Bueno OF, Van Rooij E, Lips DJ, Doevendans PA, De Windt LJ. Cardiac hypertrophic
signaling: the good, the bad and the ugly. In: Doevendans PA, Kaäb S. Cardiovascular
genomics: new pathophysiological concepts. Dordrecht: Kluwer Academic Publishers,
2002:131-155.
3. Mummery C, Ward D, Van den Brink CE, Bird SD, Doevendans PA, Lips DJ, Opthof T,
Brutel de la Riviere A, Tertoolen L, Van der Heyden M, Pera M. In: Doevendans PA,
Kaäb S. Cardiovascular genomics: new pathophysiological concepts. Dordrecht: Kluwer
Academic Publishers, 2002:231-243.
4. Van Kraaij D, Van Pol P, Ruiters A, De Swart J, Lips D, Lencer N, Doevendans P.
Diagnosing diastolic heart failure. Eur J Heart Fail 2002 Aug;4(4):419.
5. Lips DJ, De Windt LJ, Van Kraaij DVM, Doevendans PA. Molecular determinants of
myocardial hypertrophy and failure. Alternative pathways for beneficial and maladaptive
hypertrophy. Eur Heart J 2003:24(10);883-96.
6. Bueno OF, Lips DJ, Kaiser RA, Wilkins BJ, Dai YS, Glascock BJ, Klevitsky R, Hewett
TE, Kimball TR, Aronow BJ, Doevendans PA, Molkentin JD. Targeted disruption of
calcineurin Aβ indicates a role for calcineurin in cardiac hypertrophy and ischemia-
induced injury. Circ Res 2004;94(1):91-9.
7. Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ,
Doevendans PA. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004 Feb
15;61(3):414-26.
8. Van Rooij E, Doevendans PA, Crijns HJGM, Heeneman S, Lips DJ, Van Bilsen M,
Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ. MCIP1
overexpression suppresses left ventricular remodeling and sustains cardiac function
following myocardial infarction. Circ Res. 2004 Feb 20;94(3):e18-26
9. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Kimball TF, Molkentin JD. Targeted
inhibition of p38 MAPK antagonizes cardiac injury and cell death following ischemia-
reperfusion in vivo. J Biol Chem 2004 Jan 28 [Epub ahead of print]
10. Lips DJ, Van der Nagel T, De Windt LJ, Van Empel VM, Palmen M, Van Dantzig J-M,
Doevendans PA. Left ventricular pressure-volume measurements in mice: A comparative
study between a closed-chest versus open-chest approach. In press Basic Res Cardiol.
11. Lips DJ, Van Reisen MT, Voigt V, Venekamp W. Pseudomalabsorption of
Levothyroxine. In press Netherlands Journal of Medicine.
12. Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-
Leil MK, Meloche S, Pouysségur J, Pagès G, De Windt LJ, Doevendans PA, Molkentin
JD. The MEK1-ERK2 signaling pathway protects the myocardium from ischemic injury
in vivo. In press Circulation.
13. Lips DJ, Hassink RJ, Brutel de la Riviere A, Doevendans PA. The use of genetic modified
mice in the investigation of cardiac remodeling. In: Greenberg B. Myocardial remodeling:
Mechanisms and treatment. In press 2004.
14. Palmen M, Daemen MJ, Lips DJ, Buehler A, De Theije C, Zandbergen HR, Bronsaer
RJP, Zimmermann R, Van der Zee R, De Muinck ED, Dassen WR, Van Eickels M,
Kockx MA, Smits JF, Doevendans PA. Cardiac-specific overexpression of hFGF-1
deteriorates cardiac function and alters remodeling following chronic myocardial
infarction in mice. Submitted 2003.
15. Babiker FA, Lips DJ, Delvaux E, Zandberg P, Van Eys G, Van Eickels M, Grohe C,
Janssen B, Doevendans PA. Estrogen receptor beta protects the murine heart against left
ventricular hypertrophy. Submitted 2004.
16. Lips DJ, Antos CL, Hassink RJ, De Windt LJ, Doevendans PA, Olsen EN. GSK-3β
overexpression attenuates hypertrophy and sensitizes the heart to ischemic damage and
dysfunction. In preparation.
1Acknowledgements / Dankbetuigingen
Gekomen bij het einde van mijn proefschrift, en daarmee het einde van het
wetenschappelijke werk dat aan dit proefschrift vooraf ging, benut ik graag de mogelijkheid
om diegenen te bedanken die met hun inzet en enthousiasme in mijn proefschrift en mijn
persoon hebben geïnvesteerd. Het proefschrift is dé finale van jaren proefdraaien in de
wetenschap; enkele personen hadden daar een bijzonder aandeel in.
De eerste is Pieter Doevendans. Pieter bood mij de mogelijkheid kennis te maken met
de medische wetenschap. Daarvoor had ik geen betere leermeester kunnen treffen dan Pieter
zelf. Persoonskenmerken die ik bewonder in Pieter maken hem tot de meest geschikte
begeleider in de afgelopen jaren. Ik heb onze persoonlijke omgang als zeer aangenaam
ervaren en hoop die in de toekomst te kunnen voortzetten.
 The second person I would like to express my gratitude to is Jeffery Molkentin, in
whose laboratory, based in Cincinnati USA, I probably spent as much time as I did in the
laboratory of Pieter Doevendans. The drive and knowledge of Jeff are like the water stream in
Niagara Falls: never ending and with great force, and it greatly influenced my enthusiasm for
science. I have not stopped learning from Jeff.  I hope I never will.
Een persoon die tevens een significant aandeel heeft gehad in de totstandkoming van
mijn proefschrift, is Leon de Windt. Ik dank Leon voor de gedetailleerde discussies over de
wetenschap, voor de goede ideeën met mij besproken en voor zijn kritische noot op mijn
Engelse teksten. Ik betreurde zijn vertrek naar Utrecht, waardoor onze dagelijkse interactie
aanzienlijk verminderd werd.
Another person to whom I would like to show my gratitude is Eric Olson. I want to
thank Eric for making his laboratory and knowledge available for our studies. I enjoyed being
in his laboratory in Dallas Texas, where I enormously improved my scientific skills. Even
from a distance I will continue to learn from Eric.
2Tenslotte wil ik graag mijn grote dank uitspreken jegens Hein Wellens en  Aart Brutel
de la Rivière: enerzijds voor hun beider rol als mijn promotor,  anderzijds voor hun betekenis
als onmiskenbare iconen voor jonge wetenschappers en artsen in de cardiovasculaire
wetenschap en geneeskunde. Hun aanwijzingen en correcties waren van fundamenteel belang
voor mijn proefschrift.
Een groot aantal mensen heb ik niet genoemd (co-auteurs, adviseurs, technici, etc.),
ondanks hun onmisbaar aandeel in dit proefschrift. Weet dat ik jullie zeer erkentelijk ben voor
de bijdrage geleverd. Ik zal jullie hier persoonlijk voor bedanken.
De laatste woorden van mijn proefschrift hoopte ik te kunnen vangen in een magisch
slotakkoord. Doch, net als magie geen rol heeft in de wetenschap, zo is voor Daan Lips geen
rol weggelegd als woordkunstenaar. Daarom zal ik het met het volgende motto moeten doen:
hard werken en daarmee compenseren voor deficiënties in aangeboren talenten.
Daniel J. Lips
